CHARACTERIZATION OF FACTORS THAT IMPACT APOLIPOPROTEIN B

SECRETION AND ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION by Grubb, Sarah Renee
CHARACTERIZATION OF FACTORS THAT IMPACT APOLIPOPROTEIN B 
SECRETION AND ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION 
by 
Sarah Renee Grubb 
B.S., Mercyhurst College, 2007 
Submitted to the Graduate Faculty of the 
Kenneth P. Dietrich School of 
 Arts and Sciences in partial fulfillment of 
the requirements for the degree of Doctor 
of Philosophy 
University of Pittsburgh 
2013 
ii 
UNIVERSITY OF PITTSBURGH 
Dietrich School of Arts and 
Sciences 
This dissertation was presented 
by 
Sarah Renee Grubb 
It was defended on 
November 9, 2012 
and approved by 
Deborah L. Chapman, Ph.D., Associate Professor 
Joseph Martens, Ph.D., Assistant Professor 
James M. Pipas, Ph.D., Professor 
Jonathan Minden, Ph.D., Professor 
 Dissertation Advisor: Jeffrey L. Brodsky, Ph.D., Professor 
iii 
Copyright © by Grubb 
2013 
iv 
Apolipoprotein B (ApoB) is a lipoprotein that transports cholesterol and triglycerides through the 
bloodstream.   High plasma levels of ApoB are one of the strongest risk factors for the 
development of Coronary Artery Disease.  Using a yeast expression system for ApoB, I focused 
my research on identifying new therapeutic targets to reduce the amount of ApoB secreted into 
the bloodstream.  One way that ApoB levels are regulated is through Endoplasmic Reticulum-
Associated Degradation (ERAD), a quality control mechanism that rids the secretory pathway of 
misfolded proteins.  Due to ApoB’s hydrophobic character and high number of disulfide bonds, 
one class of proteins that I hypothesized may contribute to ApoB ERAD was the Protein 
Disulfide Isomerase (PDI) family.  PDI’s catalyze the oxidation, reduction, and isomerization of 
disulfide bonds and some also have chaperone-like activity.  I found that in yeast, Pdi1 
contributes to ApoB ERAD through its chaperone like domain.  I identified mammalian PDI 
candidates that may similarly affect ApoB biogenesis based on my yeast data.  I found that in 
hepatic cells, two PDI family members, ERp57 and ERp72, contribute to ApoB ERAD, while 
another family member, PDI, promoted ApoB secretion.   
A unique aspect of ApoB ERAD is that the protein is co-translationally retrotranslocated 
and degraded.  I hypothesized that proteins that regulate the Sec61 translocon, a proteinacious 
channel that allows ApoB entrance to the ER as well as an exit to the cytoplasm for degradation, 
would contribute to ApoB retrotranslocation and degradation.  I discovered that two conserved 
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v 
ER-membrane proteins that are candidates for Sec61 regulators, Yet2 and Yet3, facilitate the 
ERAD of ApoB in yeast.  To determine whether my results are relevant in mammalian cells, I 
am currently working to determine if the mammalian homologs of Yet2 and Yet3, BAP29 and 
BAP31 facilitate ApoB ERAD in hepatic cells. 
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1.0  INTRODUCTION 
1.1 LIPID CARRIERS – CHYLOMICRONS, VLDL, LDL, HDL 
Mammals have three sources of fatty acids and cholesterol – those that are synthesized, obtained 
through the diet, and stored in cells.  The synthesis of cholesterol occurs primarily in the liver, 
where a small fraction is incorporated into hepatocyte membranes (Goldstein and Brown, 1977).  
The cholesterol that is not incorporated into membranes in the liver is exported as biliary 
cholesterol, bile acids, or cholesteryl esters to be incorporated into membranes in other tissues or 
used as a precursor for steroid hormones and vitamin D (Soccio and Breslow, 2004).  Cholesterol 
and cholesteryl esters are hydrophobic and therefore insoluble.  In order to maintain cellular 
homeostasis, lipoproteins, composed of different apolipoproteins and combinations of 
phospholipids, triacylglycerols (TAG), cholesterol, and cholesteryl esters, are necessary to 
transport these hydrophobic molecules through the bloodstream from the liver, where they are 
synthesized, or from the small intestines, where they are absorbed from dietary nutrients, to 
tissues where they will be used or stored (Goldstein and Brown, 1977; Kwiterovich, 2000).   
There are several different classes of lipoproteins - chylomicrons, very low-density 
lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL) 
(Figure 1) (Kwiterovich, 2000).  These lipoproteins have specific functions based on where they 
are synthesized, their lipid composition, and the apolipoprotein content, and they can be 
 2 
separated from the plasma by ultracentrifugation based on their densities (Dominiczak and 
Caslake, 2011).  Apolipoproteins are amphipathic lipid-binding proteins that act as detergents to 
transport TAG, phospholipids, cholesterol, and cholesteryl esters through the bloodstream.  At 
least nine different apolipoproteins can be found in lipoproteins isolated from human plasma.  In 
addition to acting as detergents, apolipoproteins can function as signal transducers by targeting 
specific lipoproteins to receptors on various tissues or they can activate enzymes that act on 
lipoproteins (Dominiczak and Caslake, 2011). 
The second source of fatty acids and cholesterol is dietary.  For example, humans obtain 
a significant portion of their daily energy requirement through dietary TAG, which are absorbed 
in the small intestine.  In the small intestine, TAG are converted from insoluble fat molecules to 
mixed micelles by bile salts, which are synthesized in the liver from cholesterol, stored in the 
gall bladder, and released into the small intestine after ingestion of a meal rich in fat (Abumrad 
and Davidson, 2012).  The mixed micelles are broken down in the small intestines by lipases 
converting TAG into monoglycerides, diacylglycerols (DAG), free fatty acids (FFA), and 
glycerol (Abumrad and Davidson, 2012).  These breakdown products are absorbed into the 
intestinal epithelial cells by diffusion where they are re-converted into TAG, packaged with 
dietary cholesterol and specific apolipoproteins, such as ApoB48 and ApoC-II, to form 
chylomicrons, a class of lipoproteins characterized by an extremely low density and large 
diameter (Mansbach and Siddiqi, 2010).   
For dietary fats to be utilized by the body, chylomicrons traffic from the intestinal 
mucosa into the lymphatic system, and then into the blood stream where they are carried to 
muscle and adipose tissue (Mansbach and Siddiqi, 2010).  Once in these tissues, apolipoprotein 
ApoC-II activates the enzyme Lipoprotein Lipase (LPL), which hydrolyzes TAG to FFA and 
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glycerol that can be utilized by the cells (Havel, 1975; Mjos et al., 1975; Kwiterovich, 2000).  
After being depleted of TAG the chylomicron remnants contain cholesterol, and the 
apolipoproteins ApoB48 and ApoE, and travel to the liver where they are endocytosed, and 
degraded by the lysosome (Kita et al., 1982; Rubinsztein et al., 1990; Rohlmann et al., 1998). 
FFA in liver cells are converted to TAG, which gets packaged with phospholipids, 
cholesterol, cholesteryl esters, and specific apolipoproteins, to form nascent VLDL particles 
(Goldstein and Brown, 1977; Dominiczak and Caslake, 2011).  The key apolipoprotein in 
VLDLs is ApolipoproteinB100 (ApoB100).  VLDLs are secreted into the bloodstream and travel 
to muscle and adipose tissue where ApoC-II activates LPL, causing the release of FFA from the 
TAG (Havel, 1975; Kwiterovich, 2000; Dominiczak and Caslake, 2011).  The FFA are absorbed 
by myocytes and adipocytes and are oxidized to provide energy or resynthesized into TAG for 
storage (Kwiterovich, 2000).  The reduction in TAG content of the VLDL by LPL increases the 
density of the particle, and it is now referred to as a LDL.   
LDLs are rich in cholesterol and cholesteryl esters and like VLDLs they also 
predominantly contain ApoB100 (Goldstein and Brown, 1977).  LDLs deliver fatty nutrients to 
peripheral tissues that require cholesterol for new membrane synthesis.  Upon conversion to an 
LDL, a portion of the ApoB100 polypeptide that was previously buried in a VLDL by lipids 
becomes exposed.  The exposed portion of ApoB is the ligand for the LDL-receptor (LDLR) 
(Boren et al., 1998), which is selectively expressed on tissues that are competent for cholesterol 
and FA metabolism, and is necessary for receptor mediated endocytosis of ApoB containing 
LDL particles (Brown and Goldstein, 1975, 1976).  Upon endocytosis in target tissues, the 
endosome fuses with the lysosome, where ApoB is degraded and the cholesteryl esters are 
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hydrolyzed into cholesterol and FA.  These fats are released into the cytosol and may be 
incorporated into membranes or re-esterified and stored (Goldstein and Brown, 1977).   
The final class of lipoproteins is HDLs, which are synthesized in the liver or small 
intestine as protein rich particles and initially contain very little cholesterol and no cholesteryl 
esters (Kwiterovich, 2000).  HDLs predominantly contain the apolipoproteins ApoC-I and 
ApoC-II and the enzyme lecithin-cholesterol acyl transferase (LCAT).  LCAT is present on 
nascent HDLs and converts cholesterol and phosphatidylcholine from chylomicron and VLDL 
remnants to cholesteryl esters (Scanu and Edelstein, 2008).  The cholesteryl esters form a core 
for the HDL particles and facilitate maturation.  The mature HDLs return to the liver and deliver 
the acquired cholesterol for conversion into bile salts (Scanu and Edelstein, 2008).    
 
 5 
 
 
Figure 1. Major classes of human plasma lipoproteins 
The four major types of plasma lipoproteins are depicted with their various components.  Chylomicrons have the 
largest diameter and are the least dense particles.  They contain the apolipoprotein ApoB48 and contain high 
concentrations of triacylglycerols.  VLDL particles have the second largest diameter and harbor the apolipoprotein 
ApoB100.  VLDLs contain a core of both triacylglycerols and cholesteryl esters, with a larger percentage of 
triacylglycerols.  LDL particles are more dense than VLDLs and have a smaller diameter.  They also contain the 
apolipoprotein ApoB100 and a core of both triacylglycerols and cholesteryl esters, with a larger percentage of 
cholesteryl esters.  The most dense lipoprotein particles with the smallest diameter are HDLs.  HDLs do not express 
ApoB, but are mainly composed of other apolipoproteins, such as ApoC-I and ApoC-II and phospholipids.  See 
(Havel, 1975), for additional details. 
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1.2 APOLIPOPROTEIN B 
Apolipoprotein B (ApoB) is a large amphipathic lipid binding protein produced in the liver and 
small intestine in two different isoforms – ApoB100 and ApoB48.  ApoB is the main structural 
component of chylomicrons, VLDLs, and LDLs.  The amphipathic nature of ApoB allows it to 
act as a detergent for the transport of the highly hydrophobic lipoproteins through the 
bloodstream. Collectively, chylomicrons, VLDLs, and LDLs distribute dietary and endogenously 
synthesized cholesterol and lipids to peripheral tissues, to be used for membrane synthesis, bile 
acid synthesis, and cellular metabolism.  Although these lipoproteins are extremely important for 
maintaining cellular homeostasis by delivering cholesterol and lipids to various tissues, ApoB 
containing lipoproteins, with the exception of chylomicrons, are particularly atherogenic.  These 
circulating particles can accumulate in atherosclerotic plaques in arteries, leading to coronary 
artery disease (Tiwari and Siddiqi, 2012).  Due to the critical role of ApoB in lipoprotein 
transport, its biogenesis is highly regulated, both at the levels of synthesis and degradation (see 
section 1.4).     
 
1.2.1 Isoforms and Structural Domains 
ApoB is encoded in the human genome by a gene that is approximately 45kb (Lusis et al., 1985).  
In hepatic cells, the gene is transcribed into a very stable 15kb mRNA that is translated into a 
single 4536 amino acid polypeptide with a mass of approximately 550kDa. This species is 
ApoB100 (Lusis et al., 1985).  The modeled secondary structure of ApoB100 is based on 
homology to the lipid associated protein lipovitellin (Segrest et al., 2001), a predominant yolk 
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protein in vertebrate eggs.  Based on sequence prediction and homology modeling, ApoB100 is 
proposed to have a five-domain secondary structure consisting of both alpha helical and beta 
sheet structures (NH2-βα1-β1-α2-β2-α3-COOH) (Figure 2) (Segrest et al., 2001).  The amphipathic 
nature of ApoB is essential for its function.  The hydrophobic regions noncovalently interact 
with hydrophobic lipids while the hydrophilic regions are essential for maintaining solubility in 
the plasma.  Other specific regions of the protein are important for targeting lipoprotein particles 
to peripheral tissues and to the liver for receptor-mediated endocytosis (see section 1.1).  
Sequence comparison, antibody binding experiments, and truncation analysis identified amino 
acid residues 3345-3381 in ApoB as the LDLR binding domain (Milne et al., 1989; Law and 
Scott, 1990; Boren et al., 1998; Segrest et al., 2001).  As described in section 1.1, after VLDL 
are converted into LDL particles, the LDLR binding domain is exposed. This helps target the 
lipoprotein to peripheral tissues that express the LDLR and that are competent for cholesterol 
metabolism. 
 In enterocytes, the 15kb ApoB mRNA is post-transcriptionally edited by the 27kDa 
enzyme ApoB mRNA editing complex-1 (apobec-1) (Chen et al., 1987; Powell et al., 1987).  
Apobec-1 binds to an AU-rich sequence five bases downstream of cytidine-6666 and deaminates 
cytidine-6666, converting it to a uridine (Navaratnam et al., 1993).  This conversion from C to U 
forms a UAA stop codon instead of a glutamine residue.  The result is a truncated protein 
comprising the N-terminal 48% of full length ApoB, ApoB48 (Figure 2).  As noted above, 
ApoB48 is the predominant component of chylomicrons (Kane et al., 1980; Chen et al., 1987; 
Lo et al., 2008; Mansbach and Siddiqi, 2010).  In rodents such as mice and rats, Apobec-1 is 
expressed in the liver in addition to the intestines, producing significant amounts of both 
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ApoB48 and ApoB100 in the liver (Tennyson et al., 1989); however, in humans, production of 
the ApoB48 isoform is restricted to the small intestine.    
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Figure 2. Isoforms and structural features of Apolipoprotein B 
(A) The linear diagram of ApoB depicts the lengths of the two predominant isofoms of ApoB, ApoB48 and ApoB100, 
and the isoform used in the majority of my experiments, ApoB29.  The C-terminus of each isoform is marked by a 
dashed line.  The ER signal sequence  (SS) consists of amino acids 1-27.  ApoB100 has a total of 25 cysteines 
(depicted with circles) and 16 of those are involved in forming 8 disulfide bonds (dark circles) and the rest are free 
sulfhydryls (open circles).  ApoB100 also contains 16 confirmed N-linked glycosylation sites (depicted with red 
pitchforks).  Adapted from Harazono et al., 2005.  (B) The model of ApoB secondary structure in an LDL particle 
from Johs et al., 2006 with permission.  Of note, the highly disulfide bonded βα1 domain is not as tightly associated 
with lipids as the other domains. 
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Another naturally occurring isoform of ApoB that was originally identified in patients 
with hypobetalipoproteinemia, a disease characterized by very low LDL levels (see section 
1.4.1), is ApoB29.  As its name implies, ApoB29 is 29% of full length ApoB, and is 1305 amino 
acids in length (Figure 2).  This ApoB isoform results from a C to T alteration in the ApoB gene 
that encodes a premature stop codon (Collins et al., 1988; Huang et al., 1989).  Studies using 
ApoB29 have found that the shorter isoform limits the amount of lipids that can associate with 
the protein to form a lipoprotein, resulting in smaller, denser, lipid poor particles (Linton et al., 
1993).  However, subsequent studies that investigated the ability of ApoB truncation mutants to 
traffic through the secretory pathway indicated that ApoB29 is the shortest isoform that is able to 
traffic normally (McLeod et al., 1994).  These results indicate that ApoB29 is the smallest 
clinically relevant ApoB isoform that can be studied; as such, this is the isoform that is used in 
the majority of my experiments.               
 
1.2.2 Translocation and Trafficking 
Synthesis of ApoB (and other secretory proteins) occurs at the ER surface after it is directed to 
the membrane by an N-terminal 27 amino acid signal sequence (see section 1.3.1) (Sturley et al., 
1994).  Translocation of ApoB into the ER lumen occurs co-translationally through a 
proteinaceous channel in the ER membrane called the translocon.  The translocon is composed 
mainly of the Sec61 protein, which binds tightly to ribosomes during translation and 
translocation into the ER (Robson and Collinson, 2006).   ApoB associates with Sec61α and 
Sec61β, two components of the translocon, during its co-translational translocation (Mitchell et 
al., 1998; Pariyarath et al., 2001).  As described above, ApoB contains highly hydrophobic β-
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sheet domains (amino acids 1000-2000 and 2600-4000) (Figure 2), which interact strongly with 
the translocon as it is translated and this interaction can cause a slowing of translocation while 
translation continues (Ginsberg and Fisher, 2009).  Translocational slowing can result in ApoB 
congestion in the translocon and allow loops of ApoB to be exposed to the cytosol through gaps 
between the ribosome and the translocon (Hegde and Lingappa, 1996).  A unique feature of 
ApoB translation is the presence of pause transfer sequences in the polypeptide, which are 
clustered in three regions of the protein (9 sequence in the N-terminal 20% of ApoB100, 4 
sequences between 46-50%, and 10 sequences between 65-95%)(Figure 2).  These pause transfer 
sequences are distinct from the β-sheet domains and may also cause a slowing of ApoB 
translocation into the ER by causing translation to stop and restart (Chuck and Lingappa, 1992, 
1993; Kivlen et al., 1997); however, recent studies suggest that the hydrophobic β-sheet domains 
are the main contributors to this phenomenon (Yamaguchi et al., 2006).   
As ApoB is translocated, an ER-resident protein, the microsomal triglyceride transfer 
protein (MTP), composed of a 97 kDa “M” subunit and Protein Disulfide Isomerase (PDI), 
facilitates the transfer of phospholipids, cholesterol, and triglycerides onto ApoB, forming a 
primordial lipoprotein (Hussain et al., 1997).  PDI keeps the M subunit soluble and retained in 
the ER and is essential for the lipid transfer activity of MTP (Wetterau et al., 1990; Wetterau et 
al., 1991).  ApoB and MTP have been shown to interact by coimmunoprecipitation (Patel and 
Grundy, 1996; Wu et al., 1996), solid-liquid interphase binding assays (Hussain et al., 1997), 
and yeast two hybrid assays (Bradbury et al., 1999; Mann et al., 1999), and this interaction 
occurs between the βα1 domain of ApoB and the M subunit of MTP (see Figure 2A) (Hussain et 
al., 2003).  The association of MTP with ApoB is increased upon treatment with oleic acid, as 
more lipid substrates are available to load onto ApoB (Homan et al., 1991).  Numerous studies 
 11 
have indicated that the lipid transfer activity of MTP is essential for the assembly and secretion 
of lipoproteins containing ApoB (Gordon et al., 1994; Leiper et al., 1994; Jamil et al., 1996; 
Benoist and Grand-Perret, 1997; Wang et al., 1997b; Davis, 1999; Gordon and Jamil, 2000). 
Lipid synthesis occurs at the ER and lipids can be sequestered and stored in cytoplasmic 
Lipid Droplets (LDs), which have a neutral lipid core surrounded by a phospholipid and sterol 
monolayer (Sturley and Hussain, 2012).  LDs are often found associated with the ER forming 
crescents around the organelle, as it is thought that they bud from the ER membrane.  They 
function to release lipids in response to cellular need and it is hypothesized that the lipid loading 
activity of MTP creates a concentration gradient that is essential for transferring neutral lipids 
into the ER (Sturley and Hussain, 2012).  The major neutral lipid cargo in LDs is TAG and TAG 
stored in LDs is the predominant source of lipid substrate for the assembly of ApoB into pre-
VLDLs in the ER (Yang et al., 1995). 
Once ApoB is successfully translocated into the ER and is assembled into a pre-VLDL 
upon lipid loading, it must exit the ER and traffic to the Golgi where the lipoprotein matures into 
a VLDL (see below).  Secretory proteins normally exit the ER in COPII vesicles composed of 
five subunits -Sar1, Sec23/24, and Sec13/31 (Kuge et al., 1994; Rothman and Wieland, 1996; 
Barlowe, 2000).  The relatively large size of ApoB containing lipoproteins has prompted 
speculation that these particles may require a unique mechanism to be transported from the ER 
(Fromme and Schekman, 2005).  Although most COPII vesicles are 60-80nm in diameter, some 
of these vesicles are able to increase their size to accommodate the transport of larger cargo such 
as procollagen, which is 300-400nm (Jin et al., 2012).  The mechanisms of coat size regulation 
have long been investigated.  TANGO1 and its partner cTAGE5 were identified as proteins that 
interact with procollagen as well as Sec23/24 and are thought to recruit procollagen to nascent 
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COPII coats (Saito et al., 2009; Saito et al., 2011); however, it was not understood how this 
interaction allowed the coat to accommodate larger cargo because it was not thought that 
TANGO1 is a regulator of coat size.  The Schekman and Rape labs recently found that the E3 
ubiquitin ligase Cul3Klhl12 monoubiquitinates the outer layer coat protein Sec31, which drives the 
assembly of larger COPII coats and promotes the trafficking of procollagen (Jin et al., 2012).  
They propose that the ubiquitination event controls the size and function of the COPII coat.  This 
mechanism may also be used to regulate that size of coats for the transport of chylomicrons and 
VLDLs, which the Fisher lab is currently investigating.  Interestingly, studies investigating the 
mechanism by which ApoB containing lipoproteins are trafficked to the Golgi revealed that the 
ER exit process of ApoB is similar to that of other canonical cargo (Gusarova et al., 2003).  
Specifically, ApoB trafficking was dependent on Sar1 activity, since ApoB did not exit the ER in 
cells expressing a dominant negative version of Sar1, and the ApoB containing vesicles 
contained other COPII proteins (Gusarova et al., 2003).  However, Siddiqi et al., proposed a 
model that COPII proteins are not required for ER exit but are necessary for the fusion of 
vesicles with the Golgi (Siddiqi et al., 2003).  Nevertheless, mutations in Sar1 family members 
result in diseases such as Chylomicron Retention Disease (Roy et al., 1987; Nemeth et al., 1995) 
and Anderson Disease (Bouma et al., 1986; Dannoura et al., 1999), which are disorders of severe 
fat malabsorption and are associated with failure to thrive in infancy, suggesting that COPII 
vesicles are necessary to traffic chylomicrons (Jones et al., 2003). 
The final lipidation step, converting the ApoB containing pre-VLDL into a mature 
VLDL, is proposed to take place after the lipoprotein has exited the ER, either in the Golgi or in 
a pre-Golgi compartment (Bamberger and Lane, 1990; Stillemark et al., 2000; Swift et al., 2001; 
Tran et al., 2002; Gusarova et al., 2003); however, other studies provide evidence that the ER 
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may be the location of final VLDL assembly (Kulinski et al., 2002; Yamaguchi et al., 2003).  
Overall, ApoB shares many similarities with canonical secretory proteins with regard to its 
synthesis, translocation, and trafficking; however, its distinct features, such as the large size, 
hydrophobic domains, and pause transfer sequences, also lead to unique characteristics.                 
1.3 POST-TRANSLATIONAL MODIFICATIONS IN THE ENDOPLASMIC 
RETICULUM  
Approximately one-third of all proteins traverse the secretory pathway and are either secreted or 
inserted into membranes to perform their specific functions (Guerriero and Brodsky, 2012).  
Nascent secretory proteins, such as ApoB, begin this journey in the ER where they undergo 
several post-translational modifications, such as signal sequence cleavage, N-linked 
glycosylation, and disulfide bond formation, which contribute to the protein’s native fold. 
1.3.1 Signal Sequence Processing 
For proteins to enter the secretory pathway, they must first be directed to the ER.  In order for 
this to occur, secretory proteins are synthesized as pre-proteins with amino-terminal extensions 
that act as “zipcodes” targeting the protein to the ER.  Specifically, as soluble secreted proteins 
emerge from the exit tunnel of the ribosome, they present a cleavable signal sequence at their 
amino terminus that is approximately 20-30 amino acids and contains features such as a basic 
motif, a hydrophobic core, and a short polar region (Hegde and Bernstein, 2006).  ApoB has a 27 
amino acid signal sequence, which is cleaved upon entrance into the ER (Chuck and Lingappa, 
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1992, 1993).  Mutations in the signal sequence have been linked to deficiencies in ApoB 
secretion causing hyperlipidemia (Sturley et al., 1994).   
In the cytosol, a ribonucleoprotein called the signal recognition particle (SRP) acts as a 
targeting factor and binds to the emerging signal sequence, which causes translational pausing 
(Keenan et al., 2001; Wild et al., 2004; Saraogi and Shan, 2011). Upon translational pausing, the 
entire ribosome-nascent chain complex is directed to the ER membrane where the SRP binds to a 
heterodimeric membrane bound SRP receptor (SR) (Powers and Walter, 1997) and the ribosome 
attaches to the translocation machinery in the membrane through its membrane-attachment site 
(M-site), forming a tight seal with the translocon (Saraogi and Shan, 2011).  The SRP is then 
released from the signal sequence of the nascent protein and translation resumes.   
As translation recommences, the nascent polypeptide is inserted into the pore of the 
Sec61 translocon.  The nascent protein’s signal sequence binds to a specific site within the Sec61 
translocon, which triggers the opening of the pore.  The binding of the signal sequence to this 
site triggering the pore opening is thought to protect aberrant proteins from entering the lumen of 
the ER and calcium from leaking out (Hizlan et al., 2012).  As the growing polypeptide chain 
emerges into the lumen of the ER, cleavage sites adjacent to the signal sequence, which remains 
bound within the pore of the Sec61 translocon, are recognized by a membrane bound signal 
peptidase and cleaved (Stroud and Walter, 1999).  Even after cleavage, the signal sequence 
remains bound to the pore of the translocon while the remainder of the protein is translocated 
into the ER lumen.  In higher eukaryotes, after the protein has been completely translocated into 
the ER lumen, the pore closes, and the translocon opens laterally to the lipid bilayer, allowing the 
signal sequence to diffuse into the bilayer where it is degraded (Weihofen et al., 2002; Brodsky 
and Skach, 2011).  A diagram of protein translocation into the ER is shown in Figure 3.   
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The nascent protein within the ER lumen is now exposed to a multitude of molecular 
chaperones.  These chaperones can either aid in the post-translational modification and proper 
folding of the protein or recognize a protein that is terminally misfolded and target that protein 
for degradation.  Examples of two post-translational modifications that occur within the ER are 
discussed in the following sections. 
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Figure 3.  Soluble secretory proteins are targeted to the ER by a cleavable signal sequence 
(1) A nascent polypeptide emerging from the ribosome exit tunnel exposes a signal sequence (SS in yellow) that is 
recognized and bound by the signal recognition particle (SRP in purple), causing translational pausing.  (2) The SRP 
directs the entire complex to the ER membrane where it binds to a membrane bound SRP receptor (SR).  (3) As 
translation recommences, the polypeptide translocates through Sec61 and the SS binds within the translocon.  (4) The 
signal peptidase cleaves the SS, which remains bound in the translocon, from the rest of the polypeptide.  (5) The 
protein fully translocates into the ER lumen and the translocon opens laterally to allow the SS to diffuse into the lipid 
bilayer.  (6) Inside the ER lumen, the polypeptide folds into its native conformation and post-translational 
modifications, such as disulfide bond formation (S-S) and glycosylation (Y), take place. 
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1.3.2 Asparagine-linked Glycosylation 
One post-translational modification that occurs within the ER lumen is the addition of sugar 
moities onto asparagine residues within the consensus sequence Asn-X-Ser/Thr, termed N-linked 
glycosylation (Moremen et al., 2012).  These sugar moities, called glycans, are transferred as 
preformed precursor oligosaccharides, composed of two N-acetylglucosamines, nine mannoses, 
and three glucoses, onto the NH2 group of asparagines within the consensus sequence as they 
enter through the translocon into the lumen of the ER (Schwarz and Aebi, 2011).  N-linked 
glycans serve numerous functions in the cell.  They can act as timers for protein folding, stabilize 
protein structure, protect proteins from proteolysis, and mediate protein-protein interactions.  
Additionally, N-linked glycans facilitate the interaction of glycoproteins with the ER quality 
control lectins, calnexin and calreticulin (Larkin and Imperiali, 2011; Schwarz and Aebi, 2011; 
Moremen et al., 2012).  
 As explained above, the sugar moity added to asparagine residues on nascent proteins is a 
precursor oligosaccharide.  Once the 14-sugar chain has been added to the protein, an enzymatic 
trimming reaction catalyzed by glucosidase I and II cleaves two of the three glucose residues 
(Deprez et al., 2005).  Following this cleavage reaction, the ER quality control lectins calnexin 
and calreticulin can bind to glycans on proteins that are incompletely folded, retaining the 
proteins in the ER and allowing them time to achieve their correct folded conformation (Aebi et 
al., 2010).  The interaction of the lectins with the glycoprotein is maintained until the third 
glucose is trimmed from the chain by ER glucosidase II and the protein is released (Sousa and 
Parodi, 1995).  At this point, an evaluation of the folded state of the protein is made by the 
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enzyme UDP-glucose:glycoprotein glycosyltransferase.  If the protein has not achieved its folded 
state, the enzyme will add a glucose back to the chain, renewing the affinity for calnexin and 
allowing it more time to remain in the ER and fold properly.  This cycle can continue until the 
protein has reached its folded conformation (Larkin and Imperiali, 2011; Schwarz and Aebi, 
2011; Moremen et al., 2012).  However, if the protein does not successfully fold within a 
timeframe, ER mannosidases remove mannose residues from the chain preventing re-entry into 
the calnexin cycle and targeting the protein for degradation by ER-Associated Degradation 
(ERAD) (Quan et al., 2008), which is described in section 1.4.2.2.  Among the ER mannosidases 
is the ER enhancing α-mannosidase-like protein I (EDEM I), which has been proposed to 
interact with specific glycan conformations to trim the mannoses, designating the protein for 
degradation (Oda et al., 2003; Cormier et al., 2009).  Interestingly, EDEM I has also been shown 
to interact with misfolded substrates regardless of their glycosylation state.  
Sixteen known genetic diseases, referred to as congenital disorders of glycosylation, arise 
from incorrect assembly or processing of N-linked glycans, which highlights the importance of 
N-linked glycosylation in human health (Jaeken, 2010; Guerriero and Brodsky, 2012).  
Additionally, the necessity of N-linked glycosylation in cellular homeostasis is evidenced by 
pharmacological manipulation of the pathway using the metabolite tunicamycin to inhibit early 
steps in the assembly of glycan chains.  When glycosylation is inhibited with tunicamycin, 
misfolded proteins accumulate in the ER causing an induction of the Unfolded Protein Response 
(UPR) (Prescher and Bertozzi, 2006), an adaptive signaling cascade to re-establish ER 
homeostasis.  Induction of the UPR has been implicated in a number of diseases from diabetes 
and neurodegeneration to a variety of cancers. 
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ApoB is subject to posttranslational modifications in the ER as it is folded into its native 
conformation and accumulates lipids to form pre-VLDLs.  N-linked glycosylation is one 
modification that affects the folding and secretion of ApoB.  ApoB100 has 19 putative N-
glycosylation sites, and 16 of those have been confirmed to be glycosylated in vivo (Figure 2) 
(Yang et al., 1989).  The C-terminal β2 domain of ApoB100 is highly glycosylated, containing 
10 of the 16 utilized glycosylation sites (Harazono et al., 2005).  Several laboratories have 
investigated the role of these carbohydrate moities on ApoB physiology.  Proteasomal and non-
proteasomal degradation of ApoB were both enhanced when a human hepatocyte cell line was 
treated with the N-glycoslation inhibitor tunicamycin (Liao and Chan, 2001).  Studies on 
truncation mutants of ApoB containing asparagine to glutamine mutations showed decreased 
secretion efficiency and reduced lipid-binding affinity of the mutants (Vukmirica et al., 2002).  
These studies indicate that efficient N-linked glycosylation is essential for secretion of the 
lipoprotein particle.                     
1.3.3 Disulfide Bond Formation 
A second post-translational modification that occurs within the oxidizing environment of the ER 
lumen is disulfide bond formation.  Disulfide bonds form through the oxidation of free thiol 
groups of two cysteine residues, either within one protein (intramolecular disulfide bond) or 
between cysteines from two different proteins (intermolecular disulfide bonds) (Hatahet and 
Ruddock, 2009).  Intramolecular disulfide bonds provide proteins structural stability and help 
proteins achieve the correct folded conformation.  Intermolecular disulfide bonds function to 
maintain the structure of oligomeric protein complexes (Hatahet and Ruddock, 2009).  Improper 
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formation and maintenance of disulfide bonds can lead to diseases, such as Marfan syndrome 
(Whiteman and Handford, 2003) and von Willebrand disease (Schneppenheim et al., 1996). 
As described in section 1.2.1, ApoB100 is a cysteine rich, secreted protein that is subject 
to disulfide bond formation upon translocation into the ER lumen.  ApoB100 has 25 cysteines, 
16 of which are linked by intramolecular disulfide bonds (Figure 2) (Yang et al., 1989; Yang et 
al., 1990).  Interestingly, the N-terminal βα1 domain of ApoB (approximately 21% of full length 
ApoB100) contains 14 of the 25 cysteines, all of which are disulfide bonded, accounting for 7 of 
the 8 disulfide bonds found in full length ApoB100 (Yang et al., 1990; Burch and Herscovitz, 
2000).  The high disulfide bond content is predicted to make this region highly compact, which 
correlates with structural data (Segrest et al., 2001; Johs et al., 2006).  Formation of disulfide 
bonds is critical for maturation of ApoB (Huang and Shelness, 1997; DeLozier et al., 2001) and 
when disulfide bond formation is inhibited using the reagent dithiothreitol (DTT), ApoB is not 
secreted (Burch and Herscovitz, 2000).  In addition, mutations in cysteines 7 and 8 that form a 
disulfide bond in ApoB have been shown to diminish VLDL assembly and secretion (Tran et al., 
1998; DeLozier et al., 2001), highlighting the necessity of this posttranslational modification for 
homeostasis.   
1.3.3.1 Protein Disulfide Isomerases 
A family of enzymes known as Protein Disulfide Isomerases (PDIs), named for the 
founding member of the family, PDI, catalyze the formation of disulfide bonds in the ER 
(Hatahet and Ruddock, 2009).  In addition to catalyzing oxidation reactions, PDIs also catalyze 
reduction and isomerization reactions, and some family members have chaperone activity (Cai et 
al., 1994; Song and Wang, 1995; Klappa et al., 1998; Gillece et al., 1999; Ellgaard and Ruddock, 
2005; Tian et al., 2006; Tian et al., 2008; Hatahet and Ruddock, 2009).  Thus, PDIs are able to 
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make, break, and rearrange disulfide bonds to help proteins achieve their correct folded 
conformation, since in their native state proteins tend to only have one pattern of disulfide bonds 
and free thiol groups.  PDIs catalyze these reactions through thiol groups on cysteine residues 
within their thioredoxin-like active sites, which have the consensus sequence Cys-X-X-Cys 
(Edman et al., 1985).  The two cysteines in the active site are able to cycle between an oxidized 
(S-S) and reduced (-SH HS-) state to interact with disulfides and free thiols on substrate proteins 
(Figure 4) (Hatahet and Ruddock, 2009).  In yeast, PDI is able to re-enter into cycles of oxidation 
and reduction with substrates by being reduced or oxidized by glutathione (Chakravarthi and 
Bulleid, 2004; Molteni et al., 2004) and the protein Ero1 (Mezghrani et al., 2001), both of which 
are present in the ER.  In mammals, two Ero1 enzymes exist, Ero1α and Ero1β, which serve as 
the primary oxidases for PDI (Araki and Inaba, 2012).  Although yeast Ero1 is an essential 
protein, Ero1α and Ero1β are dispensable in mammals.  Surprisingly, homozygous mice with 
almost complete loss-of-function mutations in Ero1α and Ero1β (Ero1αi/i;βi/i) are viable (Zito et 
al., 2010a), which suggests that in mammals Ero1 independent oxidative pathways exist (Araki 
and Inaba, 2012).  Candidates for members of an alternative oxidative pathway include Prx4 
(Tavender and Bulleid, 2010), which metabolizes H2O2 by reducing it to water, and the 
sulfhyrdyl oxidoreductases QSOX (Zito et al., 2010b).   
PDI, the founding member of the PDI family (Goldberger et al., 1964), has two 
thioredoxin-like active site domains, denoted the a and a’ active site, each with the amino acid 
sequence CGHC (Edman et al., 1985; Darby et al., 1996; Freedman et al., 1998; Alanen et al., 
2003).  The a and a’ active sites are separated by two other domains that have similarity to 
thioredoxin, a small cytoplasmic enzyme, which is involved in thiol-dependent redox reactions 
(Funato and Miki, 2007; Lemaire et al., 2007; Lillig and Holmgren, 2007; Hatahet and Ruddock, 
2009).  However, these other domains, denoted the b and b’ domains, lack enzymatic activity.  
The b’ domain provides a hydrophobic binding pocket for substrates that is responsible for PDI’s 
chaperone activity (Cai et al., 1994; Song and Wang, 1995; Klappa et al., 1998; Gillece et al., 
1999; Ellgaard and Ruddock, 2005; Tian et al., 2006; Tian et al., 2008; Hatahet and Ruddock, 
2009). 
Figure 4.  Role of PDIs in oxidation, reduction, and isomerization reactions 
(A) Reduction of a substrate by PDI occurs when PDI in its reduced state donates electrons to the substrate, forming a 
disulfide bond between its own cysteines and breaking the disulfide bond of the substrate, forming two sulfhydryl 
groups.  PDI in its oxidized state can be reduced by reduced glutathione (GSH) or Ero1. (B) Oxidation of a substrate 
occurs when electrons are transferred from the disulfide in oxidized PDI to the reduced substrate, forming a disulfide 
bond in the substrate and leaving PDI in the reduced state.  PDI  can  be  re -oxidized by Ero1 and GSSG. (C) 
During isomerization reactions there is no net change in redox potential, but substrates cycle forming intermediate 
mixed disulfides with PDI before achieving their native conformation. 
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1.3.3.2 Yeast PDIs 
The physiological functions of PDI family members are not currently clearly defined.  Members 
of the PDI family are identified by having sequence or structural homology to thioredoxin, but 
not all PDI family members have been shown to exhibit redox activity (Hatahet and Ruddock, 
2009). Different organisms have different numbers and types of PDIs, some of which may be 
functionally related and others that appear to be unique to a subset of organisms.  The yeast, 
Saccharomyces cerevisiae, has five PDI family members (Tachikawa et al., 1991; Tachibana and 
Stevens, 1992; Tachikawa et al., 1995; Tachikawa et al., 1997; Wang and Chang, 1999; Xiao et 
al., 2004; Hatahet and Ruddock, 2009), which are among the best characterized of this class of 
proteins. In contrast, humans have 21 currently identified PDI family members (Benham, 2012).  
See Table 1 for a list of all currently identified yeast and human PDIs. 
Of the five genes encoding yeast PDI family members - PDI1, MPD1, MPD2, EUG1, 
and EPS1 - only one, PDI1, is essential (Farquhar et al., 1991).  However, any of these genes can 
compensate for the loss of PDI1 when over-expressed (Norgaard et al., 2001).  Interestingly, 
when all five of the yeast PDI genes are deleted, only expression of PDI1 or over-expression of 
MPD1 can restore viability (Norgaard et al., 2001), implying that the yeast PDIs are not 
completely functionally redundant.   
Yeast Pdi1 shares a similar domain organization to human PDI (a-b-b’-a’), having two 
active sites and two catalytically inactive sites, with the b’ domain providing a hydrophobic 
chaperone-like binding pocket (Holst et al., 1997; Gillece et al., 1999; Tian et al., 2008).  The 
crystal structure of Pdi1 indicates that the protein forms a U-shaped molecule with the two redox 
active sites located across from each other at the top of the “U” and the substrate binding domain 
located within the base or pocket of the “U” opening.  It is thought that substrates may bind in 
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the b’ domain and the redox active arms of Pdi1 may bend down to interact with the substrate 
(Tian et al., 2008).   
The other four yeast PDIs share similarities with Pdi1, but also have unique attributes 
(Table 1) (Norgaard et al., 2001).  Mpd1 and Mpd2 are both soluble PDIs that have only one 
active site domain (a domain), with the sequences CGHC and CQHC respectively (Tachikawa et 
al., 1995; Tachikawa et al., 1997).  Relatively little is known about Mpd2, but the crystal 
structure of Mpd1 was solved (Vitu et al., 2008) and shows a protein with two clear thioredoxin-
like folds, one redox active (a domain) and one redox inactive (b domain).  The relative 
orientation of the two Mpd1 domains is quite different compared to Pdi1.  While the active site 
domains of Pdi1 are thought to act as flexible arms, the two domains of Mpd1 are fixed and are 
inflexible (Vitu et al., 2008).  The differences in the crystal structures of the two yeast PDIs most 
likely indicate substrate specificity among these proteins.  Another interesting feature of Mpd1 is 
that it associates with Cne1, the yeast homolog of calnexin, and this association increases the 
reductive potential of Mpd1 and abolishes the chaperone activity of Cne1 (Kimura et al., 2005).   
Eug1 is another soluble yeast PDI and shares the same domain orientation as Pdi1 (a-b-
b’-a’) (Tachibana and Stevens, 1992).  Interestingly, the two active sites of Eug1 have a C-
terminal serine residue instead of a cysteine residue, C-X-X-S. The a and a’ active site sequences 
are CLHS and CIHS respectively (Tachibana and Stevens, 1992).  These active site sequences 
indicate that Eug1 may have isomerase activity, but not oxidation or reduction potential, since 
these functions require thiols from two cysteine residues in one active site to cycle between an 
oxidized and reduced state to interact with substrates (Figure 4).  Interestingly, although Eug1 
does not have redox activity, it has been shown to interact with the last member of the yeast PDI 
family, Eps1, and to enhance its reductive and chaperone activities (Kimura et al., 2005).  
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The final yeast PDI family member is Eps1, the only transmembrane protein among this 
group.  Eps1 is homologous to the mammalian PDI TMX and has been shown to bind to Kar2, 
the yeast homolog of BiP, Pdi1, Mpd1, and Eug1 (Kimura et al., 2005).  Eps1 has one active site 
with the sequence CPHC (Wang and Chang, 1999).  Eps1 has been implicated in ER quality 
control, as deletion of this gene suppresses a dominant negative mutation of the plasma 
membrane ATPase, Pma1-D378N (Wang and Chang, 1999).  The plasma membrane localized 
Pma1 is essential for yeast growth and the D378N mutation prevents this protein from trafficking 
to the plasma membrane; however, upon deletion of EPS1, both wild type and mutant Pma1 
traffic normally to the plasma membrane, indicating that Eps1 is involved in retaining the mutant 
protein in the ER.  Eps1 may act to recognize the mutant form of Pma1 through its chaperone 
binding domain at the plasma membrane and act as a bridge to other PDI proteins or to Kar2 
since it interacts with each of these.  Interestingly, Eps1 does not affect other ERAD substrates, 
indicating that there is specificity among the family members.   
1.3.3.3 Mammalian PDIs 
  Each of the 21 human PDIs (Table 1) shares at least one domain with similarity to one 
of the four PDI domains (Benham, 2012).  Due to similarities in their domain organizations and 
active sites it is likely that at least a subset of PDIs will have similar redox potentials, although 
the kinetics of these reactions may differ.  PDI, ERp57, PDIp, ERp72, and P5 when 
recombinantly expressed and purified all show similar ability in vitro to catalyze the oxidation of 
a disulfide bond in a peptide substrate (Alanen et al., 2006).  However, the large number, unique 
tissue distribution, and features of the PDIs may indicate distinct physiological functions for each 
of the family members.  The physiological functions may be determined by their interactions 
with other proteins and not necessarily by their disulfide chemistry.  Due to the sizeable number 
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of PDIs, detailed physiological studies of each of their individual functions have not been 
performed, but initial studies on select family members have been executed.  Examples of 
physiological functions of some of the better characterized PDI family members follow.  For a 
listing of known substrates of PDIs see Table 1. 
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Table 1.  Properties and substrates of identified PDI family members 
Name Domains Active Site Sequences Known Substrates*
PDI a-b-b'-a' CGHC, CGHC
Ero1!, ApoB, cholera toxin, SV40, pro-
insulin, lysozyme, ADAM17
PDIp a-b-b'-a' CGHC, CTHC
ERp57 a-b-b'-a' CGHC, CGHC
Ero1!, SV40, MHC-I, laminin "3, collagen, 
clusterin, lysyl hydroxylase 2, laminins ("1 
and #1), Integrins, LDL receptor, Plexin A1, 
Agrin, Fibrillin, Fibulin-like Protein, 
Discoidin, Lysyl oxidase 2, ADAM17, 
Adam10, Melanotransferin, 
Glucosyltransferase family member, 
Tapasin, 
ERp72 ao-a-b-b'-a' CGHC, CGHC, CGHC thrombospondin, thyroglobulin
PDIR b-ao-a-a' CSMC, CGHC, CPHC
P5 a-a'-b CGHC, CGHC MICA
PDILT a-b-b'-a' SKQS, SKKC calmegin, calsperin
ERdJ5 J-a-b-b-a-a-a CSHC, CPPC, CHPC, CGPC
ERp44 a-b-b' CRFS  adiponectin, IP3 Receptor
ERp46 ao-a-a' CGHC, CGHC, CGHC
Ero1!, lysyl hydroxylase 2, laminins ("1, "2, 
"3, #1 and #2), Integrins, collagen, LDL 
receptor, ERAP1, ERAP2, EDEM3, LTBP1, 
Polycystic Kidney Disease 1, 
apartyl/arparagine "-hydroxylase, Nidogen-
1, Peroxiredoxin IV
ERp18 a CGAC Ero1!, lysyl hydroxylase 2, laminins ("3 
and #2), ER glucosidase II, PTX3
ERp27 b-b' none
ERp29 b'-D none polyomavirus VPI
TMX a CPAC
TMX2 a SNDC
TMX3 a-b-b' CGHC
TMX4 a CPSC
TMX5 a CRFS
AGR2 a CPHS
AGR3 a CQYS
ERp90 Trx1-5 unknown
Pdi1 a-b-b'-a' CGHC, CGHC p!f, CPY*
Mpd1 a-b CGHC
Mpd2 a CQHC
Eug1 a-a' CLHS, CIHS
Eps1 a CPHC Pma1-D378N
Human 
PDI 
family 
members
Yeast 
PDI 
family 
members
* from (Hatahet and Ruddock, 2009; Jessop et al., 2009; Benham 2012) 
 28 
 
PDIs play an important role in lipid homeostasis.  As described in section 1.2.2, PDI is a 
subunit of MTP that is responsible for loading lipids onto ApoB as it is translocated into the ER 
(Wetterau et al., 1990).  PDI is thought to retain the M-subunit of the complex in the ER, since it 
does not have an ER retention signal (Wetterau et al., 1991).  Interestingly, when PDI levels 
were reduced specifically in hepatocytes, MTP activity decreased by approximately 40%, 
consistent with the reduction in PDI (Wang et al., 2012).    A second PDI involved in lipid 
homeostasis is ERp44, which is involved in the quality control of adiponectin (Wang et al., 
2007) and regulating the Inositol Phosphate-3 Receptor Type I (Higo et al., 2005).  
PDIs have also been implicated in developmental regulation and cancer.  In zebrafish, P5 
has been shown to be required for asymmetric patterning of the heart, pancreas, liver, and 
gastrointestinal tract (Hoshijima et al., 2002).  When P5 is inactivated with morpholinos, the 
patterning defect can be rescued with exogenous expression of P5, indicating that the deficiency 
arises solely from the loss of P5 (Hoshijima et al., 2002).  P5 has also been linked to cancer.  P5 
associates with MICA, a ligand for the natural killer cell activating receptor on the surface of 
tumor cells and reduces its disulfide bond, facilitating a cleavage reaction which allows MICA to 
be shed from the cell surface (Kaiser et al., 2007).  MICA shedding aids the tumor cell in 
immune evasion (Kaiser et al., 2007).  In turn the PDI family member AGR2 is important for ER 
homeostasis and is upregulated in a number of cancer cells, such as malignant prostate epithelial 
cells (Fletcher et al., 2003), ovarian high-grade serous carcinoma cells (Fletcher et al., 2003; 
Darb-Esfahani et al., 2012), and, along with another PDI family member, AGR3, in estrogen-
positive breast tumors (Thompson and Weigel, 1998).  Additionally, PDI is upregulated in 
several human cancers, although the relevance of upregulation is not clear.  These include 
prostate (Welsh et al., 2001), lung (Beer et al., 2002; Basso et al., 2005), and melanoma 
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(Talantov et al., 2005; Lovat et al., 2008).  In contrast, PDI’s activity is essential for survival and 
proliferation of ovarian cancer cells (Xu et al., 2012).  A recent study shows that inhibition of 
PDI using a small molecule inhibitor suppressed ovarian tumor growth without causing toxicity 
in non-cancerous cells (Xu et al., 2012).  Long term effects of blocking PDI function in normal 
cells was not addressed. 
A final function for PDIs, and one that is most relevant to the work described in Chapter 
2 is in ER quality control, through ERAD and ERAD-like phenomena.  The PDI ERp57 interacts 
with ER lectins calnexin and calreticulin (Oliver et al., 1999) and catalyzes the isomerization of 
disulfide bonds in glycoprotein substrates (Jessop et al., 2009).  If these substrates fail to 
properly fold, they are selected for ERAD.  For proteins to be degraded by ERAD they must be 
retrotranslocated from the ER into the cytosol, but in order for retrotranslocation to take place,  
disulfide bonds may have to be reduced.  Notably, the PDI ERdj5 reduces the disulfide bonds of 
misfolded proteins, and in association with EDEM and the chaperone BiP, promotes their ERAD 
(Ushioda et al., 2008; Hagiwara et al., 2011).  In addition, viruses and bacteria have evolved to 
co-opt the ERAD machinery, allowing them exit from the ER to the cytosol for productive 
infection.  Vibrio cholerae secrete cholera holotoxin, which is disassembled in the ER by PDI, 
facilitating the retrotranslocation of cholera toxin into the cytosol (Tsai and Rapoport, 2002; 
Taylor et al., 2011).  Furthermore, ERp29 triggers a conformational change in the polyomavirus 
protein VP1, which is necessary for its export into the cytosol for viral infection (Magnuson et 
al., 2005; Rainey-Barger et al., 2009).  Another polyomavirus, SV40, requires PDI and ERp57 
for its transport from the ER lumen (Schelhaas et al., 2007). 
At the start of my thesis project, very few PDI substrates had been identified and a 
significant question in the field was whether PDIs exhibit substrate specificity.  As time 
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progresses, more substrates and physiological roles for mammalian PDIs are being uncovered 
and it is becoming more obvious that there is specificity among the various members of this 
family; however, we are far from identifying all of the substrates and actions of the PDIs.  A 
primary hypothesis underlying my studies has been that ApoB is a potential substrate for PDI 
family members.  ApoB has 25 cysteines and forms eight disulfide bonds (Yang et al., 1989) that 
are necessary for the correct assembly and secretion of VLDL (Huang and Shelness, 1997; Tran 
et al., 1998; DeLozier et al., 2001).  ApoB has been shown to interact with PDI through the MTP 
complex (Hussain et al., 2003) and to associate with two other PDIs, ERp57 and ERp72 (Adeli 
et al., 1997; Linnik and Herscovitz, 1998; Zhang and Herscovitz, 2003).  The function of these 
PDI family members in ApoB biogenesis however, had not yet been addressed.  In Chapter 2, I 
investigated the role of PDI family members in the degradation and secretion of ApoB.    
 
1.4 APOLIPOPROTEIN B REGULATION AND RELATED DISEASES 
ApoB transport is essential for maintaining cellular homeostasis, and as a result defects in ApoB 
synthesis or regulation can lead to a number of diseases.  Naturally occurring non-sense or 
frameshift mutations in the ApoB gene result in the production of truncated versions of the ApoB 
protein; the truncated proteins are less competent to carry lipids than ApoB100 and result in low 
circulating levels of VLDL (McLeod et al., 1994; Whitfield et al., 2004).  Patients with these 
mutations have a condition known as hypobetalipoproteinemia, and exhibit symptoms that are 
associated with fat malabsorption such as ataxia, neuromuscular degeneration, and fat-soluble 
vitamin deficiencies (Linton et al., 1993; Whitfield et al., 2004).  The symptoms result from the 
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fact that peripheral tissues in these patients are starved for sufficient cholesterol and fatty acids.  
Additionally, patients develop a fatty liver because the tissue becomes overloaded with 
endogenously synthesized cholesterol that is unable to be secreted (Linton et al., 1993; Whitfield 
et al., 2004).  A second rare autosomal recessive disorder that results in the complete absence of 
ApoB containing lipoproteins is called abetalipoproteinemia.  Abetalipoproteinemia results from 
mutations that ablate the function of the MTP complex (Wetterau et al., 1992), which is 
necessary for loading ApoB with lipids (see section 1.2.2).  Patients with abetalipoproteinemia 
develop multi-systemic symptoms and are unable to solubilize fats and fat-soluble vitamins, 
which leads to failure to thrive and vitamin deficiencies (Whitfield et al., 2004).  Interestingly, a 
long-term, high-dose oral vitamin E treatment has been shown to eliminate some of the clinical 
manifestations of abetalipoproteinemia (Zamel et al., 2008). 
 In addition to human diseases arising from decreased circulating ApoB-containing 
lipoproteins, high circulating levels of ApoB have been linked to the development of 
atherosclerotic plaques and subsequently coronary artery disease (Sehayek and Eisenberg, 1994; 
Ginsberg, 2002).  In this much more common ApoB-linked disease, elevated levels of circulating 
LDL increase the risk of the lipoprotein being absorbed into the endothelial lining of the blood 
vessel wall where it can become oxidized (Kume et al., 1992; Camejo et al., 1998; Skalen et al., 
2002; Leitinger, 2003; Benn, 2009).  Oxidized LDL particles in the arterial wall trigger an 
inflammatory response, which generate an atherosclerotic lesion.  The lesions thicken the arterial 
wall and decrease the diameter of the artery, thus reducing the amount of blood that can pass 
through (Leitinger, 2003; Olofsson and Boren, 2005; Benn, 2009).  The resulting atherosclerotic 
plaques increase the risk of having a blood clot, heart attack, and stroke.       
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Coronary artery disease results from the hardening and narrowing of arteries due to the 
accumulation of atherosclerotic plaques that obstruct blood flow to the heart and is a leading 
cause of death in the United States.  Many cases of familial coronary artery disease have been 
linked to mutations in the LDLR that decrease the affinity of the receptor for ApoB (Goldstein 
and Brown, 1982).  As a result, more LDL particles circulate in the bloodstream and are unable 
to be cleared.  Several other factors can also contribute to high serum levels of LDL; for 
instance, a diet rich in fat, mutations in the TAG metabolizing enzyme LPL, and increased 
expression of ApoC-III, which inhibits LPL, can all lead to elevated levels of LDL in the 
bloodstream and atherosclerosis (Kwiterovich, 2000). 
Treatments for reducing plasma cholesterol carried by ApoB-containing lipoproteins are 
currently focused on statin treatment; there are several other medications that can lower LDL 
levels, albeit to a lesser extent (Joy, 2012).  Statins are a class of cholesterol lowering drugs that 
act by decreasing the synthesis of cholesterol in the liver by inhibiting the enzyme 3-hydroxy-3-
methyl-glutaryl (HMG)-CoA reductase (see section 1.4.2) (Endo et al., 1976).  Unfortunately, up 
to 25% of patients using statins are unresponsive to the treatment or have serious side effects 
such as myopathy and kidney disease (Yan et al., 2006).  Another serum cholesterol lowering 
treatment in clinical trials is mipomersen, an antisense oligonucleotide that inhibits expression of 
the APOB gene, thus reducing the amount of cholesterol that can be packaged and transported 
through the bloodstream (Ito, 2007).  Trials with mipomersen have reported modest decreases in 
serum cholesterol levels, although adverse side effects such as flu-like symptoms and increased 
intra-hepatic TAG levels were reported (Kastelein et al., 2006; Akdim et al., 2010; Visser et al., 
2010; Akdim et al., 2011).  A third group of cholesterol lowering treatments are MTP inhibitors 
(Joy, 2012).  As evident by patients with abetalipoproteinemia, inhibiting MTP prevents ApoB-
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containing lipoproteins from circulating in the bloodstream.  Non-specific as well as intestine-
specific MTP inhibitors are in development, but clinical trials for some of these drugs have been 
stalled due to increases in hepatic TAG levels (Chandler et al., 2003).  However, one non-
specific MTP inhibitor, Lomitapide, reduced TAG levels by 87% and LDL levels by 29% in rats 
(Dhote et al., 2011), but in human trials, adverse gastrointestinal and liver effects were observed 
(Cuchel et al., 2007).     
Currently each of the possible treatments for high serum cholesterol levels is either not 
sufficiently effective or comes with the risk of serious side affects (Joy, 2012).  Therefore, 
reducing plasma levels of ApoB through other methods will be greatly aided by identifying new 
therapeutic targets.  In order to identify new targets for reducing serum cholesterol levels, I have 
focused my efforts on understanding how ApoB is regulated.                            
 
1.4.1 Regulation of Apolipoprotein B Synthesis 
As mentioned in section 1.2.1 ApoB48 transcription is regulated by the enzyme apobec-1.  In 
humans, apobec-1 is expressed specifically in enterocytes and converts a cytidine in the ApoB 
mRNA to a uridine, creating a premature stop codon that creates a truncated version of the 
protein (Chen et al., 1987; Navaratnam et al., 1993).  As ApoB48 is found only in chylomicrons, 
which absorb dietary cholesterol, this conversion is restricted to the small intestine.   
Surprisingly, ApoB levels are predominantly regulated by degradation and not by the 
amount of ApoB synthesis; however, the availability of cholesterol and lipids determines 
whether ApoB is secreted or degraded and whether synthesis in the cholesterol biosynthetic 
pathway is regulated.  A rate-limiting step in the mevalonate pathway that generates cholesterol 
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and other isoprenoids is the conversion of HMG-CoA to mevalonate by the enzyme HMG-CoA 
reductase (Goldstein and Brown, 1990), this enzyme is the target of the statins.  HMG-CoA 
reductase transcription is regulated by sterol-mediated feedback inhibition, ensuring that 
cholesterol synthesis meets but does not exceed cellular requirements (Siperstein and Guest, 
1960; Goldstein and Brown, 1990; Goldstein et al., 2006).  When cholesterol is depleted, the 
transcription factor sterol regulatory element-binding protein (SREBP) traffics to the Golgi 
where it is cleaved and activated, allowing it to enter the nucleus and activate HMC-CoA 
reductase transcription (Espenshade and Hughes, 2007). Additionally, HMG-CoA reductase can 
be regulated by degradation via the ubiquitin-proteasome pathway, i.e. via ERAD (McGee et al., 
1996; Ravid et al., 2000). 
1.4.2 Regulation by Degradation 
As mentioned in the preceding sections, the correct folding of ApoB requires its proper targeting 
to the ER, the addition of posttranslational modifications such as N-glycans and disulfide bonds, 
and lipid loading by the MTP complex.  As evident by the fact that reduced levels of ApoB in the 
serum as well as excess circulating ApoB both lead to disease states, the assembly and secretion 
of ApoB-containing lipoproteins must be a highly regulated process.  The regulation of ApoB 
occurs predominantly through cotranslational and posttranslational targeting of ApoB for 
degradative pathways (Brodsky and Fisher, 2008; Ginsberg and Fisher, 2009).  These processes, 
described in the following sections, are mainly controlled by the availability of core lipids to load 
onto the lipoprotein, the variety of dietary fatty acids consumed, and by hormonal signaling.        
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1.4.2.1 Autophagy 
 
One degradative pathway that regulates ApoB secretion is a form of autophagy called Post-ER 
Presecretory Proteolysis (PERPP) (Fisher et al., 2001).  Autophagy mediates the degradation of 
cytosolic proteins, protein aggregates, and fragments of damaged organelles, by engulfing the 
substrates in vesicles called autophagosomes so that they are delivered to the lysosome and 
degraded (Levine and Kroemer, 2008; Martinez-Borra and Lopez-Larrea, 2012).  PERPP is a 
posttranslational process that acts on ApoB that has been lipid loaded and trafficked from the ER 
to the Golgi but that has been damaged by oxidative stress, causing the formation of aggregates 
(Fisher et al., 2001; Djousse et al., 2003).  Polyunsaturated fatty acids consumed in the diet, such 
as eicosapentaenoic acid and docosahexaenoic acid, stimulate PERPP due to the oxidative stress 
caused by their metabolism (Pan et al., 2004).  Interestingly, these data correlate with studies 
indicating that a diet rich in omega-3 fatty acids, which oxidize ApoB to result in a decreased 
risk for the development of coronary artery disease (Williams and Fisher, 2005).  The oxidative 
stress-induced degradation of ApoB aggregates requires active autophagy since this process is 
inhibited by the compounds 3-methyladenine and E64d, or when the autophagy–requiring gene 
Atg7 is depleted by siRNA treatment (Pan et al., 2008).   
In addition to PERPP, which is stimulated by polyunsaturated fatty acids, there are other 
examples of post-ER degradation of ApoB.  The ApoB mutant A31P that is associated with 
familial hypobetalipoproteinemia was found to traffic through the ER and to the Golgi; however, 
secretion of this mutant protein was impaired (Zhong et al., 2010).  It was discovered that the 
A31P mutant was degraded by the lysosome after trafficking to the Golgi (Zhong et al., 2010).  
In addition to polyunsaturated fatty acids, another factor that enhances the degradation of ApoB 
 36 
by PERPP is insulin (Chirieac et al., 2000; Taghibiglou et al., 2000; Chirieac et al., 2004; 
Biddinger et al., 2008).  While the mechanisms that select ApoB for PERPP are still poorly 
understood, the Golgi-localized protein sortilin was recently shown to act as a sorting receptor 
that binds to ApoB-containing lipoproteins and targets them for lysosomal degradation 
(Musunuru et al., 2010; Strong et al., 2012).  Future research efforts are sure focus on defining 
the factors that specifically target ApoB to the autophagic pathway and to the lysosome, and may 
uncover new therapeutic targets for lowering the production of atherogenic lipoproteins.  
1.4.2.2 Endoplasmic Reticulum Associated Degradation (ERAD) 
 
While degradation by PERPP occurs posttranslationally and is dependent on lysosomal 
proteases, the second degradative pathway that regulates ApoB biogenesis is ERAD and occurs 
cotranslationally.  ERAD is a quality control mechanism that prevents the accumulation of 
misfolded proteins in the ER through molecular chaperone recognition, polyubiquitination, 
retrotranslocation, and proteasomal degradation of the misfolded substrate (for a recent review 
see (Guerriero and Brodsky, 2012)).  Interestingly, the ERAD of ApoB is unique because it 
occurs cotranslationally and is metabolically regulated (Dixon et al., 1991; Yeung et al., 1996; 
Benoist and Grand-Perret, 1997; Fisher et al., 1997; Yao et al., 1997; Liao et al., 1998; Mitchell 
et al., 1998; Gusarova et al., 2001; Pariyarath et al., 2001; Liang et al., 2003; Oyadomari et al., 
2006; Fisher et al., 2008).   
 As ApoB is synthesized by the ribosome, it is cotranslationally translocated into the ER, 
where it is loaded with lipids by the MTP complex (see above and section 1.2 (Hussain et al., 
1997)).  When the MTP complex is functional and lipids are abundant, ApoB is fully 
translocated into the ER and assembles into a pre-VLDL that can be trafficked from the ER to 
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the Golgi, where it undergoes further maturation (Figure 5)(Gusarova et al., 2003).  Within the 
ER lumen, ApoB interacts with a number of molecular chaperones that help fold ApoB into its 
correct conformation and determine if it has properly assembled into a pre-VLDL.  Some of 
these chaperones include BiP, p58IPK, GRP94, ERp57, ERp72, PDI, calnexin, and calreticulin 
(Adeli et al., 1997; Benoist and Grand-Perret, 1997; Linnik and Herscovitz, 1998; Tatu and 
Helenius, 1999; Zhang and Herscovitz, 2003; Oyadomari et al., 2006).  When ApoB is 
improperly folded, these chaperones target the protein for ERAD, although in most cases this has 
not been specifically shown.  In one example however, glucosamine treatment of hepatic cells 
led to increased levels of BiP in the ER and, in turn, ApoB100 ubiquitination and proteasomal 
degradation were enhanced (Qiu et al., 2005).  Additionally, in the absence of the BiP interacting 
co-chaperone p58IPK ApoB ERAD was reduced (Oyadomari et al., 2006).     
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Figure 5.  ApoB ERAD is metabolically regulated by lipid availability 
(A) (1) When a sufficient amount of lipids are available in the ER, the MTP complex loads ApoB with lipids and 
it is assembled into a pre-VLDL.  (2) The pre-VLDL is packaged into a COPII vesicle and (3) traffics from the ER 
to the Golgi.  (4) If the pre-VLDL passes a quality control event it undergoes further maturation and can be 
secreted.  If the lipoprotein has been oxidatively damaged or does not pass quality control, it is degraded by  
PERPP.  (B) (1) When lipids are limiting in the ER, the MTP complex cannot assemble ApoB into a pre-VLDL.  
(2) ApoB loops accumulate in the cytosol due to ongoing synthesis that are recognized by the heat shock proteins 
Hsp70 and Hsp90.  (3) ApoB is polyubiquitinated, retrotranslocated out of the ER and into the cytosol and (4) 
degraded by the 26S proteasome. 
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When the MTP complex is not fully functional, or during times when the intracellular 
concentrations of phospholipids and TAG are depleted, cotranslational translocation of ApoB 
into the ER stalls and loops of ApoB protein are exposed to the cytosol due to continued 
translation in the absence of translocation (Dixon et al., 1991; Yeung et al., 1996; Fisher et al., 
1997; Liao et al., 1998; Pariyarath et al., 2001; Cardozo et al., 2002).  The cytoplasmic loops of 
ApoB are bound by the heat shock proteins Hsp70 and Hsp90, which target the protein for 
degradation by ERAD (Fisher et al., 1997; Gusarova et al., 2001).  Following recognition by the 
heat shock proteins, ApoB is poly-ubiquitinated by the E3 ubiquitin ligase Gp78, 
retrotranslocated out of the same Sec61 translocon into which it was inserted, and degraded by 
the 26S proteasome (Figure 5) (Yeung et al., 1996; Benoist and Grand-Perret, 1997; Zhou et al., 
1998; Du et al., 1999; Gusarova et al., 2001; Zhang et al., 2001; Liang et al., 2003).  Unlike the 
majority of ERAD substrates that are fully translated and translocated into the ER lumen or 
membrane before they are targeted for ERAD, ApoB is unique in that it is degraded 
cotranslationally and remains associated with the Sec61 translocon during degradation (Mitchell 
et al., 1998; Oyadomari et al., 2006).  
 40 
 
 
  
!"
#$
%&
&'
()#*+,-./0/1-2#3'
-34'567)62#3'
()#*468)-4-2#3'
!"#$
%&'(()$
%&'*)$
%&'+)$
,'*-$
'.-/#0$
1'23$
Figure 6.  Mammalian proteins that contribute to ApoB biogenesis 
The secretion and degradation of ApoB are finely balanced to ensure that the risk of disease from inadequate or 
excess circulating cholesterol is minimized.  The MTP complex and the heat shock protein Hsp110 have been 
shown to favor ApoB stabilization and promote its secretion, while p58IPK, Gp78, and the heat shock proteins 
Hsp70 and Hsp90 have been shown to promote ApoB degradation when conditions do not favor lipoprotein 
assembly.  
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Although a number of factors involved in the ERAD of ApoB have been identified (see 
below) and (Figure 6), it is likely that many more contribute to this process, and several 
questions with regards to the mechanism underlying ApoB degradation remain.  For example, 
Gp78 has been identified as the E3 ubiquitin ligase for ApoB (Liang et al., 2003), but there are 
many functionally redundant E3s in the cell (Nakatsukasa et al., 2008).  Do any of the other 
ubiquitin ligases participate in ApoB turnover?  Additionally, a previous graduate student in the 
Brodsky lab, Stacy Hrizo showed that ApoB29 is stabilized in yeast lacking the E2 ubiquitin 
conjugating enzyme Ubc7; however, the mammalian E2 for ApoB has not been identified.  As 
mentioned above and in section 1.3.3 ApoB forms eight disulfide bonds and interacts with the 
PDI family members PDI, ERp57, and ERp72.  Although PDIs have been shown to function in 
ERAD and ERAD-like processes (Wang and Chang, 2003; Schelhaas et al., 2007; Ushioda et al., 
2008; Moore et al., 2010; Hagiwara et al., 2011), and that ERp57 and ERp72 bind ApoB it is 
unknown whether these PDIs directly contribute to ApoB degradation, which was a main focus 
of my dissertation research.  In addition, whether the ER mannosidase, EDEM-I, which interacts 
with proteins and targets them for degradation, is involved in the recognition and degradation of 
ApoB has not been investigated.  Another important question regards the fact that the ribosome 
associates with the Sec61 translocon pore to facilitate entry of proteins into the ER.  But, during 
ApoB retrotranslocation this association must change, allowing a gap to form between the 
ribosome and Sec61 so that ApoB loops can slip out into the cytosol.  Are there proteins that 
regulate the interaction between the ribosome and Sec61 or facilitate the reversed direction of 
ApoB transport through the channel, an event that dictates translocation vs retrotranslocation?  
Finally, after ApoB is retrotranslocated from the ER, how is the lipoprotein maintained in a 
soluble state in the cytosol before being degraded by the proteasome?  Are there chaperones or 
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chaperone-complexes that prevent ApoB aggregation in the cytosol?  Some of these questions 
have been addressed in Chapters 2 and 3, while speculation as to the answers of the other 
questions are presented in Chapter 4.       
1.5 MODEL SYSTEMS TO STUDY APOB 
1.5.1 Mouse Models 
When studying atherosclerosis in animals, the mouse model is the predominant system, due to 
the ability to construct transgenics and the significant decrease in cost compared to rabbits and 
primates (Veniant et al., 2008).  A number of knockout and conditional mice have been created 
to study lipoprotein trafficking, with the hope that we can better understand the processes leading 
to the development of atherosclerosis.  LDL receptor deficient mice (Ldlr-/-) have been used to 
model familial hypercholesterolemia (Ishibashi et al., 1993; Ishibashi et al., 1994; Farese et al., 
1996; Powell-Braxton et al., 1998).  When fed on a normal chow diet, these mice develop 
moderate increases in circulating LDL associated cholesterol and atherosclerotic lesions 
(Nakashima et al., 1994).  Additionally, to better study the contribution of ApoB isoforms to the 
development of atherosclerosis, the Young lab developed models with mice that solely expressed 
ApoB48 (Apob48/48) or ApoB100 (Apob100/100) (Veniant et al., 1998).  When the Apob100/100 mice 
were crossed with Ldlr-/- mice the offspring had extremely high plasma cholesterol levels, much 
higher than the offspring when the same cross was performed with ApoB48/48 mice (Veniant et 
al., 1998).  These data provide support that the LDL receptor clears ApoB100 from the 
bloodstream.  Another mouse model that contributed to our knowledge of the ApoB biogenesis 
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pathway was the MTP+/- mouse.  Consistent with MTP’s role in the loading of lipids onto ApoB 
and the assembly of VLDLs, MTP+/- mice had a 50% reduction in LDL cholesterol and a 28% 
reduction in circulating ApoB100 (Raabe et al., 1998).  In contrast, MTP-/- mice were 
embryonically lethal (Raabe et al., 1998), indicating the importance of lipid homeostasis in 
development.   
Although the mouse model is extremely useful in understanding the full range of effects 
when ApoB biogenesis is modulated in an organism, teasing out pathways contributing to ApoB 
biogenesis and identifying key protein regulators can be quite difficult and time consuming.  As 
a result, other model systems have been used to elucidate factors contributing to ApoB secretion 
and degradation, including primates, cell culture models, a cell-free in vitro system, and a yeast 
expression system.  
1.5.2  Non-human Primates 
Another organism used to study the contribution of ApoB to the development of atherosclerosis 
is a non-human primate, the cynomolgus monkey.  To determine whether reduced levels of 
circulating ApoB could reduce serum cholesterol levels in primates, APOB-specific siRNAs 
were encapsulated in stable nucleic acid lipid particles and intravenously injected into monkeys 
(Zimmermann et al., 2006).  A dose dependent silencing of APOB was observed in the liver of 
treated monkeys and was maintained for 11 days following injection.  As early as 12 hours after 
siRNA injection, plasma levels of ApoB100 were reduced and maximum reduction was achieved 
by 72 hours.  Serum cholesterol levels were reduced by 62%, which in patients with 
hypercholesterolemia would be clinically significant and exceeds the amount of cholesterol 
reduction achieved by approved cholesterol lowering drugs (Zimmermann et al., 2006).  This 
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study was the first to show that clinically relevant RNAi treatments could be used in primates 
and supports the use of RNAi therapeutics as a new class of drugs.  Additionally, this work 
established the cynomolgus monkey as a model for studying cholesterol related diseases in non-
human primates.       
1.5.3 Tissue Culture Systems 
Three cell lines are most commonly used to study ApoB biogenesis, McArdle-RH7777 cells, 
Huh7 cells, and HepG2 cells.  McArdle cells are rat hepatoma cells that express substantial 
amounts of both ApoB100 and ApoB48 (see section1.2.1) (Fainaru et al., 1977; Windmueller 
and Spaeth, 1985; Leighton et al., 1990).  McArdle cells express the MTP complex (Swift et al., 
2003), and as a result ApoB is loaded with lipids and secreted (Boren et al., 1994).  The 
Olofsson lab showed that in McArdle cells ApoB100 is secreted in lipoproteins corresponding to 
the density of VLDLs, and if the cells are supplemented with oleic acid, ApoB100 is also present 
in LDL particles (Boren et al., 1994); however, ApoB48 was only secreted in VLDL particles in 
the presence of oleic acid (Boren et al., 1994).  These studies indicated that ApoB is synthesized 
and trafficked normally in McArdle cells, establishing this cell line as a good model system for 
studying ApoB biogenesis.  Additionally, the Fisher lab has shown that polyunsaturated fatty 
acids in fish oils decrease ApoB secretion and increase intracellular degradation in McArdle cells 
(Wang et al., 1993; Wang et al., 1994).   
While McArdle cells secrete much of their ApoB in lipoprotein particles, making them a 
favorable model system, it is often desirable to use a similar system of human origin.  The other 
common and established cell culture systems for studying ApoB are HepG2 cells or Huh7 cells, 
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both of which are human hepatoma cell lines.  Although ApoB is secreted predominantly as an 
LDL particle in these cells, nevertheless, in a normal human liver the majority of ApoB is 
secreted as a VLDL (Meex et al., 2011).  ApoB degradation is robust in these cells and the 
ubiquitin proteasome pathway has been shown to mediate ApoB turnover in this system 
(Brodsky and Fisher, 2008; Meex et al., 2011).  Together, HepG2 and Huh7 cells behave very 
similarly with respect to ApoB biogenesis and as such both are favorable models for studying 
ApoB. 
1.5.4 Cell-free In vitro System 
To investigate how ApoB interacts with select molecular chaperones and how ApoB is targeted 
for degradation, the Fisher lab developed a cell-free in vitro system to study the degradation of 
ApoB (Gusarova et al., 2001).  This system utilizes human ApoB48 that is in vitro transcribed 
and translated in the presence of dog pancreatic microsomes.  The ApoB48 isoform was used for 
simplicity due to its smaller size and similar properties to ApoB100 in cell culture, with respect 
to its translocation, membrane integration, and degradation pathway (Davis et al., 1990).  The 
activity of the MTP complex and active lipid synthesis are absent in the cell-free system, making 
this a good model for the lipid deficient state in hepatic cells.  In this system, the Fisher lab 
showed that ApoB48 is incorporated into the microsomes, is glycosylated, associates with 
microsomal membrane lipids, and is ubiquitinated.  These properties demonstrated that the early 
events during ApoB biogenesis can be recapitulated in vitro and suggested that this system could 
be used to study factors that impact ApoB degradation.  Using the in vitro system, Hsp90 was 
identified as a pro-degradation factor for ApoB, which was confirmed in rat hepatoma cells 
(section 1.5.2) (Gusarova et al., 2001).  Additionally, Sse1, the yeast homolog of Hsp110, was 
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identified as a pro-stabilization factor for ApoB using this system, which was also confirmed 
using the yeast expression system (section 1.5.5) and hepatic cells (section 1.5.3) (Hrizo et al., 
2007).     
1.5.5 Yeast Expression System 
In order to create a genetic system in which components required for ApoB biogenesis could be 
more rapidly screened and examined, the Brodsky lab developed a yeast expression system for 
the ApoB29 isoform (Hrizo et al., 2007).  As mentioned in section 1.2.1, ApoB29 is the shortest 
isoform of ApoB that traffics normally through the secretory pathway (Segrest et al., 2001).  
Importantly, ERAD is a highly conserved process, and many yeast strains with deletions or 
mutations in the ERAD machinery are readily available.    In this model system, ApoB29 
expression was driven by a galactose inducible promoter and an HA-tag was appended.  The 
signal sequence of ApoB was also replaced with a signal sequence from a yeast protein, pre-pro 
alpha factor, which had been previously used to direct the β-amyloid precursor protein to the 
yeast ER (Zhang et al., 1994).  This was necessary because the endogenous ApoB signal 
sequence exhibited poor yeast codon bias (Hrizo et al., 2007).  To validate the expression 
system, Hrizo et al., showed that a protein of the expected molecular mass, that was recognized 
by both HA and anti-ApoB antibodies, was expressed in yeast and that ApoB29 localized to ER 
membranes in yeast and was associated with the Sec61 translocon.  Additionally, ApoB29 was 
degraded in an ERAD dependant manner (Hrizo et al., 2007), as would be expected since yeast 
lack the MTP complex.  Using this expression system, the Brodsky lab then showed that Hsp110 
contributes to the stabilization of ApoB, which was confirmed using hepatic cells (see above), 
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thus validating the use of this system to identify factors that regulate ApoB biogenesis.  The 
majority of the work presented in this thesis was performed using the yeast expression system.   
1.6 SUMMARY 
Since the amount of secreted ApoB that circulates in the bloodstream correlates directly to serum 
cholesterol levels (Crooke et al., 2005; Zimmermann et al., 2006), a better understanding of 
ApoB secretion is vital for the treatment and prevention of hypobetalipoproteinemia and 
coronary artery disease.  As described in section 1.4, ApoB secretion is tightly controlled, in 
large part through regulated degradation, an important component of which is accomplished via 
the ERAD pathway (Fisher and Ginsberg, 2002; Brodsky and Fisher, 2008; Rutledge et al., 
2010).  ERAD involves four major steps:  selection of a misfolded protein, retrotranslocation of 
the protein from the ER to the cytosol, substrate ubiquitination, and proteasome-mediated 
degradation, described section 1.4.2.2 (Meusser et al., 2005; Vembar and Brodsky, 2008; Xie 
and Ng, 2010).  Since ERAD results in lower intracellular and secreted levels of ApoB, it 
follows that a decline in ApoB production via ERAD will decrease serum lipid and cholesterol 
levels.  Thus, I have sought to better define the ERAD pathway for ApoB using both yeast and 
mammalian cell culture systems, in an effort to provide novel future therapeutic targets to treat 
cardiovascular and other, related diseases.     
In the following chapters I describe the identification of two classes of proteins that, 
through different mechanisms, impact ApoB secretion and/or degradation.  I first asked whether 
members of the PDI family exhibit substrate specificity and contribute to the biogenesis of 
ApoB.  In Chapter 2, I show that two members of the mammalian PDI family, ERp57 and 
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ERp72, promote ApoB ERAD, while another member, PDI, promotes ApoB secretion.  I next 
focused on identifying regulators of the Sec61 translocon and asked whether selected candidate 
proteins are modulators of ApoB ERAD.  In Chapter 3, I identify two members of the yeast Yet 
family of proteins, Yet2 and Yet3, as potential regulators of Sec61 that facilitate the ERAD of 
ApoB.  
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2.0  PROTEIN DISULFIDE ISOMERASES CONTRIBUTE TO THE ENDOPLASMIC 
RETICULUM-ASSOCIATED DEGRADATION OF APOLIPOPROTEIN B 
Disulfide bonds, such as those found in ApoB, are formed within the oxidizing environment of 
the ER by PDI family members (Kleizen and Braakman, 2004; Anelli and Sitia, 2008; Hatahet 
and Ruddock, 2009; Brodsky and Skach, 2011; Bulleid and Ellgaard, 2011).  PDIs are identified 
by the presence of one or more thioredoxin-like motifs (Cys-X-X-Cys) and can catalyze the 
oxidation, reduction, and/or isomerization of disulfide bonds.  Along with catalytic redox or 
isomerase activity, some PDI family members also possess chaperone activity due to the 
presence of a hydrophobic substrate binding domain (Cai et al., 1994; Song and Wang, 1995; 
Klappa et al., 1998; Gillece et al., 1999; Ellgaard and Ruddock, 2005; Tian et al., 2006; Tian et 
al., 2008; Hatahet and Ruddock, 2009).  As noted in section 1.3.3, in mammals there are twenty-
one PDI family members, one of which is known as PDI and associates with the M subunit to 
form the MTP complex; however, with few exceptions (Hatahet and Ruddock, 2009; Jessop et 
al., 2009; Park et al., 2009; Rutkevich et al., 2010; Brodsky and Skach, 2011; Benham, 2012), 
specific functions for each of these proteins have not been assigned.  In contrast, in the yeast S. 
cerevisiae there are five PDI family members, which are encoded by the PDI1, MPD1, MPD2, 
EUG1, and EPS1 genes.   PDI1 is the only essential gene among this group (Farquhar et al., 
1991), and contains two active site thioredoxin-like domains (denoted the a and a’ active sites), 
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each with a CXXC motif and a substrate binding domain in the b’ domain (Holst et al., 1997; 
Gillece et al., 1999; Tian et al., 2008).  Although PDI1 is essential, the expression of Mpd1 from 
the PDI1 promoter supports cell viability in pdi1Δ yeast (Norgaard et al., 2001).   
Select examples exist in which a clear link between PDI family members and ERAD or 
an ERAD-like phenomenon has been established.  For example, in yeast the chaperone activity 
of Pdi1 is required for the recognition and degradation of an ERAD substrate, pro-α factor (pαf), 
which lacks disulfide bonds (Gillece et al., 1999), and Eps1, appears to help target a misfolded 
membrane protein, Pma1-D378N, for ERAD (Wang and Chang, 2003).  In mammalian cells, 
ERdj5, a protein that contains both a J-domain that interacts with BiP and six thioredoxin repeat 
motifs, may reduce disulfide bonds to facilitate ERAD substrate retrotranslocation (Ushioda et 
al., 2008; Hagiwara et al., 2011).  Further, some PDIs bind to select bacterial toxins and viruses 
prior to their retrotranslocation and delivery to the cytoplasm in infected cells (Magnuson et al., 
2005; Forster et al., 2006; Schelhaas et al., 2007; Rainey-Barger et al., 2009; Moore et al., 2010; 
Taylor et al., 2011). 
As mentioned above, mammalian PDI is one component of the MTP complex that helps 
load lipids onto ApoB (Hussain et al., 2003), but it is unknown if PDI targets the protein for 
ERAD under lipid-poor conditions.  Two other mammalian PDI family members, ERp57 and 
ERp72, can be coprecipitated with ApoB (Adeli et al., 1997; Linnik and Herscovitz, 1998; 
Hussain et al., 2003; Zhang and Herscovitz, 2003), but their roles during ApoB biogenesis are 
also unknown.  Using both yeast and mammalian cell systems, I now report on the specific 
action of PDI family members during the ERAD of ApoB.  I also show that the degradation of 
ApoB and CPY*, a soluble ERAD substrate, require different Pdi1-encoded functions in yeast: 
ApoB utilizes Pdi1’s chaperone activity, whereas CPY* utilizes the thioredoxin-like motifs.  I 
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then discovered that Pdi1 is dispensable for the turnover of another ERAD substrate, the alpha 
subunit of the epithelial sodium channel (α-ENaC), and with the exception of Mpd1 the genes 
encoding the remaining three PDI relatives can be ablated without an effect on the ERAD of any 
of the substrates examined in this study.  Finally, I found that two human PDI family members 
also facilitate the ERAD of ApoB in hepatic cells, although PDI—which is a component of the 
MTP complex—enhanced ApoB secretion.  These data demonstrate the diverse PDI activities 
that are required during ERAD and that different PDI family members can act either to fold or 
degrade ApoB. 
 
 
2.1 MATERIALS AND METHODS 
2.1.1 Yeast strains, strain construction, and growth assays 
Yeast strains were grown at 26°C using standard conditions for growth, media preparation, and 
transformation unless otherwise noted (Adams et al., 1997).  A complete list of yeast strains used 
in this study can be found in Table 2. 
To create the PDI single deletion strains (mpd1Δ, mpd2Δ, eug1Δ, and eps1Δ) PCR-
mediated gene disruption was employed using the W303 background (Brachmann et al., 1998).  
In each case, the KanMX cassette was amplified from the pFA6a-KanMX6 plasmid using 
primers containing twenty nucleotides of homology to the KanMX cassette (underlined) and 
forty nucleotides of homology flanking the gene to be disrupted.  To amplify KanMX for the 
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disruption of MPD1 the following primers were used, (forward) 5’- TCC ACT TAA CAC AAT 
TAG GAG AGA CAA AAT TTG ACA TAT AAG ATT GTA CTG AGA GTG CAC -3’ and 
(reverse) 5’- TGT GTT TAA TTA GAT AAT CAT TGA ATG AGG AAA CGT ACC ACT 
GTG CGG TAT TTC ACA CCG -3’.  To amplify KanMX for the disruption of MPD2 the 
following primers were used, (forward) 5’- GTC TAG TGC AAG TAC GTC GGC AAA GTA 
AAA CAC AAA GGA GAG ATT GTA CTG AGA GTG CAC -3’ and (reverse) 5’- TCG GTA 
TTC GTA AAG TAA AAG ACA GAG CGA AGC TTA TGT TCT GTG CGG TAT TTC ACA 
CCG -3’.  To amplify KanMX for the disruption of EUG1 the following primers were used, 
(forward) 5’- ATA TGG CAA TCT CCC AAC AAG CAC CCG CTC ATA TAA TAC CAG 
ATT GTA CTG AGA GTG CAC -3’ and (reverse) 5’- AGA TGT TAA AAA TGT GCA TTA 
TAT ATG CTT TAT TTA TTG ACT GTG CGG TAT TTC ACA CCG -3’.  To amplify 
KanMX for the disruption of EPS1 the following primers were used, (forward) 5’- AAA AAT 
ACT ATC TAT AAA AAC TAG CTG TAA GGC AGC AGC CAG ATT GTA CTG AGA GTG 
CAC -3’ and (reverse) 5’- AGA TAT CAG CAT TCT TTT ATT TTT ATA ACT ACT TAA 
GCG TCT GTG CGG TAT TTC ACA CCG -3’.  The deletions of MPD1, MPD2, EUG1, and 
EPS1 were confirmed by PCR. 
   Strain SRH01 was created using a plasmid shuffle.  Briefly, plasmid pSG01 (see below) 
was transformed into strain M4492, kindly provided by the Schmitt lab (Saarland University).  
Transformants were plated on medium containing 5-FAA, which selects for cells that have lost 
the TRP1 gene.  Therefore, the MPD1-TRP plasmid from strain M4492 was lost and replaced 
with a plasmid in which the expression of Pdi1 was driven from its own promoter.  Dithiothreitol 
(DTT) sensitivity was determined by growing cells overnight at 26°C to logarithmic phase in the 
appropriate selective medium.  The number of cells in each culture was normalized and a 
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dilution series from each culture (1:10, 1:100, 1:1000) was plated on yeast extract-peptone-
dextrose (YPD) solid media (pH 5.5) either containing or lacking a final concentration of 5 mM 
DTT.  The plates were incubated at 30°C for 2 days. 
 
Table 2:  Yeast strains used in PDI study 
 
Strain Genotype Source
W303 MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1 This lab
mpd1"
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
mpd1::KANMX
This study
mpd2"
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
mpd2::KANMX
This study
eug1"
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
eug1::KANMX
This study
eps1"
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
eps1::KANMX
This study
M4492
MAT! pdi1::HIS3 !eps1 !eug1 !mpd1 !mpd2::G418 ura3 trp1 his3 
[pBH1800 (MPD1 CEN TRP1)]
Norgaard et al., 
2001
SRH01
MAT! pdi1::HIS3 !eps1 !eug1 !mpd1 !mpd2::G418 ura3 trp1 his3 
[pSG01]
This study
pdi1"[PDI1CGHC-CGHC]
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
pdi1::HIS3, [pBH1464]
Luz and Lennarz, 
1998
pdi1"[PDI1SGHS-CGHC]
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
pdi1::HIS3, [pBH1852]
Luz and Lennarz, 
1998
pdi1"[PDI1CGHC-SGHS]
MAT!, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
pdi1::HIS3, [pBH1630]
Luz and Lennarz, 
1998
pdi1"[PDI1222-302!]
MATa, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1, 
pdi1::HIS3, [pRS-!222-302]
Gillece et al., 
1999
M4130 MAT!, pdi1::HIS3, ade2, can1, ura3, leu2, trp1, his3, [pCT37]
Norgaard et al., 
2001
ire1" Mat!, lys2, his3, leu2, ura3, ire1::KANMX This lab
SEY6210 MAT!, ura3-52, leu2-3,112, trp1-"901, his3-"200, lys2-801, suc2-"9
Nakatsukasa et 
al., 2001
htm1"
MAT!, ura3-52, leu2-3,112, trp1-"901, his3-"200, lys2-801, suc2-"9, 
htm1::HIS3
Nakatsukasa et 
al., 2001
W303 MATa, ade2-1, can1-100, his3-11,15, leu2-3,112, trp1-1, ura3-1
Gauss et al., 
2011
KKY415
MATa, pdi1-1, his3-11::HIS3-UPRE LacZ, trp1-1, his3-11,15, ura3-1 , 
can1-100, ade2-1 , leu2-3,112
Gauss et al., 
2011
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2.1.2 Plasmids 
The plasmids used in this study are shown in Table 3.  To assess the degradation of ApoB29 in 
yeast, pSLW1-B29 was used (Hrizo et al., 2007).  To monitor the degradation of CPY*, we 
utilized pRS316CPY*-3HA, which was kindly provided by the Weissman lab (University of 
California, San Francisco)(Bhamidipati et al., 2005). 
Plasmids pBH1464, pBH1852, pBH1630, and pCT37 (Holst et al., 1997) were generous 
gifts from the Schmitt lab (Saarland University).  Plasmid pSG01 was constructed by subcloning 
a PstI-BamHI fragment from plasmid pBH1464 into the same sites in pRS314.  To study the 
degradation of pαF, pSM36 was used (Kim et al., 2005).  To monitor the degradation of α-ENaC 
in the non-essential PDI deletion strains, I used plasmid pRS426GPD ENaC-HA (Buck et al., 
2010).  To measure the degradation of α-ENaC in strains M4492 and SRH01 (Table 2) a 
methionine repressible α-ENaC plasmid was constructed by a rotation student, Jessica Coblentz.   
To this end, an EcoRI-XhoI fragment, corresponding to the coding sequence of α-ENaC and the 
HA epitope tag from plasmid pRS426GPD α-ENaC-HA, was subcloned into the same sites in 
pRS426MET25 (Mumberg et al., 1994) and was named pRS426MET25 α-ENaC-HA.  To assess 
the degradation of PrA*-Ab-HA, plasmid pKK223 (Kanehara et al., 2010) was kindly provided 
by the Ng lab (National University of Singapore, Singapore). 
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!
Plasmid Name Notes Selectable Marker Reference 
pRS316CPY*-3HA CPY* expression URA3 Bhamidipati et al., 2005 
pSLW1-B29 ApoB29 expression URA3 Hrizo et al., 2007 
pBH1800 CEN MPD1 TRP1 Norgaard et al., 2001 
pBH1464 CEN PDI1CGHC-CGHC TRP1 Holst et al., 1997 
pBH1852 CEN PDI1SGHS-CGHC TRP1 Holst et al., 1997 
pBH1630 CEN PDI1CGHC-SGHS TRP1 Holst et al., 1997 
pRS-!222-302 CEN PDI1222-302! TRP1 Gillece et al., 1999 
pCT37 Galactose inducible PDI1 URA3 Norgaard et al., 2001 
pFA6a-KanMX6 KanMX AMPR Longtine et al., 1998 
pSG01 CEN PDI1CGHC-CGHC LEU2 This Study 
pRS426GPD ENaC-HA ENaC alpha 
subunit expression 
URA3 Buck et al., 2010 
pRS426MET25 ENaC-HA 
Methionine 
repressible ENaC 
alpha subunit 
expression 
URA3 This Study 
pSM36-pp"f!G-HA p"f expression URA3 Kim et al. 2005 
pKK223 PrA*-Ab expression LEU2 Kanehara et al. 2010 
pJJB20 
Vector control 
corresponding to 
ApoB29 
URA3 Hrizo et al., 2007 
pRS316 
Vector control 
corresponding to 
CPY* 
URA3 Bhamidipati et al., 2005 
pcDNA3.1 
Vector control 
corresponding to 
PDI, ERp57, and 
ERp72 
NeomycinR Invitrogen, Iowa City, IA 
pcDNA3.1-hPDI Human PDI expression Neomycin
R This Study 
pcDNA3.1-hERp57 Human ERp57 
expression 
NeomycinR This Study 
pcDNA3.1-hERp72 Human ERp72 expression Neomycin
R This Study 
Table 3.  Plasmids used in the PDI study 
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2.1.3 Assays to measure the degradation of ERAD substrates in yeast 
To assess the degradation of ApoB29 in yeast, cells transformed with pSLW1-B29 were grown 
to logarithmic phase (OD600=0.4-1.0) overnight at 26°C in synthetic complete medium lacking 
uracil but supplemented with glucose to a 2% final concentration.  The cells were harvested and 
resuspended in complete medium supplemented with galactose to a final concentration of 2% 
and were grown for five hours at 26°C to obtain maximal expression of ApoB29.  The 
cycloheximide chase analysis was performed at 30°C as previously described (Hrizo et al., 
2007).  Total protein was precipitated as described (Zhang et al., 2001) and immediately 
resolved by SDS-PAGE before immunoblot analysis.  ApoB29 was detected using an anti-
hemagglutinin (HA)-horseradish peroxidase conjugated (HRP; clone 3F10; Roche) antibody.  
Immunoblots were also probed with anti-glucose-6-phosphate dehydrogenase (G6PD) (Sigma-
Aldrich, St. Louis, MO) antiserum as a loading control.  The G6PD primary antibody was 
decorated with donkey HRP-conjugated anti-rabbit IgG secondary antibody (GE Healthcare, 
Waukesha, WI).  The Supersignal West Femto Chemiluminescent Substrate (Pierce, Rockford, 
IL) was used for the detection of anti-HA ApoB29 in immunoblots and the Supersignal West 
Pico Chemiluminescent Substrate (Pierce, Rockford, IL) was used for the detection of anti-G6PD 
in immunoblots.  The signals were quantified using a Kodak 440CF Image Station and the 
associated Kodak 1D software (Eastman Kodak, Rochester, NY).   
To monitor the degradation of CPY*, cells expressing pRS316CPY*-3HA were grown in 
the appropriate selective media overnight at 26°C to logarithmic phase (OD600=0.4-1.0).   
Cycloheximide chase at 30°C, protein precipitation, and SDS-PAGE were performed as 
previously described (Tran et al., 2011).  Immunoblots were probed with an anti-HA-HRP 
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conjugated (clone 3F10; Roche) antibody to detect CPY*, and with anti-Sec61 antiserum 
(Stirling et al., 1992), which served as a loading control.  The anti-Sec61 primary antibody was 
probed with donkey HRP-conjugated anti-rabbit IgG secondary antibody (GE Healthcare, 
Waukesha, WI).  The Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) 
was used to detect anti-HA CPY* and immunoblots were probed with anti-Sec61. The resulting 
signals were quantified as described above. 
The degradation of the α subunit of ENaC (α-ENaC) was assessed by introducing 
plasmid pRS426GPD α-ENaC-HA (see above and Table 3) into the recipient strains that lacked 
single, non-essential PDI family members.  The cells were grown in selective medium overnight 
at 26°C to logarithmic phase, and cycloheximide chases, protein precipitation, and SDS-PAGE 
were performed as described (Buck et al., 2010).  α-ENaC degradation in strains M4492 and 
SRH01 was determined by introducing plasmid pRS426MET25 α−ENaC-HA (see above), 
which is engineered for the methionine repressible expression of α-ENaC.  The cells were grown 
at 26°C in selective medium with 2mM methionine overnight to logarithmic phase.  To obtain 
maximal expression of α-ENaC, cells were harvested and resuspended to an initial concentration 
of 0.5 A600/mL in selective medium lacking methionine and were grown for another 1.5 h.  
Cycloheximide chases, protein precipitation, and SDS-PAGE were performed as published 
(Buck et al., 2010). Immunoblots were probed with an anti-HA-HRP conjugated antibody (clone 
3F10; Roche) to detect α-ENaC, and with anti-G6PD antiserum, which served as a loading 
control.  The anti-G6PD primary antibody was probed with donkey HRP-conjugated anti-rabbit 
IgG secondary antibody (GE Healthcare, Waukesha, WI).  The Supersignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL) was used to detect the anti-HA-α-ENaC and 
anti-G6PD antibodies on the immunoblots and the signals were quantified as described above. 
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The ERAD of pαF was measured using plasmid pSM36 (see Table 3 and above).  In 
brief, cells were grown in selective medium at 26°C overnight to logarithmic phase, and were 
harvested and resuspended to 0.5 A600/mL.  Next, the cells were pre-incubated at 30°C with 
vigorous shaking for 10 min and then protein synthesis was stopped by the addition of 
cycloheximide to a final concentration of 50 µg/mL.  At the indicated time points, 1 mL of cells 
were harvested and frozen in liquid nitrogen.  Total protein was precipitated as described (Zhang 
et al., 2001) and was resolved by SDS-PAGE followed by Western blot analysis. Immunoblots 
were probed with an anti-HA-HRP conjugated (clone 3F10; Roche) antibody to detect pαf, and 
with anti-G6PD antiserum, which served as a loading control.  The anti-G6PD primary antibody 
was probed with donkey HRP-conjugated anti-rabbit IgG secondary antibody.  The Supersignal 
West Pico Chemiluminescent Substrate was used to detect the bound antibodies and the signals 
were quantified as above. 
To monitor the degradation of PrA*-Ab, cells expressing pKK223 were grown in the 
appropriate selective media overnight at 26°C to logarithmic phase (OD600=0.4-1.0).   A 
cycloheximide chase at 30°C, protein precipitation, and SDS-PAGE were performed as 
described above.  Immunoblots were probed with an anti-HA-HRP conjugated antibody to detect 
PrA*-Ab, and with anti-G6PD antiserum, which served as a loading control.  The anti-G6PD 
primary antibody was probed with donkey HRP-conjugated anti-rabbit IgG secondary antibody 
(GE Healthcare, Waukesha, WI).  The Supersignal West Pico Chemiluminescent Substrate 
(Pierce, Rockford, IL) was used for detection of anti-HA PrA*-Ab and anti-G6PD immunoblots 
and the signals were quantified as described above. 
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2.1.4 Coimmunoprecipitation assay 
Disulfide conjugated proteins were immunoprecipitated using a previously published protocol 
with minor modifications (Sakoh-Nakatogawa et al., 2009).  In brief, spheroplasts were prepared 
from cells expressing ApoB29 or CPY*, as described (McCracken and Brodsky, 1996) and were 
resuspended in buffer containing 1.2 M sorbitol for 30 min at 30°C.  Proteins were precipitated 
with 10% trichloroacetic acid (TCA), centrifuged at 15,000g for 5 min at 4°C, and resuspended 
in 2% SDS, 20 mM HEPES-KOH, pH 7.4, 50 mM NaCl, and 35 mM iodoacetamide with a 
protease inhibitor cocktail.  The solution was incubated at 75°C for 5 min and insoluble material 
was removed by centrifugation at 15,000g for 5 min at 4°C.  The supernatant was diluted 10-fold 
with 20 mM HEPES-KOH, pH 7.4, and 50 mM NaCl, with protease inhibitors, and incubated 
with anti-HA conjugated resin (Roche) or Sepharose 6B resin (Sigma-Aldrich), as a negative 
control, for 3 h at room temperature.  The immunoprecipitates were washed three times with 20 
mM HEPES-KOH, pH 7.4, 50 mM NaCl, and eluted in sample buffer prepared with 120 mM of 
freshly added DTT for 3 min at 75°C for SDS-PAGE, as described above.  Prior to the 
immunoprecipitation, 1% of the lysate was retained and loaded as a control.  The samples were 
immunoblotted with anti-Pdi1 antibody (a kind gift from V. Denic, Harvard University) and the 
primary antibody was probed with donkey HRP-conjugated anti-rabbit IgG secondary.  The 
Supersignal West Pico Chemiluminescent Substrate was used for detection. ApoB was detected 
as described above. 
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2.1.5 Cysteine modification assay 
Cysteines were modified by the addition of maleimide-PEG5000 using a previously published 
protocol (Tetsch et al., 2011) that we adapted for yeast.  Briefly, spheroplasts were prepared 
from cells expressing ApoB29 and were resuspended in 20 mM HEPES, pH 6.8, 150 mM 
KOAc, 5 mM MgOAc, 1.2 M sorbitol.  Iodoacetamide was added to a final concentration of 10 
mM and cells were incubated at 30°C for 15 min.  Following incubation, proteins were 
precipitated by the addition of TCA to a final concentration of 10% and were incubated on ice 
for 30 min.  The cells were centrifuged (16,000g, 4°C, 15 min) and the pellets were resuspended 
in denaturing buffer (6 M urea, 200 mM Tris-HCl, pH 8.5, 10 mM EDTA, 0.5% SDS) containing 
1 mM DTT and were incubated at 37°C for 1 hr.  The samples were then divided into two tubes 
and again proteins were precipitated with 10% TCA on ice for 30 min.  Following centrifugation 
(15 min, 4°C, 16, 000g) and removal of residual TCA, the pellets were resuspended in either 
denaturing buffer (see above) or denaturing buffer with 10mM maleimide-PEG5000 (Layson Bio 
Inc., Alabama).  Samples were incubated at 37°C for 1 h.  TCA was added again to a final 
concentration of 10% and the samples were kept on ice for 15 min before centrifugation (15 min, 
4°C, 16,000g).  After removal of all TCA, pellets were resuspended in denaturing buffer and 2x 
non-denaturing sample buffer was added.  Samples were heated to 75°C for 5 min and subjected 
to SDS-PAGE and immunoblotting.  Pdi1 and ApoB were detected as described above. 
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2.1.6 PDI, ERp57, and ERp72 expression and ApoB analysis in rat hepatoma cells 
The genes encoding human PDI, ERp57, and ERp72 cDNA were obtained from Open 
Biosystems Inc. (Huntsville, AL MHS1011-98054157, MHS1011-98054265, MHS1011-75436 
respectively).  The cDNA was amplified using standard PCR conditions and the following 
primers, which contained a Kozak consensus sequence (in bold) and KpnI or XbaI restriction 
sites (underlined).  PDI was amplified using the primers (forward) 5’- G TAC GGT ACC ACC 
GCC ACC ATG CTG CGC CGC GCT CTG CTG-3’ and (reverse) 5’- G TAC TCT AGA TTA 
CAG TTC ATC TTT CAC AGC-3’.  ERp57 was amplified using the primers (forward) 5’-G 
TAC GGT ACC ACC GCC ACC ATG CGC CTC CGC CGC CTA GCG-3’ and (reverse) 5’-G 
TAC TCT AGA TTA GAG ATC CTC CTG TGC CTT C-3’.  ERp72 was amplified using the 
primers (forward) 5’-G TAC GGT ACC ACC GCC ACC ATG AGG CCC CGG AAA GCC 
TTC CTG-3’ and (reverse) 5’-G TAC TCT AGA TTA TCA AAG CTC TTC CTT GGT CCT G-
3’.  The engineered restriction sites at the 5’ and 3’ ends allowed for subcloning into the 
pcDNA3.1 vector.  High fidelity amplification and cloning was confirmed by sequence analysis. 
      Rat hepatoma McArdle (McA-RH7777) cells (ATCC CRL-1601) were cultured at 37°C 
in Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, 10% horse 
serum, L-glutamine, and pencillin/streptomycin.  Cells were transfected with 2µg of pcDNA3.1 
vector (control), pcDNA3.1-hPDI expression vector, pcDNA3.1-hERp57 expression vector, or 
pcDNA3.1-hERp72 expression vector, prepared as described above, using FuGENE HD 
transfection reagent according to the manufacturer’s specifications (Roche).  A total of 24 h after 
the initial transfection a second transfection with 2µg of DNA was performed.  A pulse-chase 
analysis was performed 48 h after the second transfection, as previously described (Gusarova et 
al., 2001).  The proteasome-dependence of ApoB100 degradation and secretion was performed 
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as described (Meex et al., 2011) with either dimethyl	   sulfoxide	   (DMSO)	  or	   the	  proteasomal	  inhibitor	  MG132	  (Z-­‐Leu-­‐Leu-­‐Leu-­‐al;	  Sigma,	  St.	  Louis,	  MO)	  added to a final concentration of 
25µM. 
 
2.2 RESULTS 
2.2.1 Pdi1 is the major contributor to ERAD in yeast 
Disulfide bond formation is critical for ApoB maturation and secretion (Yang et al., 1989; Yang 
et al., 1990; Burch and Herscovitz, 2000).  In addition, as described in Section 1.3.3, PDI is a 
component of the MTP complex and two PDI family members, ERp57 and ERp72, have been 
found associated with ApoB (Adeli et al., 1997; Linnik and Herscovitz, 1998; Hussain et al., 
2003; Zhang and Herscovitz, 2003).  In order to perform a systematic analysis of the roles of 
PDIs in the ERAD of ApoB, I first examined ApoB stability in the yeast Saccharomyces 
cerevisiase in which the genes encoding the nonessential PDIs were deleted.  Because the wild 
type yeast strain W303 provided a more consistent read-out for the extent of ApoB degradation 
than the BY4742 strain (Figure 7), I constructed all of our mutants and performed each of the 
following experiments in this background (Table 2).   
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Figure 7: ApoB is degraded more reproducibly in the W303 yeast background than in BY4742  
Cycloheximide chase reactions were performed as described in Materials and Methods in two different wild type 
yeast strains, BY4742 (o) and W303 () expressing ApoB29.  Chase reactions were performed at 30°C, and lysates 
were immunoblotted with anti-HA antibody.  Anti-G6PD antiserum was used as a loading control.  Data represent 
the means of five experiments, ± S.D.  The bold error bars correspond to W303 and the light error bars correspond 
to BY4742.   
0
0.2
0.4
0.6
0.8
1
1.2
0 20 40 60 80 100
BY4742
W303
R
el
at
iv
e 
am
ou
nt
 o
f A
po
B
 r
em
ai
ni
ng
Time (min)
 64 
 
 
The gene encoding Pdi1 is essential (Farquhar et al., 1991), so to assess whether any of 
the other PDI family members were important for the degradation of ApoB, mpd1Δ, mpd2Δ, 
eug1Δ, or eps1Δ cells were transformed with the ApoB expression vector and the degradation 
rate was measured using a cycloheximide chase assay, as described in the section 2.2.3.  For 
these studies, I chose to express ApoB29 from an inducible reporter; ApoB29 is the shortest 
ApoB isoform whose degradation is metabolically controlled (Wang et al., 1994; Segrest et al., 
2001). ApoB29 also contains seven of the eight disulfide bonds found in full length ApoB (Yang 
et al., 1990; Harazono et al., 2005).  In each mutant, I found that ApoB was degraded at wild 
type levels (Figure 8A).   I also measured the ERAD of a well-characterized substrate CPY*, 
which is a misfolded version of carboxypeptidase Y that has five disulfide bonds (Wolf and Fink, 
1975; Finger et al., 1993).  In contrast to ApoB, CPY* was stabilized when MPD1 was deleted, 
although no stabilization was evident when the other non-essential PDIs were deleted (Figure 
8B). 
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Figure 8:  Mpd1 contributes to the ERAD of CPY*, but not ApoB29 
Cycloheximide chase reactions were performed as described in the Materials and Methods in wild type (), mpd1Δ 
(), mpd2Δ (), eug1Δ (), or eps1Δ () yeast strains expressing ApoB29 (A) or CPY* (B). Chase reactions were 
performed at 30°C, and lysates were immunoblotted with anti-HA antibody.  Anti-Sec61 antiserum was used as a 
loading control for chase reactions monitoring CPY* turnover and anti-G6PD antiserum was used as a loading 
control for chase reactions measuring ApoB29 degradation.  In the top panels quantitative data are shown, and the 
bottom panels display representative images.  Data represent the means of 4-6 experiments, ± SEM.  The lack of 
visible error bars indicates that the SEM is less than the size of the symbol.  Where indicated (**) p<0.01.  
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Additionally, I examined the degradation of pαf, a yeast ERAD substrate that lacks 
cysteines and that was previously shown to be selected by Pdi1 for degradation (Gillece et al., 
1999), as well as α-ENaC, a mammalian protein with seven disulfide bonds whose proteasome- 
and chaperone-dependent degradation were characterized in yeast (Kashlan et al., 2007; Buck et 
al., 2010).  I found that deletion of the non-essential PDIs also had no effect on the ERAD of 
these proteins (Figure 9).  Combined with previous data demonstrating that Eps1 is required for 
the ERAD of a mutant form of Pma1, Pma1-D378N, see Section 2.1 (Wang and Chang, 2003), 
these results indicate substrate specificity amongst the non-essential PDI family members.  
I next asked whether yeast Pdi1 facilitates the ERAD of ApoB.  Because previous work 
indicated that Mpd1 over-expression from the PDI1 promoter supported the growth of a pdi1Δ 
mutant (Norgaard et al., 2001), I examined ApoB degradation in pdi1Δmpd2Δeug1Δeps1Δ cells 
in which Mpd1 is the only PDI family member expressed (strain M4492). In this strain, ApoB 
was completely stabilized (Figure 10A, open circles).  I also examined the degradation of ApoB 
in a strain in which Pdi1 is the only yeast PDI family member expressed (strain SRH01).  In 
these yeast, ApoB degradation was mostly restored (Figure 10A, open squares).  I then measured 
the degradation of CPY* in these strains, since Pdi1 facilitates the ERAD of CPY* (Gillece et 
al., 1999; Sakoh-Nakatogawa et al., 2009).  As with ApoB, CPY* was also significantly 
stabilized when Mpd1 is the only PDI family member expressed, and protein degradation was 
again mostly restored when only Pdi1 was expressed (Figure 10B).  Because there was a residual 
degradation defect when ApoB and CPY* turnover were assessed in SRH01, at least one of the 
other PDI family members may contribute during the process of substrate selection and/or 
retrotranslocation.    
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Figure 9:  The non-essential PDIs do not contribute to the ERAD of pαf or α-ENaC 
Cycloheximide chase reactions were performed as described in the Materials and Methods in wild type (), mpd1Δ 
(), mpd2Δ (), eug1Δ (), and eps1Δ () yeast strains expressing pαf (A) from the pSM36-ppαfΔG-HA plasmid 
or α-ENaC (B) from the pRS426GPD ENaC-HA plasmid. Chase reactions were performed at 30°C, and lysates 
were immunoblotted with anti-HA antibody.  Anti-G6PD antiserum was used as a loading control.  Data represent 
the means of 4-6 experiments, ± SEM.  The lack of visible error bars indicates that the SEM is less than the size of 
the symbol.  
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Figure 10:  The ERAD of ApoB29 and CPY* is slowed by the loss of PDI1 
Cycloheximide chase reactions were performed as described in the Materials and Methods in wild type (), M4492 
(pdi1Δmpd1Δmpd2Δeug1Δeps1Δ [MPD1]) (), or SRH01 (pdi1Δmpd1Δmpd2Δeug1Δeps1Δ [PDI1]) () yeast 
strains expressing ApoB29 (A) or CPY* (B).  Chase reactions were performed at 30°C, and lysates were 
immunoblotted with anti-HA antibody.  Anti-Sec61 antiserum was used as a loading control for chase reactions 
monitoring CPY* turnover and anti-G6PD antiserum was used as a loading control for chase reactions measuring 
ApoB29 degradation.  In the top panels quantitative data are shown, and the bottom panels display representative 
blots.  Data represent the means of 4-6 experiments, ± SEM.  The lack of visible error bars indicates that the SEM is 
less than the size of the symbol.  Where indicated (*) p<0.05 and (**) p<0.01. 
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The chaperone activity of Pdi1 was previously found to be important for pαf ERAD 
(Gillece et al., 1999), but the ability of Mpd1 to support the degradation of this substrate as the 
only expressed PDI family member has not been investigated.  I observed measureable 
stabilization of pαf when only Mpd1 was expressed, but degradation was robust when only Pdi1 
was expressed (Figure 11A). Interestingly, although α-ENaC has seven disulfide bonds that are 
important for protein folding and function (Firsov et al., 1999; Kashlan et al., 2011), an ERAD 
defect was absent when only Mpd1 was expressed (Figure 11B).  These data suggest that Pdi1 is 
not required for the ERAD of all substrates.  Normally, ENaC functions as a heterotrimer 
composed of three subunits, α, β, and γ (Snyder, 2002; Jasti et al., 2007), but in this expression 
system α-ENaC is an orphan subunit.  Therefore, the “decision” to select α-ENaC for 
degradation may be distinct from other substrates in which intermolecular folding events or 
protein assembly are monitored.  Together, these results suggest that Pdi1 function is not 
imperative for the ERAD of all substrates, and consistent with previous data (Gillece et al., 1999; 
Wang and Chang, 2003), my data also indicate that some substrates rely in part on the function 
of other PDI family members during ER quality control.   
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Figure 11: Pdi1 is necessary for the degradation of pαf, but not α-ENaC 
Cycloheximide chase reactions were performed as described in the Materials and Methods in wild type (), M4492 
(), or SRH01 () yeast strains expressing pαf (A) from the pSM36-ppαfΔG-HA plasmid or α-ENaC (B) from the 
pRS426MET25 ENaC-HA plasmid. For expression of α-ENaC, strains were grown overnight at 26°C in selective 
medium supplemented with 2mM methionine to repress the expression of α-ENaC.  The cells were then harvested 
and resuspended in selective medium without methionine for 90 min to induce the expression of α-ENaC .  Chase 
reactions were subsequently performed at 30°C, and lysates were immunoblotted with anti-HA antibody.  Anti-
G6PD antiserum was used as a loading control.  Data represent the means of 4-6 experiments, ± SEM.  The lack of 
visible error bars indicates that the SEM is less than the size of the symbol. Where indicated (**) p<0.01.  
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2.2.2 ApoB and CPY* associate with Pdi1, and their degradation requires either the 
chaperone activity or the thioredoxin-like motifs 
I next assessed if Pdi1 directly associates with ApoB and CPY*.  To this end, the ability of Pdi1 
to form a mixed disulfide with the ER lumenal protein, Htm1/Mnl1, was assessed (Sakoh-
Nakatogawa et al., 2009).  In this protocol, yeast cells expressing ApoB are spheroplasted and 
lysed, and then proteins are precipitated under conditions in which preformed disulfide bonds are 
trapped (see Section 2.2.4).  I therefore precipitated ApoB under these conditions and asked 
whether Pdi1 bound to this substrate after adding reductant and performing SDS-PAGE.  When 
ApoB was immunoprecipitated, Pdi1 was also present, but an abundant, cytosolic protein 
(G6PD) that contains a single cysteine was absent (Figure 12A, lane 5).  I will note that a minor 
amount of Pdi1 associated with resin when strains lacked ApoB (lane 6), but neither ApoB nor 
PDI were precipitated using unconjugated resin, indicating a specific association between Pdi1 
and ApoB.  Consistent with Pdi1 having a direct effect on the degradation of CPY*, I also 
observed a Pdi1-CPY* interaction (Figure 12B, lane 5).  A prominent association between these 
proteins was absent in precipitations from lysates that lacked the substrate (Figure 12B, lane 6) 
or in mock precipitations (Figure 12B, lanes 3 and 4), although here too a small amount of Pdi1 
appears to nonspecifically associate with the resin.  Nevertheless, these results strongly suggest 
that ApoB and CPY* form mixed disulfides with Pdi1. 
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Figure 12:  Pdi1 physically interacts with ApoB29 and CPY* 
Native immunoprecipitation reactions were performed using anti-HA resin, or unconjugated Sepharose (“Mock”), 
using lysates from wild type yeast strains expressing ApoB29 (A) or CPY* (B).  In both panels, cell lysates were 
also examined that contained a vector control (“-“) in place of the ApoB29 (“+”) expression vector.  A total of 1% of 
the input for the precipitation was also examined (“Lysate”).  After precipitation and SDS-PAGE, the indicated 
proteins were examined by immunoblot analysis. 
  
!"#$ !"#$
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Because Pdi1 interacts with ApoB and facilitates its degradation, I next investigated 
which Pdi1-embedded function was important for ApoB ERAD.  I first asked whether the a or a’ 
thioredoxin-like active site was necessary.  To this end, strains were used in which PDI1 had 
been deleted, but the cells expressed wild type PDI1 on a plasmid (PDI1CGHC-CGHC), PDI1 on a 
plasmid with both cysteines in the a active site mutated to serines (PDI1SGHS-CGHC), or PDI1 on a 
plasmid with both cysteines in the a’ active site mutated to serines (PDI1CGHC-SGHS).  ApoB 
degradation was then measured by cycloheximide chase analysis.  When either active site’s 
cysteines were mutated, ApoB was degraded at wild type levels (Figure 13A).  In contrast, when 
either active site was mutated, CPY* was completely stable (Figure 13B), indicating that both 
thioredoxin-like motifs—and their redox activities—are necessary for CPY* but not ApoB 
degradation.   
Another interpretation of the data presented in Figure 13A is that the a and a’ sites 
function redundantly to support ApoB degradation; however, it is thought that the two sites are 
not equivalent (Holst et al., 1997; Hatahet and Ruddock, 2009; Wang et al., 2009; Vitu et al., 
2010), and at least one of the thioredoxin motifs must be capable of forming a thiolate to support 
cell viability (Laboissiere et al., 1995; Chivers et al., 1996).  A more likely possibility is that 
Pdi1’s chaperone activity, which mediates Pdi1’s ability to bind some peptides in the ER 
(Klappa et al., 1998; Gillece et al., 1999), is necessary for ApoB degradation.  To test this 
hypothesis, I used strains in which PDI1 was deleted, but the cells expressed either wild type 
PDI1 on a plasmid or PDI1 with its b’ chaperone domain deleted (PDI1222-302Δ).  As shown in 
Figure 13C, ApoB was completely stable when Pdi1’s chaperone domain was absent.   
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Figure 13:  The chaperone-like activity and the oxidoreductase activity of Pdi1 respectively facilitate 
the ERAD of ApoB29 and CPY 
Cycloheximide chase reactions were performed as described in the Materials and Methods in pdi1Δ [PDI1CGHC-CGHC] 
(), pdi1Δ [PDI1SGHS-CGHC] (ο), or pdi1Δ [PDI1CGHC-SGHS] () yeast strains expressing ApoB29 (A) or CPY* (B).  
Cycloheximide chase reactions were also performed in pdi1Δ [PDI1CGHC-CGHC] () or pdi1Δ [PDI1222-302Δ] (ο) yeast 
strains expressing ApoB29 (C).  Chase reactions were conducted at 30°C, and lysates were immunoblotted with 
anti-HA antibody.  Anti-Sec61 antiserum was used as a loading control for chase reactions monitoring CPY* and 
anti-G6PD antiserum was used as a loading control for chase reactions measuring ApoB29 degradation.  In the top 
panels quantitative data are shown, and the bottom panels display representative blots.  Data represent the means of 
5-7 experiments, ± SEM.  The lack of visible error bars indicates that the SEM is less than the size of the symbol.  
Where indicated (**) p<0.01. 
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In order to determine if the chaperone mutant strain supported the ERAD of other 
substrates, CPY* degradation was measured. Consistent with previous results (Gillece et al., 
1999), no CPY* degradation defect was observed when the Pdi1 chaperone domain was mutated 
(Figure 14A).  I also confirmed that the mutant Pdi1 protein was expressed to the same level as 
wild type Pdi1 and remained stable over the 90 min chase period (Figure 14B).   Together, these 
results indicate distinct requirements for Pdi1-embedded activities during ERAD: some 
substrates (α-ENaC) are Pdi1-independent, some (ApoB and pαF) require the protein’s 
chaperone activity, and others (CPY*) require both of the enzyme’s thoredoxin-like motifs. 
 
 
Figure 14:  The chaperone activity of Pdi1 is not necessary for the ERAD of CPY* 
Cycloheximide chase reactions were performed as described in the Materials and Methods in pdi1Δ [PDI1CGHC-CGHC] 
() and pdi1Δ [PDI1222-302Δ] () yeast strains expressing CPY* (A). Chase reactions were performed at 30°C, and 
lysates were immunoblotted with anti-HA antibody.  Anti-G6PD antiserum was used as a loading control.  Data 
represent the means of 4-6 experiments, ± SEM.  The lack of visible error bars indicates that the SEM is less than 
the size of the symbol.  Lysates were also immunoblotted with anti-Pdi1 antiserum and representative images are 
shown (B).  
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One surprising aspect of this study is that ApoB forms a disulfide crosslinked species 
with Pdi1 in the yeast ER (Figure 12A).  Thus, one might predict that the redox or isomerization 
activity—but not the chaperone activity—of Pdi1 might have been most important for ERAD.  
Unexpectedly, mutating the cysteine residues in the a or a’ sites had no effect on the rate of 
ApoB degradation, although CPY* degradation was blocked.  There are two explanations for 
these data.  First, there may be two pools of ApoB: One that has formed crosslinks and one that 
is en route for degradation, an event that may require a non-covalent, chaperone-like association 
between ApoB and Pdi1.  In fact, the ERAD of ApoB is incomplete when chase reactions are 
conducted in yeast (see for example Figure 7), so perhaps the remaining, stable material 
represents the crosslinked pool.  Second, Pdi1’s two activities, as a redox enzyme and as a 
chaperone (LaMantia and Lennarz, 1993; Gillece et al., 1999), may provide unique functions 
during ApoB biogenesis. For example, Pdi1 may initially form disulfide bonds with ApoB, 
which may represent an attempt by Pdi1 and other chaperones to assist protein folding.  But, 
because yeast lack the MTP complex, the chaperone activity of Pdi1 then becomes essential to 
maintain ApoB’s retrotranslocation-competence prior to degradation.  Consistent with this view, 
I found that ApoB can crosslink to Pdi1 even if the chaperone domain or the a or a’ active sites 
have been mutated (Figure 15A).  I also found that CPY* crosslinks to each Pdi1 species ( Figure 
15B), which is anticipated since each active site is necessary for CPY* ERAD and because 
degradation is unaltered in the chaperone mutant, suggesting that Pdi1 and CPY* are still able to 
interact through the active sites when the b’ domain is deleted.   
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Figure 15.  Mutant forms of Pdi1 co-precipitate with ApoB29 and CPY* 
Native immunoprecipitation reactions were performed using anti‐HA resin, or unconjugated 
Sepharose (“Mock”), using lysates from pdi1Δ yeast strains expressing active site mutant (lanes 1-6 
and 7-12) or chaperone mutant (lanes 13-18) forms of PDI1 on a plasmid.  As indicated, each strain 
also expressed (A) ApoB29 (“ApoB”), (B) CPY* (“CPY*”), or harbored an empty vector control (“-”).  
A total of 1% of the input for the precipitation was also examined (“Lysate”). After precipitation and 
SDS‐PAGE, the indicated proteins were examined by immunoblot analysis.  The doublet observed for 
Pdi1 in some panels is due to differential glycosylation. 
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2.2.3 Yeast expressing only Mpd1 or expressing specific mutant forms of Pdi1 are 
sensitive to DTT 
I hypothesized that if the chaperone mutant strain (pdi1Δ[PDI1222-302Δ]) was more sensitive to ER 
stress and less viable, then the stabilization of ApoB observed in these Pdi1222-302Δ–expressing 
yeast could have resulted from a non-specific effect on induction of ER stress and compromised 
cell growth.  Therefore, the sensitivities of all of the examined mutants to an ER stress-inducing 
agent, dithiothreitol (DTT), were measured.  I first found that the strains with a single deletion of 
any of the individual non-essential PDIs were DTT-insensitive. In contrast, and as a control, 
ire1Δ yeast, which are unable to induce the unfolded protein response (Cox and Walter, 1996), 
were inviable when plated on DTT (Figure 16).  Strain M4492 (pdi1Δmpd1Δmpd2Δeug1Δeps1Δ 
[MPD1]) was significantly sicker than wild type cells on rich media, and was extremely DTT 
sensitive; however, when Pdi1 was the only PDI family member expressed (strain SRH01, 
pdi1Δmpd1Δmpd2Δeug1Δeps1Δ [PDI1]), DTT sensitivity was absent (Figure 16). In accordance 
with previous data (Holst et al., 1997), I also found that mutation of the a active site in Pdi1 
(pdi1Δ[PDI1SGHS-CGHC]) led to modest DTT sensitivity. Notably, the b’ chaperone mutant strain 
(pdi1Δ[PDI1222-302Δ]) was DTT insensitive.  These results suggest that ApoB stabilization in the 
Pdi1222-302Δ chaperone-defective strain does not result from unmitigated stress and poor cell 
growth. 
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Figure 16: Strains with deletions of or mutations in the PDI family members exhibit varying 
sensitivities to the reducing agent, dithiothreitol (DTT) 
The indicated yeast strains were grown in selective medium to mid log phase.  Serial dilutions of the cells were spot 
plated onto medium containing either 0mM DTT or 5mM DTT, as indicated, and grown for 2 d at 30°C.  The data 
are representative of several independent trials, and in liquid culture the doubling times for the single deletions in the 
absence of DTT were essentially identical. 
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2.2.4 ApoB degradation is EDEM independent 
Pdi1 interacts with and is required for the oxidation of an intermolecular disulfide bond in 
Htm1/Mnl1 (Clerc et al., 2009; Sakoh-Nakatogawa et al., 2009), which is the ER degradation 
enhancing α-mannosidase-like lectin (EDEM) homolog in yeast.  As in mammals, Htm1 
recognizes misfolded glycoproteins and targets them for degradation (Jakob et al., 2001; 
Nakatsukasa et al., 2001).  Recently, a mutation in PDI1, pdi1-1, was identified in a screen for 
yeast that require a functioning unfolded protein response for viability (Gauss et al., 2011).  The 
pdi1-1 mutation harbors a leucine in place of a proline in the center of the b’ domain (amino acid 
313) and disrupts the interaction of Pdi1 with Htm1.  This, in turn, affects the ERAD of select 
substrates.  Formally, then, the delayed degradation of ApoB, a glycoprotein, in the PDI1222-302Δ 
strain (Figure 13C) might have arisen from an indirect effect on Htm1 activity. 
To address this possibility, I asked whether ApoB degradation was altered in the pdi1-1 
mutant.  ApoB was degraded at wild type levels in the pdi1-1 strain (Figure 17A).  As a control 
for this experiment, PrA*-Ab, a mutated version of the vacuolar protein Proteinase A that 
requires Htm1 (Finger et al., 1993; Spear and Ng, 2005; Kanehara et al., 2010), was stabilized in 
pdi1-1 yeast (Figure 17B).  These data suggest that ApoB degradation is Htm1-independent, and 
that the effect of the PDI1222-302Δ mutant on ApoB (Figure 13C) was not due to a secondary 
effect via disrupted association between Htm1 and Pdi1.  Consistent with this hypothesis, I also 
failed to observe an effect on ApoB stability in htm1Δ strains compared to wild type yeast 
(Figure 17C).  Further, as shown above, ApoB was degraded at wild type levels in pdi1Δ [PDI1 
SGHS-CGHC] and pdi1Δ [PDI1 CGHC-SGHS] strains (Figure 13A). These mutants have previously been 
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reported to ablate the function of Htm1 during ERAD (Sakoh-Nakatogawa et al., 2009).  Overall, 
these data indicate that the yeast EDEM homolog is dispensable for ApoB turnover and confirm 
that ApoB degradation requires Pdi1’s chaperone activity. 
 
 
 
 
Figure 17:  The EDEM homolog Htm1 does not play a role in the degradation of ApoB 
Cycloheximide chase reactions were performed as described in the Materials and Methods in wild type W303a () 
or KKY415 (pdi1-1) () yeast strains expressing ApoB29 (A) or PrA*-Ab (B).  Cycloheximide chase reactions 
were also performed in wild type SEY6210 () or htm1Δ () yeast strains expressing ApoB29 (C).  Chase 
reactions were performed at 30°C, and lysates were immunoblotted with anti-HA antibody.  Anti-G6PD antiserum 
was used as a loading control.  Data represent the means of 4-6 experiments, ± SEM.  The lack of visible error bars 
indicates that the SEM is less than the size of the symbol.  Where indicated (*) p<0.05 and (**) p<0.01. 
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Defects in chaperone function can affect the biochemical properties of an ERAD 
substrate in yeast (Nishikawa et al., 2001; Kabani et al., 2003).  Because the chaperone activity 
of Pdi1 was required for maximal ApoB turnover, I was curious whether ApoB’s conformation 
was altered in the b’ mutant strain.  As a read-out for ApoB’s conformation in the yeast ER, I 
chose to measure the reactivity of any free cysteines in ApoB to the thiol-modifying reagent, 
maleimide-PEG5000, after ApoB isolation and reduction.  In previous work, maleimide-
PEG5000 was used to quantify the free cysteines that were available in Pdi1 mutants that lacked 
active site cysteines, and to assess whether the loss of Htm1/Mnl1 association altered cysteine 
modification (Sakoh-Nakatogawa et al., 2009).  
When ApoB was expressed in the pdi1Δ[PDI1CGHC-CGHC], pdi1Δ[PDI1SGHS-CGHC], or 
pdi1Δ[PDI1CGHC-SGHS] strains and—after reduction—the maleimide-PEG5000-modified protein 
was detected by immunoblotting, a prominent species at the predicted molecular weight of 
ApoB29 (~150,000) as well as a high molecular weight “smear” was observed (Figure 18, lanes 
2, 4, and 6, compared to samples without maleimide-PEG5000, lanes 1, 3, and 5).  These data 
suggest that there is no gross difference in the degree of modification when the degradation of 
ApoB is robust in the pdi1 mutants.  Interestingly, when ApoB was expressed in the 
pdi1Δ[PDI1222-302Δ] strain and was modified with maleimide-PEG5000 after reduction, the 
magnitude of the high molecular weight pool was significantly reduced (Figure 18, lane 8).  This 
can be seen better in the two separate examples with 5-fold more protein loaded on the gel 
(Figure 18, lanes 10 and 12).  In the pdi1Δ[PDI1222-302Δ] strain, the amount of a lower molecular 
weight band (~110,000) specific to ApoB also increased (Figure 18, lanes 7). These combined 
results suggest that when the chaperone domain of Pdi1 is absent, the conformation of ApoB 
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may be altered such that several of its disulfide bonds are no longer available for maleimide-
PEG5000 modification and that the protein becomes more protease susceptible.  
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Figure 18.  Deletion of the chaperone domain of Pdi1 alters the modification of ApoB by maleimide-
PEG5000 
(A) A schematic representation of the cysteine modification assay is depicted.  The blue line represents ApoB29 
with its 15 cysteines.  (B) Cysteine modification assays were performed as described in the Materials and Methods.  
Spheroplasts expressing ApoB29 from pdi1Δ cells expressing wild type Pdi1 (PDI1CGHC-CGHC) or the indicated 
mutants first were treated with iodoacetamide followed by DTT, and were then treated with maleimide-PEG5000 
(Lanes 2, 4, 6, 8, 10, and 12) or a vehicle control (Lanes 1, 3, 5, 7, 9, and 11).    The samples were analyzed by SDS-
PAGE and immunoblotted with anti-HA antibodies.  Molecular mass markers (x 10-3 Da) are indicated to the left of 
the gel.  The predicted size of ApoB29 is ~150kDa, indicated with ().  Note that lanes 9-12 are from two 
independent experiments with 5-fold more sample loaded on the gel in order to visualize the smear of modified 
protein upon the addition of Maleimide-PEG5000 in the chaperone mutant strain (lanes 10 and 12).  Maleimide-
PEG5000 modified protein is indicated with a red bracket.  The protease susceptible degradation product is indicated 
with a black arrow. 
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2.2.5 Distinct PDI family members contribute differently to ApoB biogenesis in hepatic 
cells 
To assess whether the knowledge acquired from the use of the yeast system might indicate which 
mammalian chaperones similarly mediate ApoB quality control, I examined the contributions of 
select mammalian PDI family members on ApoB biogenesis in hepatic cells.  While there are 
only five yeast PDI family members, mammals express twenty PDI-like proteins (Hatahet and 
Ruddock, 2009).  In order to identify which of these PDIs to examine, I first performed a BLAST 
search with yeast Pdi1 against the human protein database.  The three best hits were ERp72, PDI, 
and ERp57 (Figure 19). 
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Figure 19: BLAST search of yeast Pdi1 against the human protein database 
(A) A BLAST search was performed using default parameters for yeast Pdi1 against the human protein database and 
the top five results indicating highest degree of similarity to Pdi1 are pictured.  The alignments of yeast Pdi1 
compared to the top three mammalian PDI homologs (B) ERp72, (C) PDI, and (D) ERp57 are shown. 
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Another criterion for this study was to ascertain which PDIs exhibited overlapping expression 
patterns with ApoB.  PDI, ERp57, and ERp72 are all expressed in the liver (Marcus et al., 
1996)(http://www.hprd.org/), but the fourth and fifth best hits from the BLAST search, PDIp and 
PDILT, respectively, are not expressed in this tissue.  Further, PDI, ERp57, and ERp72 have a 
similar domain organization to Pdi1 (a-b-b’-a’), although ERp72 has an additional thioredoxin 
like active site (a°-a-b-b’-a’) (Hatahet and Ruddock, 2009).   The crystal structures of yeast Pdi1 
and mammalian ERp57 have been solved (Tian et al., 2006; Tian et al., 2008; Dong et al., 2009) 
and share broad overall similarity, having domains organized in a U-shaped conformation, 
although ERp57 has a more twisted conformation than Pdi1 (Dong et al., 2009).  In ERp57 the 
two halves of the protein are less compact and pivot at the connection point, as compared to PDI.  
Interestingly, PDI and ERp72 are also able to support the growth of pdi1Δ yeast strains (Gunther 
et al., 1993).   
Because Pdi1’s b’ domain was required to facilitate ApoB ERAD in yeast (Figure 13C), I 
also wanted to examine mammalian PDI family members that harbor substrate binding domains.  
PDI, ERp57, and ERp72 all have substrate binding domains, and specific substrates have been 
identified for each of these proteins.  The chaperone activity of PDI is necessary to refold pro-
insulin (Winter et al., 2002) and lysozyme (Puig and Gilbert, 1994). ERp57 specifically binds 
lectins through a binding site in its b’ domain (Russell et al., 2004) and a range of substrates 
have been identified for ERp57 in vivo, including, laminin, collagen, and clusterin (Jessop et al., 
2009).  Similarly, ERp72 is found within chaperone complexes and interacts with 
thrombospondin (Kuznetsov et al., 1997) and thyroglobulin (Menon et al., 2007); however, it is 
unknown if these interactions occur through the b’ substrate binding domain.   Nevertheless, 
PDI, ERp57, and ERp72 have all previously been shown to precipitate with ApoB, and through 
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its integration into the MTP complex, PDI interacts with ApoB during lipid-loading ((Adeli et 
al., 1997; Linnik and Herscovitz, 1998; Zhang and Herscovitz, 2003).  However, the roles of 
PDI, ERp57, or ERp72 as regulators of ApoB degradation in the mammalian ER have not been 
examined.   
In collaboration with Charles Guo in the Fisher lab at NYU Medical School, to determine 
whether PDI, ERp57, or ERp72 contribute to ApoB ERAD, I overexpressed each protein in rat 
hepatoma McA-RH7777 cells, an established cell line for studying ApoB biogenesis (Tanabe et 
al., 1989).  First, to monitor whether each protein could be overexpressed, cells were assayed 
after they were transfected with a vector control or vectors engineered for the transient 
expression of human PDI, ERp57, or ERp72. After 48 h the cells were broken and the lysates 
were subjected to SDS-PAGE and probed with anti-PDI, anti-ERp57, or anti-ERp72 antibodies.   
When duplicate samples were analyzed and the signals were quantified relative to a loading 
control, PDI and ERp72 were over-expressed by ~7-fold and ~6-fold, respectively (Figure 20A) 
and—assuming similar antibody avidity—the quantity of overexpressed ERp57 appears 
comparable to PDI and ERp72 when overexpressed (Figure 20A).  
I hypothesized that if PDI played a strong MTP complex-independent role in mammalian 
cells during ApoB degradation, then its overexpression would result in decreased recovery of 
ApoB (Wang et al., 1997a).  However, if PDI’s only role in ApoB biogenesis was through the 
MTP complex, I predicted that increased recovery of ApoB would be evident because the MTP 
complex promotes ApoB secretion (Gordon et al., 1994; Leiper et al., 1994; Haghpassand et al., 
1996) and escape from ERAD.   No change in ApoB recovery could indicate that a pro-
degradative role of PDI was balanced by the stabilizing role of the MTP complex.   When the 
amount of radiolabeled ApoB recovered after a 60 min chase in PDI-overexpressing cells was 
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compared to the control, a 37% overall increase in ApoB recovery was evident (Figure 20B, 
left).  These results suggest that the expression of greater amounts of PDI improve MTP complex 
function and augment ApoB transport and escape from ERAD.  As controls for this experiment, 
Charles Guo in the Fisher lab also assessed the secretion of albumin, as described (Hrizo et al., 
2007; Gusarova et al., 2007) but found that its biogenesis was unaffected by PDI over-expression 
(data not shown).  In addition, Charles asked whether PDI over-expression enhanced ApoB 
secretion because it inhibited ERAD.  However, he found that PDI over-expression, regardless of 
whether the proteasome was active or not (i.e., in the presence of MG-132), led to an increase in 
the amount of secreted ApoB (Figure 21).  
 
 
 
 
 
 
Figure 20: Over-expression of ERp57 or ERp72 leads to an increase in ApoB100 ERAD 
(A) McArdle-RH7777 cells were transfected with pcDNA3.1 lacking an insert  (-), or containing PDI, ERp57, or 
ERp72.  Equal amounts of cell lysates were analyzed by immunoblotting with an anti-PDI antibody, anti-ERp57 
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antibody, or anti-ERp72 antibody.  (B) Following a metabolic labeling reaction, a 60 min chase was performed as 
described in the Materials and Methods in McArdle-RH7777 cells transfected with a vector control (pcDNA3.1 
lacking an insert), or containing the PDI, ERp57, or ERp72 genes.  The bars indicating the “Relative Recovery of 
ApoB” indicate the amount of ApoB-precipitable material recovered from cell lysates and secreted into the medium 
at the completion of the chase divided by the amount of ApoB-precipitable material recovered after 15 min of chase.  
This prolonged period is required to complete the synthesis of ApoB (Gusarova et al., 2001). Data represent the 
means of 3 experiments, ± SEM.  Where indicated (*) p < 0.05 and (**) p<0.01.  
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Figure 21:  PDI promotes ApoB secretion independent of ERAD activity 
Following a metabolic labeling reaction in the presence of either DMSO or the proteasome inhibitor MG132, as 
indicated, a 90 min chase was performed as described in the Materials and Methods in McArdle‐RH7777 cells 
transfected with a vector control (pcDNA3.1 lacking an insert), or containing the PDI gene in pcDNA3.1. The 
“Relative Recovery of ApoB” indicates the amount of ApoB‐precipitable material recovered from cell lysates and 
secreted into the medium at the completion of the chase divided by the amount of ApoB‐precipitable material 
recovered after 30 min of chase.  Data represent the means of 3 independent experiments, ± SEM. Where indicated 
(*) p < 0.05.  
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If yeast Pdi1 is required for ApoB degradation (Figures 10 & 13), why isn’t the closest 
homolog in human cells, PDI, similarly required for ERAD?  Instead, human PDI over-
expression stabilized the protein and increased its recovery in this experiment.  The simplest 
explanation for this result is that yeast lack the MTP complex, which is required to load lipids 
onto maturing, ApoB-containing chylomicrons and VLDLs in the ER.  In mammalian cells, the 
loss of MTP function—brought about either by genetic means or through the use of small 
molecule inhibitors—is accompanied by increased ApoB degradation (Jamil et al., 1996; Benoist 
and Grand-Perret, 1997; Zimmermann et al., 2006). Thus, our yeast ApoB model most closely 
resembles the lipid- or MTP complex-deficient state.  I conclude that Pdi1 is a pro-degradative 
factor for ApoB in yeast, yet when complexed with the M subunit in mammals, the closest Pdi1 
homolog, PDI, promotes ApoB folding and secretion. 
Based on my yeast data, I also hypothesized that over-expression of ERp57 and ERp72 
would lead to increased ApoB degradation.  As predicted, when either ERp57 or ERp72 was 
over-expressed, ~33% less ApoB was recovered compared to the vector control (Figure 20B, 
middle and right panels).  To confirm that ApoB degradation was proteasome-mediated and that 
the effect of ERp57 and ERp72 was via the ERAD pathway and not an alternate degradative 
system (Pan et al., 2008), I assessed the impact of a proteasome inhibitor, MG132, on ApoB 
recovery when ERp72 was overexpressed.  In this experiment, in the presence of DMSO, less 
ApoB was again recovered when ERp72 was overexpressed compared to the vector control, but 
when cells were treated with MG132, ApoB recovery in both the mock and ERp72 
overexpressing cells rose (Figure 22).   Overall, these data indicate that PDI is primarily an 
ApoB stabilizing chaperone in mammalian cells, most likely through its function as a component 
of the MTP complex, but that ERp57 and ERp72 facilitate ApoB ERAD (see model Figure 23).  
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More generally, these results support the use of the yeast ApoB expression system as a means to 
identify components that play diverse roles during the ERAD of this protein in mammals. 
 
 
 
 
Figure 22.  ApoB degradation is proteasome mediated when ERp72 is overexpressed 
Following a metabolic labeling reaction in the presence of DMSO or MG132, an inhibitor of the proteasome, a 60 
min chase was performed as described in the Materials and Methods in McArdle-RH7777 cells transfected with a 
vector control (pcDNA3.1 lacking an insert), or containing the ERp72 gene.  The bars indicating the “Relative 
Recovery of ApoB” indicate the amount of ApoB-precipitable material recovered from cell lysates and secreted into 
the medium at the completion of the chase divided by the amount of ApoB-precipitable material recovered after 15 
min of chase.  Data represent the means of 3 experiments, ± SEM.  Where indicated (*) p < 0.05.  
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Figure 23.  Model depicting the opposing roles PDI family members play in ApoB biogenesis in 
mammals 
(A) PDI acts as a pro-stabilization and secretion factor for ApoB in mammalian cells.  PDI is a subunit of the MTP 
complex.  Its association with the M-subunit keeps the M-subunit retained and stable in the ER, suggesting that 
over-expression of PDI leads to an increase of the MTP complex in the ER (1).  Having more MTP complex in the 
ER lumen allows for increased lipid loading of ApoB as the nascent protein is translated and translocated into the 
ER (2).  Upon lipid loading, ApoB assembles into a pre-VLDL (3).  The pre-VLDL is packaged into COPII vesicles 
(4) and trafficked to the Golgi where it undergoes further maturation into a VLDL and is then secreted into the 
bloodstream (5).  (B) ERp57 and ERp72 are pro-degradation factors for ApoB in mammalian cells.  When lipid 
levels are low in cells or the MTP complex is compromised, the MTP complex cannot load lipids onto ApoB as it is 
translated and translocated into the ER (1), leaving hydrophobic patches of ApoB exposed.  To prevent aggregation 
of ApoB within the lumen of the ER, ERp57 and ERp72 bind to hydrophobic segments of ApoB through their 
chaperone binding domains (2).  Since ApoB is not loaded with lipids, translocation of ApoB stalls and large 
cytoplasmic loops of ApoB accumulate that are recognized by molecular chaperones (3).  ApoB is then poly-
ubiquitinated and retrotranslocated out of the ER (4) and is ultimately degraded by the 26S proteasome (5). 
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2.3 DISCUSSION 
In this chapter, I show for the first time that PDI family members play opposing roles during the 
degradation of an ERAD substrate in mammalian cells.  Specifically, I found that ERp57 and 
ERp72 facilitate the proteasome-mediated degradation of ApoB, but PDI helps stabilize ApoB in 
hepatic cells, an effect most likely brought about by its membership in the MTP complex.  In 
yeast, which lack the MTP complex, I discovered that Pdi1 facilitates the ERAD of ApoB.  I also 
discovered that the chaperone activity of Pdi1 is required for degradation, and that in the absence 
of chaperone activity ApoB’s conformation appears to be altered.  In contrast, the degradation of 
another substrate (i.e., CPY*) is dependent on Pdi1’s thioredoxin motifs, and yet another ERAD 
substrate’s destruction (i.e., α-ENaC) is PDI-independent.  These data highlight the complex and 
unique actions of PDI family members during ERAD. 
Interestingly, it still remains mysterious how the generated disulfide bonds in ApoB 
might be broken prior to retrotranslocation.  Yeast lack ERdj5, which has been proposed to 
perform this function in mammalian cells (Ushioda et al., 2008).  So, one is left with the scenario 
that an as-yet to be identified enzyme is capable of breaking disulfides in the yeast ER.  
Alternatively, the reduction of disulfide bonds may be unnecessary for Sec61-dependent 
retrotranslocation and proteasome degradation.  It is worth noting that polypeptide “loops” can 
be inserted into the Sec61 translocon (Skach, 2009).  Disulfide bonded substrates and circular 
substrates can also be degraded by the proteasome (Lee et al., 2002; Liu et al., 2003).  In 
addition, large, folded domains have been shown to retrotranslocate across the ER membrane 
(Fiebiger et al., 2002; Tirosh et al., 2003; Schelhaas et al., 2007). 
In summary, I have shown in this chapter that members of the PDI family exhibit 
substrate specificity and play opposing roles in the ERAD of ApoB.  In the next chapter, I 
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investigated factors that may mediate the interaction between the ribosome and the Sec61 
translocon and facilitate the retrotranslocation and proteasomal degradation of ApoB. 
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3.0  THE YET PROTEINS, PUTATIVE REGULATORS OF THE SEC61 
TRANSLOCON, PROMOTE APOLIPOPROTEIN B ENDOPLASMIC RETICULUM – 
ASSOCIATED DEGRADATION IN YEAST 
3.1 INTRODUCTION 
During the biogenesis of ApoB, as occurs for almost all secreted proteins, the ribosome 
synthesizes ApoB at the surface of the ER and ApoB is co-translationally translocated through a 
channel in the ER membrane, known as the Sec61 translocon, into the lumen of the ER.  Once in 
the lumen of the ER, ApoB is loaded with lipids and assembles into a pre-VLDL, which can 
traffic through the secretory pathway, mature, and be secreted into the plasma (Tran et al., 2002), 
as described in Section 1.2.2.  If ApoB is not loaded with lipids, it becomes a substrate for 
ERAD and must be retro-translocated out of the ER into the cytosol where it is poly-
ubiquitinated and degraded (Yeung et al., 1996; Benoist and Grand-Perret, 1997).   
In order for ApoB translocation to initiate, the ribosome must form a tight seal with 
Sec61, allowing ApoB entrance in to the ER without exposure to the cytosol; however, for ApoB 
to be retro-translocated and escape the ER lumen for degradation, the ribosome must be liberated 
from the ER membrane or the seal between Sec61 and the ribosome must be loosened 
(Beckmann et al., 1997; Menetret et al., 2000; Potter and Nicchitta, 2000; Beckmann et al., 
2001).  Several candidate proteins may regulate the interaction between Sec61 and the ribosome 
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to facilitate the formation of a gap, which would allow ApoB exposure to the cytosol for 
degradation (see below).   
Of the many known and characterized ERAD substrates, ApoB is the only substrate that 
has been shown to remain associated with the Sec61 translocon and is co-translationally 
degraded by the proteasome (Mitchell et al., 1998; Pariyarath et al., 2001; Oyadomari et al., 
2006).   In contrast, most ERAD substrates are fully translated and translocated into the ER 
before selection for ERAD.  As a result of ApoB’s unique association with Sec61 during 
translocation, retrotranslocation, and degradation, I hypothesized that proteins that regulate the 
translocon to allow both the entrance to and exit from the ER will impact ApoB biogenesis. 
Candidate yeast proteins that may regulate the Sec61-ribosome interaction include Ysy6, 
Ykl207w, and the YET proteins.  Ysy6 is the yeast homolog of the mammalian protein RAMP4, 
which is suggested to be involved in the ER stress response, and is associated with both Sec61 
and calnexin (Gorlich et al., 1992; Schroder et al., 1999; Yamaguchi et al., 1999; Lee et al., 
2003).  Calnexin has also been shown to co-precipitate with ApoB (Ou et al., 1993; Patel and 
Grundy, 1996; Chen et al., 1998; Zhang and Herscovitz, 2003).  The expression of Ysy6 in E. 
coli is also sufficient to suppress a mutation in the SecY protein, the bacterial homolog of 
Sec61(Sakaguchi et al., 1991), suggesting that Ysy6 may aid in Se61-mediated protein 
translocation.  A second candidate translocon regulator is Ykl207w, which is a component of the 
yeast ER Membrane protein Complex (EMC).  The EMC is composed of 6 proteins that 
genetically and physically associate with one another (Jonikas et al., 2009).  The Weissman lab 
used phenotypic interaction maps to show that the genetic stress response profiles of EMC 
mutants, in combination with other mutant strains, were very similar to the profiles exhibited by 
strains containing mutations in the translocon.  Additionally, they showed that loss of the EMC 
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proteins leads to an accumulation of misfolded membrane proteins (Jonikas et al., 2009), 
suggesting that the EMC may be involved in the quality control of membrane proteins.  Even 
though ApoB is not a bona fide membrane protein because it has no transmembrane domains, it 
has been found in close association with ER microsomal membranes through its hydrophobic 
domains, perhaps during an initial stage of lipid recruitment (Zhou et al., 2011) and, as such, 
may require quality control machinery utilized by membrane proteins. 
Two other candidates that may act as translocon regulators are members of the YET 
family.  The yeast proteins Yet1 and Yet3, whose human homologs are BAP29 and BAP31 
respectively, are integral membrane proteins that have been proposed to aid in the biogenesis of 
membrane proteins (Annaert et al., 1997; Schamel et al., 2003; Paquet et al., 2004; Ladasky et 
al., 2006; Wilson and Barlowe, 2010).    In mammalian cells, BAP31 co-precipitates with the 
translocon (Wang et al., 2008a), and in yeast the association between Yet1 and the translocon is 
increased with ER stress (Wilson and Barlowe, 2010).  Additionally, BAP31 has been shown to 
aid in the retro-translocation of an ERAD substrate, the Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR), and in association with Derlin to contribute to CFTR ERAD in 
mammalian cells (Lambert et al., 2001; Wang et al., 2008a).  Furthermore, BAP31 promotes the 
escape of the SV40 virus from the ER into the cytosol during infection (Geiger et al., 2011).   
I hypothesized that because BAP29, BAP31, and their yeast homologs interact with the 
translocon and facilitate the biogenesis of membrane proteins, as well as contribute to the ERAD 
of another known substrate, they may facilitate ApoB retro-translocation and degradation.  By 
using a yeast expression system for ApoB29 to initially investigate the contribution of these 
proteins to ApoB degradation, I found that in the absence of YET3 or another member of the Yet 
family, YET2, ApoB is significantly stabilized, while the ERAD of two other substrates, CPY* 
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and pαf, remains unaltered.  Additionally, I found that Yet3 and ApoB coimmunopreciptiate.  
These preliminary results indicate that Yet3 interacts with and contributes to the degradation of 
ApoB.  Based on my preliminary work, I have begun to investigate whether the human homolog 
of Yet3, BAP31 contributes to the ERAD of ApoB100 in hepatic cells.  
3.2 MATERIALS AND METHODS 
3.2.1 Yeast Strains 
All yeast strains were grown at 26°C using standard conditions for growth, media preparation, 
and transformation unless otherwise noted (Adams et al., 1997).  A complete list of yeast strains 
used in this study can be found in Table 4.  Strain yet1,2,3Δ was kindly provided by the Barlowe 
lab (Dartmouth College). 
 
Table 4. Yeast strains used in the Yet study 
 
Strain Genotype Source
BY4742 MAT! his3!1 leu2!0 lys2!0 ura3!0 This lab
yet1! MAT! his3!1 leu2!0 lys2!0 ura3!0 yet1::KANMX Research Genetics
yet2! MAT! his3!1 leu2!0 lys2!0 ura3!0 yet2::KANMX Research Genetics
yet3! MAT! his3!1 leu2!0 lys2!0 ura3!0 yet3::KANMX Research Genetics
yet1,2,3! 
(CBY2357)
MAT! his3!1 leu2!0 lys2!0 ura3!0 yet1::KANMX 
yet2::KANMX yet3::KANMX
Barlowe lab
ysy6! MAT! his3!1 leu2!0 lys2!0 ura3!0 ysy6::KANMX Research Genetics
ykl207W! MAT! his3!1 leu2!0 lys2!0 ura3!0 ykl207W::KANMX Research Genetics
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3.2.2 Plasmids 
The plasmids used in this study are shown in Table 5.  To assess the degradation of ApoB29 in 
yeast, plasmid pSLW1-B29 was used (Hrizo et al., 2007).  To monitor the degradation of CPY*, 
I utilized pRS316CPY*-3HA, which was kindly provided by the Weissman lab (University of 
California, San Francisco)(Bhamidipati et al., 2005).  To examine the degradation of pαf, 
plasmid pSM36-ppαfΔG-HA was used (Kim et al., 2005). 
Table 5. Plasmids used in the Yet study 
 
3.2.3 Cycloheximide chase analysis of ERAD substrates 
The degradation of ApoB29, CPY*, and pαf were assessed as described in section 2.2.3.  
3.2.4 Coimmunoprecipitation Assays 
Yeast cells expressing ApoB29 were immunoprecipitated using anti-HA resin and Western blot 
analysis was used to determine whether candidate proteins immunoprecipitated with ApoB29.  
Briefly, yeast cells expressing ApoB29 were grown to log phase in selectable medium containing 
glucose and the expression of ApoB29 was induced with galactose as described in section 2.2.3.  
Cells were harvested and resuspended in 10mM Tris-HCl pH7.6, 10mM EDTA, and 10% 
sucrose, with protease inhibitors.  The cells were lysed with glass beads and were spun at 2000xg 
Plasmid Name Notes Selectable Marker Reference
pSLW1-B29 ApoB29 expression URA3 Hrizo et al., 2007
pRS316CPY*-HA CPY* expression URA3 Bhamidipati et al., 2005
pSM36-pp!f"G-HA paf expression URA3 Kim et al., 2005
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at 4°C for 5 minutes to remove unbroken cells and any aggregated material.  The supernatant 
was diluted 2-fold with 20mM HEPES-KOH, pH 7.4, 50mM NaCl, 1% NP-40, and protease 
inhibitors, and incubated overnight at 4°C with anti-HA conjugated resin (Roche) or Sepharose 
6B resin (Sigma-Aldrich), as a negative control.  The immunoprecipitates were washed two 
times with 20mM HEPES-KOH, pH 7.4, 150mM NaCl, and 0.1% NP-40 and two times with 
20mM HEPES-KOH, pH 7.4, 300mM NaCl, and 0.1% NP-40 and bound proteins were eluted in 
sample buffer prepared with 120 mM of freshly added DTT for 5 min at 75°C for SDS-PAGE.  
Prior to the immunoprecipitation, 1% of the lysate was retained and loaded as a control.  The 
samples were immunoblotted with anti-Yet3 antibody (a kind gift from C. Barlowe, Dartmouth 
Medical School) and the primary antibody was probed with donkey HRP-conjugated anti-rabbit 
IgG secondary.  The Supersignal West Pico Chemiluminescent Substrate was used for detection. 
ApoB was detected as described above in Section 2.2.3. 
 
3.2.5 siRNA knockdown of BAP31 in rat hepatoma cells and ApoB secretion and 
degradation  
Rat hepatoma McA-RH7777 cells (ATCC CRL-1601) were cultured at 37°C in Dulbecco’s 
Modified Eagle’s Medium supplemented with 10% fetal bovine serum, 10% horse serum, L-
glutamine, and pencillin/streptomycin.  Cells were transfected with a range of concentrations of 
siRNA against BAP31 or, as a control, firefly luciferase (20nM to 100nM) using Lipofectamine 
2000 transfection reagent according to the manufacturers specifications (Invitrogen).  This list of 
siRNAs used can be found in Table 6.  Effective knockdown of BAP31 was assessed by Western 
Blot analysis after varying lengths of time (24 – 72 hrs post transfection (hpt)).  BAP31 was 
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detected using an anti-BAP31 (H-90) antibody (Santa Cruz Biotechnology, Inc.).  The BAP31 
primary antibody was decorated with donkey HRP-conjugated anti-rabbit IgG secondary 
antibody (GE Healthcare, Waukesha, WI).  Immunoblots were also probed with an anti-beta 
actin (AC-15) antiserum as a loading control (Abcam, Cambridge, MA).  The actin primary 
antibody was decorated with sheep HRP-conjugated anti-mouse IgG secondary antibody (GE 
Healthcare, Waukesha, WI).  The Supersignal West Pico Chemiluminescent Substrate (Pierce, 
Rockford, IL) was used for the detection of BAP31 and actin immunoblots.  The signals were 
quantified using a Kodak 440CF Image Station and the associated Kodak 1D software (Eastman 
Kodak, Rochester, NY).   
 
Table 6. siRNA sequences 
 
 
3.2.6 Pulse Chase Analysis of ApoB100 
A pulse-chase analysis of ApoB100 was performed, as previously described (Gusarova et al., 
2001), after treatment with 100nM siRNA for 72 hrs.  Briefly, cells were starved in medium 
lacking cysteine and methionine before a 15 min incubation with 35S-methionine to label newly 
translated protein.  After labeling, cells were chased with medium containing cold cysteine and 
methionine and medium and lysates were collected 25 min after the chase and 60 min after the 
Oligo Name siRNA sequence Source
Bap31_5 CAAGAAAUACAUGGAGGAGAAUU Geiger et al., 2011
Bap31_6 AAAGGUGAACCUCCAGAACAAUU Geiger et al., 2011
FFL GAAUAUUGUUGCACGAUUUUU
Weiss Lab, University 
of Pittsburgh School of 
Medicine
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chase as an endpoint.  ApoB was precipitated using as anti-ApoB antibody (Chemicon, Billerica, 
MA) and subjected to SDS-PAGE and phosphorimaging.  The relative amount of ApoB 
recovered was determined by dividing the amount of ApoB present in lysates and medium at the 
60 min time point divided by the amount of ApoB present in lysates at 25 min.   
 
3.2.7 Computational Analysis 
The Basic Local Alignment Search Tool or BLAST was used to compare the amino acid 
sequences of each of the Yet proteins to the human protein database, using the blastp algorithm 
and the BLOSUM62 scoring matrix using default parameters.  The multiple sequence alignment 
algorithm T-coffee (http://tcoffee.crg.cat/apps/tcoffee/do:regular) was used to compare the amino 
acid sequence each of the Yet proteins to themselves and to the BAP proteins to determine the 
percent similarity and identity of each of the proteins (Notredame et al., 2000).  
 
3.3 RESULTS 
3.3.1 Yet2 and Yet3 contribute to the ERAD of ApoB in yeast 
In order to determine whether any of the candidate translocon regulators affect the ERAD of 
ApoB, I examined the stability of ApoB29 by cycloheximide chase analysis in yeast strains in 
which the genes encoding the potential translocon regulators were deleted (Table 4).  With the 
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help of a rotation student, Lynley Doonan, we first measured the degradation of ApoB in yeast 
strains where YSY6, the yeast homolog of RAMP4, or YKL207w, a subunit of the EMC, were 
deleted.  In both mutant strains we found that ApoB was degraded at wild type levels (Figure 
24A and B), indicating that these proteins do not contribute to the ERAD of ApoB.  I next 
assessed the stability of ApoB in a yeast strain where all three of the YET genes, which encode 
the yeast homologs of BAP29 and BAP31, were deleted – strain yet1,2,3Δ.  In the absence of the 
Yet proteins, ApoB was significantly stabilized (Figure 24C), suggesting that one or more of 
these proteins facilitates the ERAD of ApoB.  To determine which of the Yet proteins contribute 
to ApoB ERAD, I examined the degradation of ApoB in yeast strains in which each of the genes 
encoding these proteins had been deleted individually.  When either YET2 or YET3 were deleted 
ApoB was significantly stabilized, but in the absence of YET1 ApoB was degraded at wild type 
levels (Figure 24D).    
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Figure 24.  Yet2 and Yet3 contribute to the ERAD of ApoB 
Cycloheximide chase reactions were performed as described in the Materials and Methods in WT (), and in (A) 
ysy6Δ, (B) ykl207wΔ,  (C) yet1,2,3Δ, or (D) yet1Δ (),  yet2Δ (Δ), and yet3Δ (ο) yeast strains expressing ApoB29.  
Chase reactions were conducted at 30°C, and lysates were immunoblotted with anti-HA antibody.  Anti-G6PD 
antiserum was used as a loading control.  Data were standardized such that the “0” time point represents 100% of the 
protein.  Data represent the means of 5-7 experiments, ± SEM.  Where indicated (**) p<0.01 and (*) p<0.05. 
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The Barlowe lab had previously reported that CPY*, a soluble ERAD substrate, and 
Ste6*, an integral membrane ERAD substrate, are degraded at wild type levels in the yet1,2,3Δ 
strain.  They also indicated that CFTR-HA is degraded at wild type levels in the absence of 
YET3, and CPY and α-factor are translocated proficiently in the yet1,2,3Δ mutant (Wilson and 
Barlowe, 2010).  In order to determine if the Yet proteins contribute to the degradation of other 
ERAD substrates in addition to ApoB, I measured the degradation of CPY*, to confirm or refute 
their results, and pαf, another soluble ERAD substrate (Caplan et al., 1991), in strains deleted for 
either YET2 or YET3.  Consistent with results from the Barlowe lab (Wilson and Barlowe, 2010), 
CPY* and pαf were not significantly stabilized in these YET mutants (Figure 25 A and B).  
These data suggest that the Yet proteins exhibit substrate specificity during the degradation of 
ApoB.  Based on ApoB’s unique association with Sec61 during ERAD, these results suggest that 
the Yet proteins, which also interact with Sec61, may regulate Sec61 to facilitate the 
retrotranslocation and degradation of ApoB.   
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3.3.2 ApoB and Yet3 coimmunoprecipitate 
Since ApoB was stabilized in the absence of YET3, I next asked whether ApoB and Yet3 
coimmunoprecipitate.  I found that when ApoB was immunoprecipitated with anti-HA resin 
Yet3 was present, but an abundant cytosolic protein, G6PD, did not coimmunoprecipitate (Figure 
26).  Because both ApoB and Yet3 interact with the Se61 translocon (Pariyarath et al., 2001; 
Oyadomari et al., 2006; Wilson and Barlowe, 2010), this observed interaction might not be 
direct.  In order to confirm this interaction between ApoB and Yet3, I am currently optimizing 
conditions for in vivo cross-linking immunoprecipitation using Dithiobis[succinimidyl 
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Figure 25. Yet2 and Yet3 do not contribute to the ERAD of CPY* or pαf 
Cycloheximide chase reactions were performed as described in the Materials and Methods in (A) wild type (), yet2Δ 
(), or yet3Δ () yeast strains expressing CPY* or (B) pαf. Chase reactions were performed at 30°C, and lysates were 
immunoblotted with anti-HA antibody.  Anti-G6PD antiserum was used as a loading control.  Data were standardized 
such that the “0” time point represents 100% of the protein.  Data represent the means of 4 experiments, ± SEM.   
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propionate] (DSP) based on a protocol from the Hampton lab (Gardner et al., 2000).  
Additionally, to better understand mechanistically how the Yet proteins contribute to ApoB 
ERAD, I would also like to use chemical cross-linking to investigate whether the interaction of 
ApoB with the degradation machinery is altered in the absence of the Yet proteins (discussed in 
more detail in section 4.2). 
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Figure 26.  ApoB and Yet3 coimmunoprecipitate 
Immunoprecipitation reactions were performed using anti-HA resin, or unconjugated Sepharose (“-”), using lysates 
from wild type yeast strains expressing ApoB29.  A total of 1% of the input for the precipitation was also examined 
(“input”).  After precipitation and SDS-PAGE, the indicated proteins were detected by immunoblot analysis. 
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3.3.3 BAP31 knockdown and pulse chase of ApoB in hepatic cells 
To determine whether the results acquired from the use of the yeast system could be 
corroborated in mammalian cells, I began to examine the contribution of the mammalian Yet 
homolog, which may also be a potential translocon regulator, on ApoB biogenesis in hepatic 
cells.  While there are three YET family members in yeast, mammals express two clear 
homologs, BAP29 and BAP31 (Wilson and Barlowe, 2010).  In order to identify which of the 
BAP proteins to examine, I performed a sequence alignment of each of the yeast Yet proteins 
with each of the mammalian BAP proteins using the multiple sequence alignment program T-
Coffee.  I found that Yet3 is more similar to BAP31 than BAP29, while Yet1 and Yet2 are more 
similar to BAP29 (Figure 27).  Because BAP31 is the closest homolog of Yet3, has been shown 
to promote the retro-translocation and degradation of another ERAD substrate, CFTR (Wang et 
al., 2008a), and facilitates the dislocation of the SV40 virus from the ER to the cytosol during 
infection (Geiger et al., 2011) I decided to initially investigate the affect of Bap31 knockdown on 
the biogenesis of ApoB100 in McArdle cells, which are rat hepatoma cells that are an established 
model for studying ApoB (see section 1.5.2).  I chose not to investigate the effects of BAP31 
over-expression because upon over-expression, BAP31 localizes to large aggregates, as observed 
by immunofluorescence, and the ER and ERAD machinery are severely disrupted (Helenius lab, 
personal communication). 
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Figure 27. Percent similarity and identity between the Yet proteins and the BAP proteins 
A sequence alignment of (A) Bap29 or (B) Bap31 compared to Yet1, Yet2, and Yet3 was performed using the multiple 
sequence alignment program T-Coffee.  Identical residues are indicated with a (*) and similar residues are indicated with a (.) 
or (:).  The transmembrane domains of the BAP proteins are shown on the alignment.  Percent identity and similarity between 
the two proteins is reported.  (C) The pentagram depicts the percent identity and similarity between each of the Yet and BAP 
proteins.  Percent identity and similarity are recorded on the lines connecting the two compared proteins.  The thicker lines 
indicate the BAP protein that is most similar to a particular Yet protein. 
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Many labs have silenced BAP31 using siRNA, and the sequences of these siRNAs have 
been published (Ladasky et al., 2006; Regan and Laimins, 2008; Wang et al., 2008a; Bartee et 
al., 2010; Geiger et al., 2011).  I chose two different siRNAs, Bap31_5 and Bap31_6 (see Table 
6 for sequences), which showed a high degree of knockdown in HeLa cells (Geiger et al., 2011). 
I checked that the sequences for these siRNAs would work for rat BAP31 in addition to human, 
and found that the sequences were conserved with the exception of one nucleotide in siRNA 
Bap31_5 that I changed to fit the sequence of rat BAP31 (G to A change).  In order to establish 
knockdown conditions for BAP31 in McArdle cells, I transfected cells with a range of 
concentrations of siRNA (20nM -100nM) against either BAP31 or a negative control, siRNA 
against firefly luciferase (FFL).  I measured the amount of BAP31 protein remaining in cell 
lysates at 24 hpt, 48 hpt, and 72 hpt by Western blot analysis.  Consistent with other reports, I 
did not observe knockdown of BAP31 until 72 hpt (Ladasky et al., 2006; Regan and Laimins, 
2008; Wang et al., 2008a; Geiger et al., 2011) and efficient knockdown was achieved using 
100nM siRNA (Figure 28).  Additionally, a double transfection of the cells 24 hrs apart did not 
yield additional knockdown, but caused the cells to become sick and round up (Figure 28D). 
After determining that 100nM siRNA for 72 hrs provided efficient knockdown of 
BAP31, I wanted to repeat the transfection in quadruplicate and quantify the amount of 
knockdown achieved.  I found that 20-30% of BAP31 protein remained after knockdown 
compared to the control (Figure 29), which I hypothesized would be a sufficient reduction in 
protein to see an effect on ApoB ERAD.  Under these conditions, I performed an initial pulse 
chase analysis of ApoB100 to determine if ApoB ERAD was defective when BAP31 was 
silenced.   
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When the amount of radiolabeled ApoB100 recovered from cell lysates and secreted into 
the medium after a 60 min chase in BAP31 knockdown cells was compared to the control cells, 
no difference in ApoB recovery was evident (Figure 30).   To determine if I would be able to 
observe stabilization of ApoB when ERAD was blocked, I also measured the amount of ApoB 
recovered from cell lysates and secreted into the medium from the control knockdown cells when 
the proteasome was inhibited MG-132.  In this experiment, ~3.3 to 5 fold more ApoB was 
recovered from both cell lysates and the medium (Figure 30 – FFL-MG132 lanes).  These data 
suggest that if knockdown of BAP31 did prevent ApoB ERAD I would have observed increased 
ApoB100 recovery.   
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Figure 28. Establishing knockdown conditions for BAP31 in McArdle cells 
McArdle cells were transfected with a range of siRNA concentrations against BAP31 (Bap31_5 and Bap31_6) or, as a 
control, Firefly Luciferase (FFL) (20nM to 100nM) using Lipofectamine 2000.  Effective knockdown of BAP31 was 
assessed by Western Blot analysis (A) 24 hrs post transfection (hpt), (B) 48 hpt, or (C) 72 hpt using an antibody 
against BAP31.  Anti-beta actin antiserum was used as a loading control.  For (D), cells were transfected with a range 
of siRNA concentrations, as in (A,B,and C), but 24 hrs after the first transfection, the cells were again transfected with 
the same concentration of siRNA.   Effective knockdown of BAP31 was assessed by Western Blot analysis 72 hrs 
after the second transfection using an antibody against BAP31.  Anti-beta actin antiserum was used as a loading 
control. 
 117 
 
Figure 29. BAP31 protein is reduced 72hpt using 100nM siRNA 
McArdle cells were transfected in quadruplicate with 100nM of siRNA against BAP31 (Bap31_5 and Bap31_6) or, 
as a control, Firefly Luciferase (FFL) using Lipofectamine 2000.  (A) Effective knockdown of Bap31 was assessed 
by Western Blot analysis 72 hpt using an antibody against BAP31.  Anti-beta actin antiserum was used as a loading 
control.  (B) A quantification of the relative amount of BAP31 protein remaining 72 hpt standardized to the FFL 
control ± SEM is shown.  
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Figure 30. Proteasome inhibition leads to increased recovery of ApoB100 
Following a metabolic labeling reaction, a 60 min chase was performed as described in the Materials and Methods 
(section 3.1.6) in McArdle-RH7777 cells transfected in triplicate with 100nM of a control siRNA (FFL), or siRNAs 
against Bap31 (Bap31_5 or Bap31_6) for 72 hrs.  During the pulse chase the FFL transfected cells were treated with 
either DMSO, as a control, or 25µM MG132, to inhibit the proteasome.  (A) The image represents ApoB-
precipitated material subjected to SDS-PAGE and phosphorimaging.  The red arrow indicates the band 
corresponding to ApoB100.  (B) The “Relative Recovery of ApoB” is shown under the indicated conditions.  Data 
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were standardized by measuring the amount of ApoB precipitated material recovered from cell lysates and secreted 
into the medium at the completion of the chase divided by the amount of ApoB-precipitable material recovered after 
25 min of chase, i.e. the total ApoB pool.  Data represent the means of 3 experiments, ± SEM. 
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The results presented in Figure 30 can be explained by several possible scenarios.  The 
first scenario is that although I observed stabilization of ApoB in yeast in the absence of Yet3, 
which is most similar to BAP31, in mammalian cells there may be some compensation from 
BAP29, since BAP29 and BAP31 share such a relatively high degree of similarity (Figure 27).  
Indeed, since I also observed stabilization of ApoB in the absence of Yet2, which is most similar 
BAP29, BAP29 may also contribute to ApoB ERAD.  A second possibility is that the 
transfection and knockdown may not have been efficient in this experiment.  Although I 
established consistent knockdown conditions for Bap31, in the interim between experiments our 
lab tissue culture room was moved to a new facility and a new vial of cells was used to continue 
the experiments.  A third explanation is that there are differences in the regulation of ApoB29 vs 
ApoB100 with respect to translocation and retrotranslocation.  Shorter ApoB isoforms may be 
differentially selected for ERAD and I could examine both ApoB29 and ApoB48 degradation in 
McArdle cells as well as ApoB100.  Another possibility is that BAP31 acts during early events 
that are missed in this experiment.  If BAP31 facilitates the retrotranslocation of ApoB very early 
as it is being translocated, I may have missed differences in degradation between control and 
knockdown cells because at later time-points another quality control pathway such as PERPP 
may take over.  To alleviate this possibility I can take earlier time-points (starting at 12 min 
when the S35 has been incorporated into translating ApoB) to ensure that I do not miss a 
population of ApoB that will be degraded early in its synthesis.  In any event, to determine 
whether BAP31 had been efficiently depleted from the cells used in the pulse chase experiment, I 
performed a Western blot analysis of the lysates.  Although I had previously observed 
knockdown of BAP31 at 72 hpt with 100nM siRNA, in this experiment BAP31 protein levels 
were not significantly reduced in the knockdown samples (Figure 31).  The lack of knockdown 
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most likely explains why I failed to observe a difference in the amount of ApoB recovered in 
“knockdown” cells vs control cells.  Needless to say, these experiments will be repeated after 
knockdown of BAP31 is verified. 
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Figure 31.  Bap31 was not efficiently knocked down in the cells used for the pulse chase experiment 
shown in Figure 30 
Cell lysates from the pulse chase experiment in Figure 30 were subjected to SDS-PAGE and Western blot analysis to 
determine if BAP31 had efficiently been knocked down.  (A) The Western blots were probed with an anti-BAP31 
antibody or an anti-beta actin antibody as a loading control.  (B) A quantification of the relative amount of BAP31 
protein remaining 72 hpt compared to the control FFL_DMSO cells, with the numerical values listed above the graph is 
shown.  The solid red line indcates 100% of BAP31 protein remaining and the dashed red lines indicate standard 
deviation of the mean from the FFL-DMSO samples. 
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3.4 DISCUSSION 
In this chapter I showed first that two potential translocon regulators Ysy6 and Ykl207w did not 
impact ApoB ERAD.  In contrast, two members of the Yet family of proteins, Yet2 and Yet3, 
contribute to the degradation of ApoB29 in yeast.  Among the substrates that we and other labs 
have investigated, the impact of Yet2 and Yet3 on ERAD was unique for ApoB.  I also began to 
investigate whether the mammalian homolog of Yet3, BAP31, contributes to the ERAD of 
ApoB100 in rat hepatoma cells.  Thus far, I have developed silencing conditions for BAP31, but 
still need to work on consistent knockdown.  Together, the results in this chapter suggest that the 
unique attributes of ApoB, namely the continued association with Sec61 during ERAD, lead to 
the specific requirement of the Yet proteins for ApoB in yeast. 
 One surprising aspect of this study was that while Yet2 and Yet3 were necessary for 
ApoB ERAD, Yet1 was not essential.  This was surprising because the Barlowe lab has been 
unable to phenotypically separate the function of Yet1 and Yet3 and they suggest that these 
proteins act as a Yet1-Yet3 complex (Wilson and Barlowe, 2010).  However, the phenotype that 
they were observing was growth sensitivity to inositol starvation, which may not be as sensitive 
of an assay as a degradation assay or the requirement for Yet1 and Yet3 may be different for 
ERAD than for growth without inositol.  Interestingly, deletion of YET3 is more disruptive than 
deletion of YET1 such that in a yet3Δ mutant most of the Yet1 protein is depleted whereas in a 
yet1Δ mutant the majority of the Yet3 protein remains stable (Wilson and Barlowe, 2010).  This 
could indicate that there is some redundancy among these proteins.  ApoB is significantly 
stabilized when YET3 is deleted and, as described above, under these conditions, Yet1 protein 
levels are drastically reduced.  This data suggests that one or both of these proteins contributes to 
ApoB ERAD.  However, when YET1 is deleted there is still a sufficient amount of Yet3 protein 
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present.   If Yet1 and Yet3 have redundant functions in ERAD, in a yet1Δ mutant Yet3 is still 
present and sufficient to function in promoting ApoB degradation, so no defect in ERAD is 
observed.  
 A second confusing result that I observed was the lack of knockdown of BAP31 when I 
did the pulse chase analysis of ApoB.  One reason for the lack of knockdown is that when I 
thawed a new vial of cells, the new cells were stressed, perhaps as a result of dehydration from 
being frozen too quickly and did not transfect well.  To test this hypothesis, I have currently 
broken out a new aliquot of cells and I will transfect them with siRNA and test for knockdown 
before doing a pulse chase experiment.  A second explanation for the lack of knockdown is that 
my siRNA aliquots have become unstable from repeated freeze/thaw in our -20°C freezer and is 
no longer functioning.  I can verify the concentration of the siRNAs using a UV 
spectrophotometer at 260nm.  If I still do not observe knockdown using new cells, I will order 
fresh siRNAs to continue these experiments.  It is also possible that even after efficient silencing 
of BAP31 the ERAD of ApoB will remain unaltered in McArdle cells.  In this case I will try to 
knockdown both BAP31 and BAP29 to avoid possible redundancy and compensation.  
Additionally, when I repeat the pulse chase experiments I will examine other isoforms of ApoB 
(i.e. ApoB48) as well as examine earlier time-points within the chase to avoid missing any early 
ERAD decisions.   
 Overall, my yeast data suggest that the Yet proteins facilitate ApoB retrotranslocation 
and degradation (for a model see Figure 32).  Using hepatic cells, I hope to recapitulate and 
extend these findings.  
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Figure 32. The Yet proteins in yeast facilitate ApoB retrotranslocation and degradation 
(A) In yeast, lipids cannot be loaded onto ApoB and it is selected for ERAD. The Yet proteins may facilitate the 
loosening of the seal between the ribosome and Sec61 allowing ApoB to be retrotranslocated out of the ER.  Loops of 
ApoB accumulate in the cytosol that are recognized by Hsp70 and Hsp90, and the AAA-ATPase Cdc48.  ApoB is 
polyubiquitinated, and degraded by the 26S proteasome.  (B) In the absence of the Yet proteins, when lipids cannot be 
loaded onto ApoB, the seal between the ribosome and Sec61 may remain intact allowing ApoB to be fully translated and 
translocated into the ER.  This population of ApoB may remain stable in the ER in a conformation that does not allow 
for retrotranslocation.  Alternatively, ApoB may be partially retro-translocated in the absence of the Yet proteins and 
may remain associated with Cdc48 as a stalled intermediate that cannot be degraded by ERAD. 
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4.0  DISCUSSION AND CONCLUSIONS 
ApoB is targeted for degradation unlike any other known ERAD substrate. Under lipid-
poor conditions in mammalian cells, ApoB is cotranslationally selected for degradation by the 
Hsp70 and Hsp90 molecular chaperones, as well as a J domain-containing co-chaperone, P58IPK.  
The apolipoprotein is then ubiquitinated by gp78 while translocon-embedded and is 
retrotranslocated into the cytosol through the Sec61 translocon by the action of the AAA-
ATPase, p97.  Ultimately, this immature form of ApoB is captured and degraded by the 
proteasome.   Given these unique attributes, and because of the profound link between ApoB 
secretion and human disease, I sought to identify and characterize other factors that impact the 
decision between stabilizing and degrading ApoB, as described in the previous chapters.  I found 
that two members of the PDI family, ERp57 and ERp72 promote the degradation of ApoB, while 
another PDI family member, PDI facilitates ApoB lipid loading and secretion.  These studies 
were first made possible by the use of a yeast expression system in which analogous PDIs 
facilitated ApoB29 degradation.  Additionally, I discovered that two members of the yeast Yet 
family of proteins contribute to ApoB degradation and have begun to investigate the role of the 
mammalian Yet homologs using a rat hepatoma cell line.    Overall, I hope that these ongoing 
studies will provide therapeutic candidates that may be targeted to prevent the catastrophic 
effects of diseases related to ApoB-containing lipoproteins, in particular atherosclerosis, which is 
the leading cause of death in western societies. 
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4.1 PDI FAMILY MEMBERS HAVE DIFFERENTIAL EFFECTS ON THE 
BIOGENESIS OF APOLIPOPROTEIN B 
ApoB maturation requires the formation of specific disulfide bonds, and mutations in cysteines 
that form disulfide bonds in ApoB diminish VLDL assembly and secretion (Huang and Shelness, 
1997; Tran et al., 1998; DeLozier et al., 2001).  Mutations in the M subunit of the MTP complex, 
which contains PDI, can also prevent ApoB maturation, a phenomena that results in 
abetalipoproteinemia (Narcisi et al., 1995; Ohashi et al., 2000).  Because I observed measureable 
effects of PDI, ERp57 and ERp72 over-expression on the amount of secreted ApoB, my results 
may be relevant to explain the relative severity of human diseases such as 
hypobetalipoproteinemia and atherosclerosis.  In most cases, the factor(s) that lead to differences 
in the circulating lipoprotein levels in the population are mysterious.   Polymorphisms in ApoB 
itself are known to contribute to altered levels of secreted VLDLs, as specific non-sense codons 
in APOB cause hypobetalipoproteinemia (Linton et al., 1993; Whitfield et al., 2004).  Therefore, 
it is plausible that variations in the amount or activities of components that control ApoB 
maturation, such as PDI family members, may be at-play in the development of human diseases 
such as hypobetalipoproteinemia or atherosclerosis. 
Using the yeast expression system, I found that the ERAD of ApoB required Pdi1, and 
more specifically, the chaperone activity provided by the b’ domain of the protein.  When 
identifying candidate mammalian PDI proteins to investigate, one of the criteria was the presence 
of a b’ domain.  Erp57 and ERp72 both have b’ substrate binding domains; however, I did not 
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investigate whether these domains were necessary for promoting the ERAD of ApoB.  My 
working model is that when lipids are limiting, ERp57 and ERp72 bind to ApoB through their 
substrate binding domains and help to keep the protein from aggregating in the ER lumen so that 
ApoB can be retrotranslocated and degraded.    
In order to more mechanistically understand the contribution of these proteins to ApoB 
degradation, it would be interesting to make over-expression constructs of both ERp57 and 
ERp72 with various mutations.  I hypothesize that if the b’ domain of ERp57 or ERp72 was 
either deleted or residues in the binding pocket were mutated to non-hydrophobic residues and 
the proteins were over-expressed they would be unable to promote the ERAD of ApoB, as 
observed for the wild type proteins.  This hypothesis could also be investigated by over-
expressing the b’ domain mutants in ERp57 or ERp72 knockout cell lines to determine if ApoB 
degradation is restored.  Although ERp57 null mice are embryonic lethal (Coe et al., 2010), 
ERp57-/- and ERp72 -/- MEF cell lines are available (Zhang et al., 2009).  However, a defect in 
ApoB degradation when using b’ domain mutants does not rule out the possible involvement of 
the active site domains of these proteins in ApoB degradation.  The b’ substrate-binding domain 
may be necessary for PDI to interact with ApoB, which would bring the active sites in close 
enough proximity to catalyze redox reactions.  To determine whether the active site functions are 
necessary for ApoB ERAD, I could over-express ERp57 or ERp72 constructs with Cys to Ser 
mutations in each of the active sites individually and in tandem and determine if these proteins 
still contribute to ApoB ERAD. 
In my model, ERp57 and ERp72 bind to ApoB through their b’ domains because ApoB 
has highly hydrophobic patches that need to be protected from aggregation.  Alternatively, 
ERp57 may interact with ApoB because it is a highly glycosylated protein, as are the majority of 
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ERp57’s client proteins (Jessop et al., 2009).  One limitation of the yeast ApoB expression 
system is that of the 16 N-linked glycosylation sites utilized in ApoB100, only 2 are present in 
ApoB29 (Harazono et al., 2005).  Although I have not been able to confirm that they are 
glycosylated in yeast, but the Hochstrasser lab did observe ApoB29 glycosylation (Rubenstein et 
al., 2012).  To address whether the glycosylation status of ApoB influences the requirement of 
ERp57 for ApoB ERAD, I could examine the degradation of versions of ApoB with asparagine 
to glutamine mutations, which would eliminate glycosylation sites, when ERp57 is 
overexpressed or knocked down.   
In yeast, I was able to role out the possibility that the stabilization of ApoB29 that I 
observed in the absence of Pdi1 function was an indirect effect of the need for Htm1, the yeast 
homolog of EDEM.  EDEM is an α-mannosidase like protein that interacts with glycosylated 
proteins and targets them for degradation.  However, this does not eliminate the possibility that 
EDEM is involved in targeting ApoB for ERAD in mammalian cells because of the differences 
in ApoB glycosylation between the two systems.  In fact, it would be interesting to investigate 
whether EDEM contributes to ApoB ERAD in hepatic cells.  To address this question EDEM 
could be overexpressed or silenced, both of which have previously been done (Hosokawa et al., 
2006; Kosmaoglou et al., 2009) and the ERAD of ApoB could be investigated. 
Another open question is whether the EDEM associated PDI family member ERdJ5 
reduces the disulfide bonds of ApoB prior to retrotranslocation.  Are ApoB’s disulfide bonds 
oxidized before the ERAD decision is made?  One possibility is that even if disulfide bonds in 
ApoB are formed before ApoB is targeted for degradation, they do not need to be reduced for the 
protein to escape the ER and be degraded (Fiebiger et al., 2002; Lee et al., 2002; Liu et al., 2003; 
Tirosh et al., 2003; Skach, 2009).  To determine whether ApoB disulfide bonds are oxidized 
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before ERAD, a pulse chase reaction combined with a cysteine modification assay using PEG-
maleimide (see section 2.2.4) to examine the timing of oxidation compared to the timing of 
degradation could be performed.  Additionally, a co-immunoprecipitation of ApoB and ERdJ5 
would provide insight as to whether the two proteins interact.   
If the b’ domains of ERp57 and ERp72 are necessary for ApoB ERAD because of 
ApoB’s hydrophobic character, another candidate PDI family member to investigate is ERp44.  
ERp44 has an a-b-b’ domain organization and has been shown to regulate the IP3 receptor (Higo 
et al., 2005) and to interact with adiponectin (Wang et al., 2008b), which is a hormone that 
regulates fatty acid oxidation.  Interestingly, when a BLAST search was performed using only 
the b’ domain of yeast Pdi1 compared to the human protein database the only homologous 
protein returned was ERp44 (Hatahet and Ruddock, 2009).  The b’ substrate-binding domain of 
ERp44 may be important to maintain ApoB solubility in the ER lumen.  Because ERp44 cannot 
act as an oxido-reductase due to its CRFS active site sequence (although it could act as an 
isomerase), the question of redox activity vs chaperone activity for the protein’s involvement in 
ApoB ERAD would not be an issue.  Importantly, ERp44 is expressed highly in the liver (Long 
et al., 2011).     
Along with my discovery that select PDI family members contribute to ApoB ERAD, I 
also found instead that the over-expression of PDI itself promoted ApoB secretion.  Consistent 
with this finding, mice deficient for a key regulator of the unfolded protein response, Ire1, that 
was specifically deleted in their hepatocytes (Ire1α-/-) (Zhang et al., 2011) show impaired VLDL 
assembly in the ER (Wang et al., 2012). The defect in VLDL assembly resulted from a reduction 
in MTP activity because PDI expression was decreased (Wang et al., 2012).  Based on these 
results, a remaining question is whether the interaction of PDI with MTP directly promotes 
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ApoB secretion or whether PDI active sites contribute to ApoB folding, and promote secretion as 
well.  To address this question, I could create Cys to Ser active site mutants in PDI, leaving the 
PDI/M subunit interaction domain intact and over-express the construct in McArdle cells to 
determine if this mutant form of PDI facilitates ApoB secretion. 
Another limitation of the yeast expression system is that we can only investigate one arm 
of ApoB biogenesis – ERAD, not maturation and secretion.  In order to expand the yeast 
ApoB29 expression system, I would like to express the M subunit of the MTP complex in yeast 
and determine if it associates with Pdi1 to form an active complex.  To avoid having to express 
multiple plasmids in yeast, a galactose inducible bi-directional expression vector (pBEVY) 
(Miller et al., 1998) could be used to express both ApoB29 and M at the same time and in the 
same yeast cells.  Under these conditions would ApoB become lipid loaded?  This question could 
be answered using sucrose gradient floatation assays and measuring the density of the ApoB 
particles.  Additionally, oleic acid could be added to the medium to promote lipid loading.  Even 
if ApoB was lipid loaded by the MTP complex it may not be secreted, therefore one would need 
to investigate where the lipid modified protein localizes in the cell or if it becomes degraded.   
Under these conditions, another quality control pathway, such as PERPP, may recognize the 
foreign protein and degrade it.  Could we use this system to study factors involved in secretion?  
Potentially this system could be quite useful in dissecting the secretion pathway for ApoB, as a 
whole genomic screen for secretion defects of specific proteins is quite easily performed using 
yeast (Gelling et al., 2012).  Finally, because Pdi1 facilitated ApoB degradation in yeast, unlike 
that observed in mammalian cells, would Pdi1 now became a “pro-secretory” factor if the M 
subunit was present?  In mammalian cells, PDI is in excess of M.  Perhaps in yeast a population 
of Pdi1 would complex with M and a separate population would still favor ERAD.  Therefore, 
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the level of expression of the M subunit would have to be titrated to prevent depleting the yeast 
ER of all free Pdi1, which could potentially be lethal since PDI1 is an essential gene. 
4.2 YET FAMILY MEMBERS CONTRIBUTE TO APOLIPOPROTEIN B 
DEGRADATION IN YEAST 
As ApoB is translated by the ribosome in the cytosol, a 27 amino acid signal sequence directs 
the ribosome-nascent chain complex to the Sec61 translocon, which is embedded in the ER 
membrane.  The ribosome forms a tight seal with Sec61, allowing ApoB to cotranslationally 
translocate into the ER and preventing the protein from cytosolic exposure (section 1.2.2).  If 
ApoB cannot assemble into a pre-VLDL in the ER, it is selected for ERAD and is 
retrotranslocated out of the ER and into the cytosol where it is degraded by the 26S proteasome; 
interestingly, unlike the majority of ERAD substrates, which are fully translated and translocated 
before ERAD, ApoB is targeted for ERAD co-translationally and maintains an interaction with 
the Sec61 translocon during degradation (section 1.4.2.2).  In order for ApoB to be 
retrotranslocated out of the ER through the Sec61 translocon, the seal between Sec61 and the 
ribosome, that normally prevents cytosolic exposure, must be broken to allow cytoplasmic loops 
of ApoB to accumulate and be polyubiquitinated.  The mechanisms for the change in interaction 
between Sec61 and the ribosome to facilitate degradation are poorly understood, but it is 
hypothesized that there are proteins that regulate this interaction.  I identified two members of 
the Yet family of yeast proteins, Yet2 and Yet3, as potential regulators of the Sec61 translocon 
that may facilitate the retrotranslocation of ApoB through Sec61 for degradation and I have 
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started to examine the mammalian homologs of Yet2 and Yet3, BAP29 and BAP31 
respectively.  Several questions regarding how the Yet proteins facilitate ApoB degradation still 
remain. To understand how the Yet proteins mechanistically promote ApoB degradation I would 
like to ask whether the interaction of ApoB with the degradation machinery is altered in the 
absence of the Yet proteins.  By determining which steps in ApoB ERAD are affected by the loss 
of these proteins I can place the function of the Yet proteins within the ApoB degradation 
pathway.  Specifically, I would like to address the ubiquitination status of ApoB and determine 
whether the protein interacts with Cdc48/p97 in the yet2Δ and yet3Δ strains.  To do this, I could 
immunoprecipitate ApoB29 from yeast cells that either express or do not express the Yet 
proteins and determine if Cdc48 is associated with ApoB by Western blot.  Because the 
interaction between ApoB and Cdc48 is transient in nature (and may be difficult to detect by 
coimmunoprecipitation), the chemical crosslinker DSP could be added to spheroplasted yeast 
cells before immunoprecipitation, using a protocol that has been successful to immunoprecipitate 
ubiquitin ligases and their substrates (Gardner et al., 2000).  Additionally, the proteasome 
inhibitor MG132 could also be added to prevent degradation of ApoB, so that the interaction 
with Cdc48 will be favored.  To detect polyubiquitinated ApoB, an ApoB immunoprecipitation 
and the detection of ubiquitin will be performed similar to that used to detect other 
polyubiquitinated ERAD substrates, such as CFTR (Ahner et al., 2007) and ENaC (Buck et al., 
2010). Decreased ubiquitination and Cdc48 association in the absence of Yet proteins would 
support the idea that the Yet proteins facilitate retrotranslocation. 
My hypothesis is that the Yet proteins aid in the retrotranslocation of ApoB and that 
ApoB is stabilized in their absence because it does not efficiently retrotranslocate from of the 
ER; alternatively, if the Yet proteins regulate the translocon, degradation of ApoB may be 
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prevented because it is not properly translocated into the ER, causing it to aggregate within the 
cytosol and thus preventing degradation.  Although the Barlowe lab reported that CPY* and pαf 
did not display translocation defects in the yet1,2,3Δ yeast strain (Wilson and Barlowe, 2010), to 
determine whether ApoB is translocated into the ER lumen there are two experiments that I 
could perform.  First, I have shown using a cysteine modification assay (see section 2.2.4) that in 
wild type yeast cysteine residues within ApoB29 are oxidized to form disulfide bonds, a 
modification that occurs within the ER lumen.  I could perform this assay using yet2Δ or yet3Δ 
strains and determine if ApoB has been subject to disulfide bond formation in the ER.  A second 
method to determine whether ApoB is translocated into the ER could be to use an ER localized 
myc-tagged SNAP that would react with a benzylguanine labeled ApoB to form a covalent link 
between the two proteins, a method used by the Helenius lab to determine where BAP31 acts 
during SV40 infection (Geiger et al., 2011).  Using immunoprecipitation and Western blotting I 
could then determine if ApoB had translocated into the ER.  Preliminarily, I have performed 
sucrose gradient fractionation with yet3Δ cells to examine ApoB localization (Figure 33).  Based 
on these results, ApoB does co-localize with ER fractions, indicating that at least a population of 
ApoB is properly translocated when Yet3 is absent.  Additionally, to determine if the Yet 
proteins facilitate retrotranslocation through their interaction with Sec61, I could make 
mutations in the Yet proteins that disrupt their interaction with Sec61 and determine if ApoB 
degradation is prevented as well. 
As described in section 3.4, I will be repeating the pulse chase analysis of ApoB100 in 
McArdle cells when BAP31 has been knocked down and may also use siRNAs to silence 
BAP29 as well.  If ApoB is stabilized when BAP31 and BAP29 are knocked down I could 
validate these results by using siRNAs targeted to the UTR of BAP29 or BAP31, which will 
knockdown these 
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proteins, and then rescue degradation of ApoB by transfecting the cells with either BAP29 or 
BAP31 constructs that lack the UTR.  I would also like to perform indirect immunofluorescence 
to examine the localization of ApoB in mammalian cells when the BAP proteins have been 
silenced and I would expect to see an accumulation of ApoB within the ER.  
Figure 33. ApoB does not appear to be mislocalized in the absence of Yet3 
Lysates from yet3Δ cells expressing ApoB29 were loaded onto a discontinuous sucrose gradient (20%-70%) in the 
presence of EDTA and centrifuged at 100,000xg for 19 hours.  Fractions were taken from the top of the gradient and 
were subjected to SDS-PAGE and immunoblotted with anti-HA antibody to detect ApoB29.  Anti-Sec61 antiserum 
was used as an ER marker.   Anti-Anp1 antiserum served as a Golgi marker, and anti-Pma1 antiserum was used as a 
marker for plasma membrane proteins.   A total of 1% of the lysate before gradient fractionation was also examined 
(“L”).   
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If the Yet/BAP proteins regulate the translocon and loosen the change in the ribosome-
translocon interaction, another question remaining is how these proteins “decide” that ApoB 
needs to be degraded and that the ribosome seal needs to be broken to facilitate exit from the ER.  
Do they associate with other proteins that pass along this information?  Do they directly interact 
with exposed hydrophobic patches of ApoB when it is not assembled into a VLDL?  Since these 
proteins have been shown to facilitate the retrotranslocation of other proteins, the mechanism 
promoting ApoB retrotranslocation may not be specific for ApoB.  The proteins may act as 
general sensors for ER stress and facilitate the removal of proteins or viruses that could induce 
ER stress.  
A final question that should be investigated with respect to ApoB ERAD is once ApoB is 
retrotranslocated into the cytosol, how is it kept soluble before degradation?  Presumably ApoB 
is in an unfolded state with exposed hydrophobic patches in the cytosol.  It is known that the heat 
shock proteins Hsp70 and Hsp90 bind to ApoB in the cytosol and target it for degradation.  Are 
these proteins sufficient to prevent ApoB aggregation, or are there other proteins that associate 
with ApoB and perform this function?  One family of proteins that interacts with unfolded 
substrates in the cytosol to prevent aggregation are the chaperonin proteins, CCT/TRiC (Spiess 
et al., 2004).  A graduate student in the lab is currently investigating whether these proteins are 
involved in ApoB degradation.  A second group of proteins that may perform this function are 
the Get proteins.  In yeast, the Get complex, composed of Get4, Get5, and Sgt2, shields 
transmembrane domains of tail-anchored proteins from the cytosol while they are shuttled to the 
ER membrane (Chartron et al., 2012); thus, the Get complex could potentially interact with the 
hydrophobic domains of ApoB to keep it soluble.  An analogous complex to the Get4-Get5-Sgt2 
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complex in vertebrates is TRC35/Ubl4a/SGTA, which also bind to another protein, Bag6, 
which has been shown to associate with ribosomes and interact with transmembrane domains of 
newly synthesized tail anchored proteins (Chartron et al., 2012).  This complex has been shown 
to not only bring tail-anchored proteins to the ER membrane but also to mediate the degradation 
of misfolded or mislocalized membrane proteins and retrotranslocated ER proteins (Minami et 
al., 2010; Hessa et al., 2011; Wang et al., 2011).  As such, this complex of proteins would make 
a good candidate for keeping ApoB soluble in the cytoplasm before degradation and would be 
quite interesting to investigate as an ApoB solubilization factor.        
138 
APPENDIX A 
DOES THE STABLE POPULATION OF APOB LOCALIZE TO LIPID DROPLETS IN 
YEAST? 
In yeast, approximately 50% of ApoB is stable (Figure 34), and is presumably protected 
from degradation and aggregation.  I sought to determine whether the stable population of ApoB 
resided within the ER and could be kept soluble by chaperones, or if this population was 
differentially localized and protected from degradation by another mechanism.   
When examining the localization of ApoB in yeast, I found that ApoB does not 
completely localize with ER markers.  Sucrose gradient fractionation indicates that a population 
of ApoB resides in gradient fractions that are less dense than the ER and Golgi (Figure 35).  
When the gradient analysis are run in the presence of EDTA, the ribosomes are stripped from the 
ER membrane and the ER and Golgi both migrate to the same densities within the gradient 
(Figure 35A, lanes 5-12), while the plasma membrane migrates further into the gradient due to 
its higher density (Figure 35A, lanes 12-18).  ApoB predominantly localizes to the same 
fractions as the ER and Golgi, although a small amount is consistently found in a fraction or two 
that is less dense than the ER and Golgi (Figure 35A, lane 4).  To more definitively determine if 
ApoB co-migrates with the ER or with the Golgi I used a sucrose gradient poured in the presence 
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of magnesium.  In the presence of magnesium ribosomes remain associated with the ER 
membrane and the ER density is much greater, causing it to co-migrate with the plasma 
membrane fractions (Figure 35B, lanes 13-19), while Golgi distribution is unaltered (Figure 35B, 
lanes 7-11).  Interestingly, I found that when the ER and Golgi populations could be separated, a 
population of ApoB did co-migrate with the ER fractions, but a large population of ApoB did not 
shift with the ER and also peaked in less dense fractions than the Golgi (Figure 35B, lanes 4-6), 
suggesting that this population of ApoB is not localized to the ER or Golgi.  Additionally, 
indirect immuno-fluorescence performed by a previous graduate student, Stacy Hrizo, suggested 
that while some ApoB co-localizes with the characteristic perinuclear staining of the ER marker 
BiP, ApoB also localizes to cytoplasmic punctae that resemble lipid droplets (Figure 36A).  
Lipid droplets are dynamic organelles that are ER-associated and provide a storage area for 
triacylglycerol and cholesteryl esters (Sandager et al., 2002; Cermelli et al., 2006).  In 
mammalian cells a percentage of ApoB resides in lipid droplets and upon inhibition of the 
proteasome the concentration of ApoB residing in lipid droplets increases (Ohsaki et al., 2006; 
Ohsaki et al., 2008).  I hypothesized that in yeast a population of ApoB may associate with lipid 
droplets since these are a rich source of lipids that could be loaded onto ApoB and the 
structure/organization of these organelles is very similar to that of lipoproteins into which ApoB 
assembles in mammalian cells. 
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Figure 34. A population of ApoB remains stable during a cycloheximide chase 
Cycloheximide chase reactions were performed in yeast strains expressing ApoB29 in either the absence  (), or 
presence (o) of the proteasome inhibitor MG132 (100µM) after a 20 minute pre-incubation with the drug.  These 
strains were also deleted for PDR5, which facilitates the accumulation of small molecules.  Chase reactions were 
performed at 30°C, and lysates were immunoblotted with anti‐HA antibody to detect ApoB29.  G6PD antiserum 
was used as a loading control (not shown). Data represent the means of 4 experiments, ± SEM.  
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Figure 35. ApoB is present in sucrose gradient fractions that are less dense than the ER 
Lysates from yeast expressing ApoB29 were loaded onto a discontinuous sucrose gradient (20%-70%) in the 
presence of (A) EDTA or (B) magnesium and centrifuged at 100,000xg for 19 hours.  Fractions were taken from the 
top of the gradient and were subjected to SDS-PAGE and immunoblotted with anti-HA antibody.  Anti-Sec61 
antiserum was used as an ER marker.   Anti-Anp1 antiserum served as a Golgi marker, and anti-Pma1 antiserum was 
used as a marker for the plasma membrane.   A total of 1% of the lysate before gradient fractionation was also 
examined (“L”).   
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Figure 36. ApoB does not completely overlap with ER markers and can be biochemically isolated 
with Lipid Droplets 
(A) BiP exhibits the typical perinuclear staining that is reported for ER lumenal proteins. ApoB also exhibits the 
perinuclear staining, however intense staining of ApoB is observed in portions of the cytoplasm that do not overlap 
the ER staining (see white arrows).  (B) Lipid droplets were isolated from spheroplasts expressing ApoB.  Fractions 
were subjected to SDS-PAGE and immunoblotted with anti-HA antibody.  Anti-GFP was used to detect FAA4, a 
marker for lipid droplets, and anti-CPY anti-serum was used as a vacuolar marker. 
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To determine if ApoB is found in lipid droplets in yeast, I isolated lipid droplets using a 
previously published protocol (Zinser and Daum, 1995).  I found that ApoB could be isolated 
with lipid droplet fractions (Figure 36B).  Since one hypothesis is that in mammalian cells lipid 
droplets are a staging area for degradation (Ohsaki et al., 2006), I asked whether ApoB is still 
degraded when lipid droplets are absent.  I examined ApoB stability using a strain where all four 
genes responsible for lipid droplet synthesis in yeast were deleted (are1Δ, are2, iro1Δ, dga1Δ) (a 
gift from the Stymne lab at the Swedish University of Agricultural Sciences) (Sandager et al., 
2002).  Cycloheximide chase analysis suggests that lipid droplets are not required for ApoB 
degradation in yeast since ApoB is degraded at wild type levels in the absence of lipid droplets 
(Figure 37).  Interestingly, even in the absence of lipid droplets a population of ApoB remained 
stable and was not degraded, suggesting that there may be other mechanisms to protect ApoB 
from degradation in the absence of lipid droplets.  To determine whether the degradation of 
ApoB is still proteasome dependent when lipid droplets are absent, and does not occur through 
another degradation pathway (e.g. autophagy), I examined ApoB stability in the lipid droplet 
deficient yeast strain (are1Δ, are2, iro1Δ, dga1Δ), which was also deleted for the drug pump 
Pdr5, with or without the proteasome inhibitor MG132.  I found that in the absence of lipid 
droplets ApoB degradation is still proteasome dependent (Figure 38).  These data suggest that 
lipid droplets are not a staging area for ApoB ERAD in yeast.
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Figure 37. Lipid Droplets are not required for ApoB degradation 
Cycloheximide chase reactions were performed in wild type (), or are1Δ are2Δ,lro1Δ,dga1Δ (o) yeast strains 
expressing ApoB29. Chase reactions were performed at 30°C, and lysates were immunoblotted with anti‐HA 
antibody and anti‐G6PD antiserum was used as a loading control. Data represent the means of 6 experiments, ± 
SEM.  
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Figure 38. In the absence of Lipid Droplets ApoB degradation is still proteasome dependent 
Cycloheximide chase reactions were performed at 30°C in are1Δ are2Δ,lro1Δ,dga1Δpdr5Δ yeast strains  expressing 
ApoB29. Cells were incubated with the proteasome inhibitor MG132 (100µM) (o) or a vehicle control () for 20 
minutes prior to the addition of cycloheximide.  Lysates were immunoblotted with anti‐HA antibody and 
anti‐G6PD antiserum was used as a loading control. Data represent the means of 4 experiments, ± SEM.   Where 
indicated (**) p<0.01  
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My data suggest that there are two populations of ApoB in yeast, a population residing in 
the ER that can be degraded and a stable population that resides in organelles that are less dense 
than the ER, presumably lipid droplets (Figure 39).  To determine if the population of ApoB 
found in lipid droplets is protected from degradation Lynley Doonan, a graduate student in the 
lab, will continue this project and perform a number of experiments.  To determine if the 
population of ApoB found in the less dense fractions of gradients is protected from proteasomal 
degradation, Lynley will perform cycloheximide chases of ApoB and load samples onto sucrose 
gradients to determine which population of ApoB disappears over time.  Her preliminary results 
suggest that while the ER population of ApoB decreases after 60 minutes the less dense fraction 
remains.  We would also like to know if the populations of ApoB change when proteasomal 
degradation is inhibited.  If lipid droplets are protective environments for ApoB, I hypothesize 
that upon proteasomal inhibition the ER population of ApoB would shift to the lipid droplet 
fractions.  To address this, Lynley will inhibit proteasomal degradation using MG132 and then 
use sucrose gradient fractionation to determine if more ApoB resides in less dense gradient 
fractions than ER fractions.  Additionally, we would like to confirm that the cytoplasmic punctae 
observed by immunofluorescence and the less dense gradient fractions are lipid droplets.  I have 
created a plasmid expressing Erg6, a protein known to localize to lipid droplets in yeast, fused to 
GFP that can be used for co-localization experiments and we will use this to determine whether 
ApoB resides in lipid droplets.   
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Figure 39. Model of the two populations of ApoB in yeast 
A population of ApoB is found associated with the ER in yeast.  This population is not actively or fully lipid loaded 
because the MTP complex is not present in yeast and is subject to degradation by the 26S proteasome.  A second 
population of ApoB associates with lipids in the ER membrane due to its hydrophobic nature, and Lipid Droplets 
bud from this region of the ER forming separate organelles.  ApoB assembled within Lipid Droplets resembles its 
lipoprotein-associated state and is protected from degradation and aggregation.   
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A.1 MATERIALS AND METHODS 
A.1.1 Degradation Assay 
Cycloheximide chases were performed as described in section 2.2.3. 
A.1.2 Sucrose Gradient Fractionation 
Forty ODs of yeast cells expressing ApoB29 were collected and resuspended in 10% STED 
Buffer (10mM Tris-HCl pH 7.6, 10mM EDTA, 10% sucrose) or 10% STMg Buffer (10mM Tris-
HCl pH 7.6, 2mM MgCl2, 10% sucrose) in the presence of protease inhibitors and 2mM DTT.  
Cells were lysed with glass beads (4 x 30 second pulses, with incubations on ice in between each 
lysis) and spun at 2000xg to remove cellular debris.  The cleared lysates were loaded onto a 
discontinuous sucrose gradient (20%-70%) in the presence of STED or STMg Buffer and 
centrifuged at 100,000xg for 19 hours.    Fractions were taken from the top of the gradient and 
were subjected to SDS-PAGE and immunoblotted with anti-HA antibody.  Anti-Sec61 antiserum 
was used as an ER marker.   Anti-Anp1 antiserum served as a Golgi marker, and anti-Pma1 
antiserum was used as a marker for plasma membrane proteins.   A total of 1% of the lysate 
before gradient fractionation was also examined.   
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A.1.3 Lipid Droplet Isolation 
Lipid droplets were isolated from yeast expressing ApoB29 using a previously published 
protocol from (Zinser and Daum, 1995).  Briefly, 2000 ODs of cells were spheroplasted and 
washed with potassium phosphate, pH 7.4, 1.2M sorbitol and then resuspended in breaking 
buffer (10mM MES-Tris pH 6.9, 12% Ficoll400, 0.2mM EDTA).  The cells were homogenized 
for 45 strokes on ice with a loose Dounce homogenizer.  A total of 9mL of breaking buffer was 
added to dilute the homogenate.  The homogenate was spun at 4°C for 5min at 5000xg.  The 
supernatant was moved into a thin walled ultracentrifuge tube and overlaid with 18mL of 
breaking buffer and centrifuged for 1hr at 4°C in a Beckman SW28 swinging bucket rotor at 
28,000rpm.  The thin floating layer at the top of the gradient was collecting using a glass Pasteur 
pipette and the volume was brought up to 18mL in breaking buffer in a think walled 
ultracentrifuge tube.  This solution was overlaid with 18mL of Solution #2 (10mM MES-Tris, 
pH 6.9, 8% Ficoll400, 0.2mM EDTA) and centrifuged for 1hr at 4°C in a Beckman SW28 
swinging bucket rotor at 28,000rpm.  The top layer was collected and resuspended in Solution #3 
(10mM MES-Tris pH6.9, 0.6M sorbitol, 8% Ficoll400, 0.2mM EDTA) and overlaid with 
Solution #4 (10mM MES-Tris pH6.9, 0.25M sorbitol, 0.2mM EDTA) and centrifuged for 30min 
at 4°C in a Beckman SW28 swinging bucket rotor at 28,000rpm.  The top layer was collect and 
precipitated with a final volume of 10% TCA on ice for 15min and spun at 5000xg at 4°C for 
5min.  The pellet was resuspended in TCA sample buffer and subject to SDS-PAGE and Western 
blot analysis.  CPY was used as a vacuolar marker, Sec61 was used as an ER marker, and FAA4 
was used as a marker of lipid droplets.    
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